content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;As filed with the Securities and Exchange Commission on March 10, 2021</P>
  
  <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9;Registration No. 333-&nbsp;&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">Danimer
  Scientific, Inc.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
  charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><B>82-1924518</B></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
  of incorporation or organization)</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer <BR>
  Identification No.)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%; text-align: center"><B>140 Industrial Boulevard<BR>
  Bainbridge, Georgia</B></TD>
      <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><B>39817</B></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Danimer Scientific, Inc. 2020 Long-Term
  Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Danimer Scientific, Inc. Employee Stock
  Purchase Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Meredian Holdings Group, Inc. 2016 Director
  and Executive Officer Stock Incentive Plan, </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>assumed by Danimer Scientific, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Meredian Holdings Group, Inc. 2016 Omnibus
  Stock Incentive Plan,</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>assumed by Danimer Scientific, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Attn.: Stephen E. Croskrey</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Danimer Scientific, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>140 Industrial Boulevard</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bainbridge, Georgia</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name and address of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copy to:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Robert L. Lawrence, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kane Kessler, P.C.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>600 Third Avenue</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10016</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 541-6222</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
  of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
  of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
      <TD STYLE="width: 16%; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT> &#9744;</TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT> &#9746;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Smaller reporting company &#9746;</FONT></TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT> &#9746;</TD>
      </TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
  registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">Title of securities to be registered</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Amount to&nbsp;be<BR> registered <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed maximum<BR> offering price<BR> per share</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed maximum<BR> aggregate <BR> offering price</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of <BR> registration fee</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><SUP>&nbsp;</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-size: 10pt; text-align: left">Class A Common Stock, par value $0.0001 per share (&ldquo;Common Stock&rdquo;)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">8,572,457</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">32.13</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">275,433,044</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">30,049.75</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><SUP>(2)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; text-align: left">Common Stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,571,737</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(4)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">27.31</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">70,234,138</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7,662.54</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(5)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 10pt; text-align: left">Common Stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,487,283</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(6)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.96</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">41,529,640</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4,530.88</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(7)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font-size: 10pt; font-weight: bold">Total</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,618,098</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">387,143,842</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">42,243.17</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>&nbsp;</SUP></TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
  this Registration Statement covers an indeterminable number of additional shares of Common Stock as may hereafter be offered or
  issued pursuant to the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the &ldquo;2020 Incentive Plan&rdquo;), Danimer
  Scientific, Inc. Employee Stock Purchase Plan (the &ldquo;ESPP&rdquo;), and the Meredian Holdings Group, Inc. 2016 Director and
  Executive Officer Stock Incentive Plan and Meredian Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan (collectively, the &ldquo;Legacy
  Plans&rdquo;) to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without receipt
  of consideration. In addition, this Registration Statement registers the resale of shares of Danimer Scientific, Inc.&rsquo;s (the
  &ldquo;Registrant&rdquo;) Common Stock by certain selling stockholders identified in the Reoffer Prospectus included in and filed
  with this Registration Statement, for which no additional registration fee is required pursuant to Rule 457(h)(3) under the Securities
  Act with respect to such of those shares being registered for issuance by the Registrant pursuant to this Registration Statement
  and on which a registration fee is already being paid.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(c) and
  457(h), the proposed maximum offering price per share is based upon a price of $32.13 (the average of the high and low prices of
  the Registrant&rsquo;s Common Stock as reported on The New York Stock Exchange on March 5, 2021).</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock of the Registrant authorized for issuance as awards under the
  2020 Incentive Plan.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">Represents shares issuable pursuant to the ESPP.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">Estimated in accordance with Rule&nbsp;457(h)&nbsp;under the Securities Act solely for the purpose
  of calculating the registration fee on the basis of 85% of the average of the high and low prices of the Registrant&rsquo;s Common
  Stock as reported on The New York Stock Exchange on March 5, 2021. Pursuant to the ESPP, the purchase price of Common Stock will
  be at least 85% of the lower of the fair market value of the Common Stock on the first trading day of the offering period or on
  the purchase date.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: justify">Represents shares of Common Stock issued pursuant to or underlying awards previously granted under
  the Legacy Plans, which awards were assumed by the Registrant in connection with the merger consummated on December 29, 2020 (the
  &ldquo;Business Combination&rdquo;) pursuant to the Agreement and Plan of Merger, dated as of October 3, 2020 (as amended by Amendment
  No.1 thereto, dated as of October 8, 2020, and Amendment No. 2 thereto, dated as of December 11, 2020, the &ldquo;Merger Agreement&rdquo;),
  by and among Live Oak Acquisition Corp., our predecessor company (&ldquo;Live Oak&rdquo;), Green Merger Corp., Meredian Holdings
  Group, Inc., (&ldquo;Legacy Danimer&rdquo;), Live Oak Sponsor Partners, LLC, as representative for Live Oak, for certain purposes
  described in the Merger Agreement and John A. Dowdy, Jr., as representative of the shareholders of Legacy Danimer for certain purposes
  described in the Merger Agreement.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(7)</TD><TD STYLE="text-align: justify">Computed in accordance with Rule&nbsp;457(h)&nbsp;of the Securities Act solely for purposes of
  calculating the registration fee. The average weighted exercise price at which the options may be exercised for the shares of Common
  Stock described above in Footnote 6 is $3.96 per share.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Registration Statement shall become
  effective upon filing </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>in accordance with Rule&nbsp;462 under
  the Securities Act.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Danimer Scientific,
  Inc., a Delaware corporation (&ldquo;Danimer&rdquo;), has prepared this Registration Statement in accordance with the requirements
  of Form S-8 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), to register 21,631,477 shares of Class
  A Common Stock, $0.0001 par value per share (the &ldquo;Common Stock&rdquo;) that are reserved for issuance pursuant to Danimer&rsquo;s
  2020 Long-Term Incentive Plan (the &ldquo;2020 Incentive Plan&rdquo;) and were issued or reserved for issuance pursuant to Danimer&rsquo;s
  Employee Stock Purchase Plan (the &ldquo;ESPP&rdquo; and together with the 2020 Incentive Plan, the &ldquo;New Plans&rdquo;), and
  the Meredian Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan and Meredian Holdings Group, Inc. 2016
  Omnibus Stock Incentive Plan (collectively, the &ldquo;Legacy Plans&rdquo; and together with the New Plans, the &ldquo;Plans&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Registration Statement
  contains two parts. The first part contains a reoffer prospectus pursuant to Form S-3 (in accordance with Section C of the General
  Instructions to the Form S-8 and in accordance with the requirements of Part&nbsp;I of Form S-3) (the &ldquo;Reoffer Prospectus&rdquo;)
  which covers reoffers and resales of &ldquo;restricted securities&rdquo; and/or &ldquo;control securities&rdquo; (as such terms
  are defined in Section C of the General Instructions to Form S-8) of Danimer. This Reoffer Prospectus relates to up to 18,969,978
  shares of Common Stock that have been or may be issued to certain officers and directors of Danimer pursuant to the Plans. Accordingly,
  this Reoffer Prospectus is a combined prospectus pursuant to Rule 429(a) of the Securities Act. The second part of this Registration
  Statement contains information required in the Registration Statement pursuant to Part II of Form S-8 and will be used for offers
  of shares of Common Stock of Danimer pursuant to the Plans. The inclusion of such shares herein does not necessarily represent
  a present intention to sell any or all such shares of Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
  the requirements of General Instruction C.2.(b) of Form S-8, because we do not satisfy the registrant requirements for use of Form
  S-3 at the time of filing the reoffer prospectus included in this Registration Statement, the amount of shares of Common Stock
  to be offered or resold by means of the reoffer prospectus, by each person, and any other person with whom he or she is acting
  in concert for the purpose of selling our Common Stock, may not exceed, during any three month period, the amount specified in
  Rule 144(e) promulgated under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: justify"><B>Item
  1. Plan Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The document(s) containing
  the information specified in Part I of Form S-8 will be sent or given to participants in the Plans as specified by Rule 428(b)(1)
  under the Securities Act. Such document(s) are not being filed with the Securities and Exchange Commission, but constitute, along
  with the documents incorporated by reference into this Registration Statement, a prospectus that meets the requirements of Section
  10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: justify"><B>Item
  2. Company Information and Employee Plan Annual Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Danimer will furnish
  without charge to each person to whom the prospectus is delivered, upon the written or oral request of such person, a copy of any
  and all of the documents incorporated by reference in Item 3 of Part II of this Registration Statement, other than exhibits to
  such documents (unless such exhibits are specifically incorporated by reference to the information that is incorporated). Those
  documents are incorporated by reference in the Section 10(a) prospectus. Requests should be directed to Danimer Scientific, Inc.,
  140 Industrial Boulevard, Bainbridge, Georgia 39817, Attention: Secretary; Telephone number (229) 243-7075.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Note</B>: The reoffer
  prospectus referred to in the Explanatory Note follows this page.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">REOFFER PROSPECTUS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">DANIMER SCIENTIFIC,
  INC.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18,969,978 Shares of Class A Common Stock,</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>par value $0.0001 per share</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Prospectus
  relates to shares (the &ldquo;Shares&rdquo;) of Class A Common Stock, par value $0.0001 per share (the &ldquo;Common
  Stock&rdquo;), of Danimer Scientific, Inc., a Delaware corporation (which may be referred to as the &ldquo;Company,&rdquo;
  &ldquo;Danimer,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo;), which may be offered and sold from time to
  time after the expiration of any applicable lock-up agreements by certain stockholders of ours (the &ldquo;Selling
  Stockholders&rdquo;) who have acquired or will acquire such Shares pursuant to stock options and stock grants issued or
  issuable under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the &ldquo;2020 Incentive Plan&rdquo;), the
  Danimer Scientific, Inc. Employee Stock Purchase Plan (&ldquo;ESPP&rdquo; and together with the 2020 Incentive Plan, the
  &ldquo;New Plans&rdquo;), and the Meredian Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan and
  Meredian Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan (collectively, the &ldquo;Legacy Plans&rdquo; and together
  with the New Plans, the &ldquo;Plans&rdquo;). See &ldquo;Selling Stockholders.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not
  receive any of the proceeds from sales of the Shares by any of the Selling Stockholders. The Shares may be offered from time
  to time after the expiration of any applicable lock-up agreements by any or all of the Selling Stockholders (and their donees
  and pledgees) through ordinary brokerage transactions, in negotiated transactions or in other transactions, at such prices as
  he or she may determine, which may relate to market prices prevailing at the time of sale or be a negotiated price. See
  &ldquo;Plan of Distribution.&rdquo; All costs, expenses and fees in connection with the registration of the Shares will be
  borne by us. Brokerage commissions and similar selling expenses, if any, attributable to the offer or sale of the Shares will
  be borne by the Selling Stockholder (or their donees and pledgees).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Selling Stockholder
  and any broker executing selling orders on behalf of a Selling Stockholder may be deemed to be an &ldquo;underwriter&rdquo; as
  defined in the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). If any broker-dealers are used to effect
  sales, any commissions paid to broker-dealers and, if broker-dealers purchase any of the Shares as principals, any profits received
  by such broker-dealers on the resale of the Shares, may be deemed to be underwriting discounts or commissions under the Securities
  Act. In addition, any profits realized by the Selling Stockholders may be deemed to be underwriting commissions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock trades
  on The New York Stock Exchange (&ldquo;NYSE&rdquo;) under the symbol &ldquo;DNMR.&rdquo; On March 9, 2021, the last reported sale
  price of our shares on the NYSE was $34.58 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please refer
  to &ldquo;Risk Factors&rdquo; beginning on page 1 for a description of the risks you should consider when evaluating this investment.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B>&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
  and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
  prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is March 10,
  2021</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information
  included in or incorporated by reference into this prospectus or information we have referred to in this prospectus. We have not
  authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell
  these securities. This prospectus is not an offer to sell, or a solicitation of an offer to buy, in any state where the offer or
  sale is prohibited. The information in this prospectus is accurate on the date of this prospectus and may become obsolete later.
  Neither the delivery of this prospectus, nor any sale made under this prospectus will, under any circumstances, imply that the
  information in this prospectus is correct as of any date after the date of this prospectus. References to &ldquo;the Company,&rdquo;
  &ldquo;Danimer,&rdquo; &ldquo;we&rdquo; or &ldquo;us&rdquo; refer to Danimer Scientific, Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-bottom: 1.5pt; width: 93%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 7%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_001"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">THE COMPANY</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">SELLING STOCKHOLDERS</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF COMMON STOCK</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 6; Options: NewSection -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>RISK FACTORS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>You should carefully consider the risk
  factors set forth below as well as the other information contained or incorporated by reference in this prospectus before investing
  in our Common Stock. Any of the following risks could materially and adversely affect our business, financial condition or results
  of operations. In such a case, you may lose all or part of your investment. The risks described below are not the only risks facing
  us. Additional risks and uncertainties not currently known to us or those we currently view to be immaterial may also materially
  adversely affect our business, financial condition or results of operations.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Company</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have a history of net losses and
  our future profitability is uncertain.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have recorded a loss
  for the fiscal year ended December 31, 2019, and our future profitability is uncertain. At December 31, 2019, our accumulated deficit
  was approximately $49.1 million. Since our inception, we have been engaged primarily in research and development and early-stage
  commercial activities. Because we have a limited history of commercial operations and we operate in a rapidly evolving industry,
  we cannot be certain that we will generate sufficient revenue to operate our business and become profitable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our ability to generate
  revenues in the near-term is highly dependent on the successful commercialization of our biopolymer products, which is subject
  to many risks and uncertainties as described below. We expect that it will take time for our PHA production to ramp up to an economical
  scale while the market for our products expands. As a result, we expect to have significant losses and negative cash flow for at
  least the next several years, as we incur additional costs and expenses for the continued development and expansion of our business,
  including the costs of establishing manufacturing capacity and ongoing expenses of research and product development. The amount
  we spend will impact our ability to become profitable and this will depend, in part, on the number of new products that we attempt
  to develop. We may not achieve any or all of these goals and, thus, we cannot provide assurances that we will ever be profitable
  or achieve significant revenues.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Even if we can successfully
  manufacture and sell our products, whether we will be able to generate a profit on any of these products is highly uncertain and
  depends on a number of factors including the cost of production, the price we are able to charge for these products, and the emergence
  of competing products.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our operating results may fluctuate
  significantly as a result of a variety of factors, many of which are outside of our control.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are subject to, among
  other things, the following factors that may negatively affect our operating results:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the announcement or introduction of new products by
  our competitors;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to upgrade and develop our systems and
  infrastructure to accommodate growth;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to attract and retain key personnel in
  a timely and cost-effective manner;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to attract new customer and retain existing
  customers;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">technical difficulties;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the amount and timing of operating costs and capital
  expenditures relating to the expansion of our business, operations and infrastructure;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to identify and enter into relationships
  with appropriate and qualified third-party providers of necessary testing and manufacturing services;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">regulation by federal, state or local governments;
  and</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general economic conditions, as well as economic conditions
  specific to the plastics industry, and other industries related to compostable or biodegradable substitutes for non-biodegradable
  plastics.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As a result of our limited
  operating history and the nature of the markets in which we compete, it is difficult for us to forecast our revenues or earnings
  accurately. We have based our anticipated future expense levels largely on our investment plans and estimates of future events,
  although certain of our expense levels will, to a large extent, become fixed. As a strategic response to changes in the competitive
  environment, we may from time to time make certain decisions concerning expenditures, pricing, service or marketing that could
  have a material and adverse effect on our business, results of operations and financial condition. Due to the foregoing factors,
  our revenues and operating results are difficult to forecast.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 7; Options: NewSection -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to secure additional
  funding and may be unable to raise additional capital on favorable terms, if at all.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We expect that we will
  have sufficient capital to fund our planned operations through the completion of Phase II of the production capacity buildout at
  the Kentucky Facility and anticipated Greenfield plant. Thereafter, we will need to raise additional capital to continue to scale
  and expand our manufacturing&nbsp;capability. If we issue equity or debt securities to raise additional funds, (i) we may incur
  fees associated with such issuance, (ii) our existing stockholders will experience dilution from the issuance of new equity securities,
  (iii) we may incur ongoing interest expense and be required to grant a security interest in our assets in connection with any debt
  issuance and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of our existing
  stockholders. In addition, utilization of our net operating loss and research and development credit carryforwards may be subject
  to significant annual limitations under Section 382 of the Code due to ownership changes resulting from future equity financing
  transactions. If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary
  to relinquish valuable rights to our potential products or proprietary technologies, or grant licenses on terms that are not favorable
  to us. In the event we are unable to obtain additional financing, we may be unable to successfully implement our business plan,
  which could have a material and adverse impact on our business, including you losing your entire investment.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our biopolymer products may not achieve
  market success.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We currently have limited
  customer commitments for commercial quantities of our biopolymer products. Some prospective customers are currently evaluating
  and testing our products prior to making large-scale purchase decisions. The successful commercialization of our biopolymers is
  also dependent on our customers&rsquo; ability to commercialize the end-products that they make from our biopolymers, which may
  never gain market acceptance.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Market acceptance of
  our products will depend on numerous factors, many of which are outside of our control, including among others:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">public acceptance of such products;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to produce products of consistent quality
  that offer functionality comparable or superior to existing or new polymer products;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to produce products fit for their intended
  purpose;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to obtain necessary regulatory approvals
  for our products;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the speed at which potential customers qualify our
  biopolymers for use in their products;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the pricing of our products compared to competitive
  products, including petroleum-based plastics;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the strategic reaction of companies that market competitive
  products;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our reliance on third parties who support or control
  distribution channels; and</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general market conditions.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We produce bio-based products from
  renewable resources, whose pricing and availability may be impacted by factors out of our control.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Pricing and availability
  of raw materials, including renewable resources, for use in our businesses can be volatile due to numerous factors beyond our control,
  including general, domestic and international economic conditions, labor costs, production levels, competition, consumer demand.
  Drought, pestilence, severe weather or other &ldquo;acts of God&rdquo; may limit our ability to procure raw materials if crops
  are lost. This volatility can significantly affect the availability and cost of raw materials for us, and may therefore have a
  material adverse effect on our business, results of operations and financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We sell formulated resins
  which include raw materials purchased from third parties, including PLA. We currently source all of our PLA from two suppliers,
  NatureWorks LLC and Total Corbion PLA. Due to the high rate of growth in the biopolymer market, the demand for PLA and other raw
  materials used in our products may outpace supply, which could result in price increases and deficits in the supply necessary to
  meet customer demand. If we are unable to secure the required quantities of PLA and other third-party raw materials, we may not
  be able to achieve our financial forecasts and fulfill customer demand.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our products and product candidates
  do not gain market acceptance among key market participants, we may be unable to generate significant revenues, if any.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Even if we obtain regulatory
  approval for our product candidates, they may not gain market acceptance among plastics manufacturers or other plastic users. Market
  acceptance will depend on our ability to demonstrate the benefits of our approved products in terms of safety, efficacy, convenience,
  biodegradability and environmental friendliness, ease of administration and cost effectiveness. In addition, we believe market
  acceptance depends on the effectiveness of our marketing strategy and the pricing of our approved products.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 8 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited experience producing
  PHA in large commercial quantities.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have limited experience
  in producing large quantities of PHA. While we have succeeded in producing smaller amounts of PHA in our pilot plant for customer
  trials and testing purposes, we only recently commenced the production of PHA in a large commercial plant with a capacity sufficient
  to meet the anticipated needs of prospective customers. We may not be able to cost effectively produce PHA at a scale consistent
  with customer demand in a timely or economical manner, or that the quality of the commercial product will be acceptable on a consistent
  basis. Further, if the Kentucky Facility is not able to meet customer demands, we will have to expand our facility, which will
  disrupt production and deplete our resources.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Some of our PHA products may never
  become commercially marketable.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Although we do currently
  sell commercial quantities of compostable PLA-based resins, we only recently commenced producing commercially viable quantities
  of PHA. Limited research and testing have been completed on some of the products that we may produce using PHA. For some applications,
  we will have to go through extensive research and testing to develop specific products and to determine or demonstrate the safety
  and effectiveness of their proposed use. Although we have already received food contact approval for some grades of PHA, some of
  our product candidates and our proposed testing of those products will require additional regulatory approvals and clearances.
  Accordingly, not all of the products we intend to pursue are presently marketable in the fields of use for which we hope to develop
  them, and it is possible (or even probable) that some or all of them may never become legally and commercially marketable. The
  development and testing of our proposed products is difficult, time-consuming and expensive, and the successful development of
  any products based on innovative technologies is subject to inherent uncertainties and risks of failure. These risks include the
  possibilities that any or all of the proposed products or procedures may be found to be ineffective, or may otherwise fail to receive
  necessary regulatory clearances; that the proposed products or procedures may be uneconomical to produce and market or may never
  achieve broad market acceptance; that third parties may hold proprietary rights that preclude us from marketing our intended products
  or procedures; or that third parties may develop and market superior or equivalent products and procedures.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to obtain certifications
  required by certain customers.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Many of our customers
  require biopolymer formulations to undergo biodegradability testing to address physical property deterioration in specific environmental
  conditions. Biodegradation certification is important for our customers to ensure those products can be effectively marketed and
  sold and meet customer demands on environmental protection. If our new PHA based resins to be sold out of the Kentucky Facility
  don&rsquo;t achieve the required certifications in a timely manner, we may experience a delay in going to market. Such a delay
  could result in us not achieving our financial forecasts and not fulfilling customer demand.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to manage rapid
  growth effectively.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our failure to manage
  growth effectively could have a material and adverse effect on our business, results of operations and financial condition. We
  anticipate that a period of significant expansion will be required to address potential growth and to handle licensing and research
  activities. This expansion will place a significant strain on our management, operational and financial resources. To manage the
  expected growth of our operations and personnel, we must establish appropriate and scalable operational and financial systems,
  procedures and controls and must establish a qualified finance, administrative and operations staff. Our management may be unable
  to hire, train, retain and manage the necessary personnel or to identify, manage and exploit potential strategic relationships
  and market opportunities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be delayed in or unable to
  procure necessary capital equipment.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">While the equipment
  we use to produce PHA and our other products is currently widely available, we must rely on outside companies to continue to manufacture
  the equipment necessary to produce our products. If our suppliers of capital equipment are unable or unwilling to provide us with
  necessary capital equipment to manufacture our products or if we experience significant delays in obtaining the necessary manufacturing
  equipment, our business, results of operations and financial condition could be adversely affected.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our success will be influenced by
  the price of petroleum relative to the price of bio-based feedstocks.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our success may be influenced
  by the cost of our products relative to petroleum-based polymers. The cost of petroleum-based polymers is in part based on the
  price of petroleum. To date, our PHA biopolymers have been primarily manufactured using canola oil, an agricultural feedstock.
  As the price of biobased feedstocks increases and/or the price of petroleum decreases, our biobased products may be less competitive
  relative to petroleum-based polymers. A material decrease in the cost of conventional petroleum-based polymers may require a reduction
  in the prices of our products for them to remain attractive in the marketplace and/or reduce the size of our addressable market.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 9 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain contracts granting exclusivity
  rights to customers may limit our ability to sell products in certain markets.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have entered into
  certain agreements with customers, which, subject to the terms therein, grant these customers the exclusive right to purchase certain
  products and, in some cases, in certain fields and/or territories from us. For example, certain clam-shell food cases we produce
  can only be sold to a single customer; certain stirrers and straw products can only be sold to several end-users, subject to the
  purchaser maintaining minimum purchase requirements; one customer has an exclusive on water bottles, while another customer has
  an exclusive on bottles containing certain alcohol products. These exclusivity arrangements will expire between 2021 and 2026.
  These agreements could prevent us from selling products to certain prospective customers or entering certain markets, which could
  have a material and adverse impact on our potential revenues and our ability more generally to expand our customer base and product
  lines.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The loss of one or more of our significant
  customers, a significant reduction in their orders, their inability to perform under their contracts, or a significant deterioration
  in their financial condition could have a material adverse effect on our business, results of operations, and financial condition.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">A few significant customers
  have in the past, and may in the future, account for a significant portion of our revenues in any one year or over a period of
  several consecutive years. For example, for the nine months ended September 30, 2020, we had two customers that individually accounted
  for more than 10% of our revenue each and collectively accounted for approximately 53% of our revenue, and for the year ended December
  31, 2019, we had four customers that individually accounted for more than 10% of our revenue each and collectively accounted for
  approximately 65% of our total revenue. The loss of one or more of our significant customers, a substantial reduction in their
  orders, their inability to perform under their contracts, or a significant deterioration in their financial condition could have
  a material adverse effect on our business, results of operations, and financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may rely heavily on future collaborative
  partners.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may enter into strategic
  partnerships to develop and commercialize our current and future research and development programs with other companies to accomplish
  one or more of the following:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">obtain capital, equipment and facilities,</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">obtain funding for research and development programs,
  product development programs and commercialization activities,</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">obtain expertise in relevant markets,</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">obtain access to raw materials and/or</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">obtain sales and marketing services or support.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may not be successful
  in establishing or maintaining suitable partnerships, and we may not be able to negotiate collaboration agreements having terms
  satisfactory to us or at all. Failure to make or maintain these arrangements or a delay or failure in a collaborative partner&rsquo;s
  performance under any such arrangements could have a material adverse effect on our business and financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face and will face substantial
  competition.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We face and will face
  substantial competition from a variety of companies in the biodegradable, renewable resource-based plastic segment, as well as
  from companies in the conventional, non-biodegradable petroleum-based industry segment. Some of their products are suitable for
  use in a range of products at a price which may be lower than our product offerings. Many of these companies have longer operating
  histories, greater name recognition, larger customer bases and significantly greater financial, sales and marketing, manufacturing,
  distribution, technical and other resources than us. Our competitors may be able to adapt more quickly to new or emerging technologies,
  changes in customer requirements and changes in laws and regulations. In addition, current and potential competitors have established
  or may establish financial or strategic relationships among themselves or with existing or potential customers or other third parties.
  Accordingly, new competitors or alliances among competitors could emerge and rapidly acquire significant market share. There can
  be no assurance that we can develop products that are more effective or achieve greater market acceptance than competitive products,
  or that our competitors will not succeed in developing products and technologies that are more effective than those being developed
  by us and that would therefore render our products and technologies less competitive or even obsolete. We cannot assure you that
  we will be able to compete successfully against current or new competitors.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to complete either
  or both phases of the proposed production capacity buildout at our Kentucky Facility.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In December 2018, we
  consummated the acquisition of the Kentucky Facility, including the equipment, machinery and other personal property located at
  such facility for a purchase price of $23 million, and simultaneously entered into a sale and leaseback transaction with a large,
  diversified commercial property REIT (the &ldquo;REIT&rdquo;) pursuant to which we sold the Kentucky Facility and certain of our
  facilities located in Bainbridge, Georgia to the REIT and leased-back the same properties from the REIT under a net-lease for an
  initial term of 20 years with renewal terms up to an additional 20 years at our option. The assets available at the Kentucky Facility
  permitted us to embark on a two-phase commissioning strategy, and we commenced production of commercial volumes of PHA in December
  2019. Several components of the first phase of the production capacity buildout were completed at the end of the third quarter
  of 2020 after investing approximately $54 million since the acquisition of the Kentucky Facility, excluding capitalized interest.
  Of this total, $7 million in real-estate improvements for the Kentucky Facility were financed by the REIT and leased back to us
  in May 2020. Once Phase I of the Kentucky Facility production capacity is operating at scale, we expect to produce approximately
  20 million pounds of finished product per year. We believe that the capacity of the plant can be expanded by another 45 million
  additional pounds of finished product, bringing total plant capacity up to approximately 65 million pounds per year, by investing
  another $100 million in the future for the Phase II production capacity buildout at such facility. There can be no assurances,
  though, that we will be able to achieve such production capacity or raise the additional financing required to complete Phase II
  of the production capacity buildout.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 10 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to identify additional
  facilities and assets or secure the funding necessary to acquire them.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Aside from the Kentucky
  Facility, we may need to identify other facilities and assets that would be beneficial to our production of PHA at the commercial
  scale or our growth in general. We cannot provide assurances that we will be successful in identifying such facilities and assets
  or, if we do, securing the funding necessary to acquire them.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Climate Change may impact the availability
  of our facilities and, in addition, we may incur substantial costs to comply with climate change legislation and related regulatory
  initiatives.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Changing weather patterns
  and the increase in frequency of severe storms such as hurricanes and tornadoes could cause disruptions or the complete loss of
  our facilities. In addition, climate change concerns, and changes in the regulation of such concerns, including greenhouse gas
  emissions, could also subject us to additional costs and restrictions, including increased energy and raw materials costs which
  could negatively impact our financial condition and results of operations. The effects of climate change can have an adverse effect
  not only to our operations, but also that of our suppliers and customers, and can lead to increased regulations and changes in
  consumer preferences, which could adversely affect our business, results of operations and financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to product liability
  claims that may not be covered by insurance and could require us to pay substantial sums.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If we are successful
  in obtaining regulatory approval for our products and/or otherwise begin marketing them, we will become subject to an inherent
  risk of, and adverse publicity associated with, product liability and other liability claims, whether or not such claims are valid.
  We intend to obtain product liability insurance coverage in amounts and scope that we believe will be adequate once we begin marketing
  any products. However, product liability insurance may not be available on commercially acceptable terms, or at all. Even if such
  insurance is available, product liability or other claims may exceed our insurance coverage limits. A successful product liability
  claim that exceeds our insurance coverage limits could require us to pay substantial sums and could have a material adverse effect
  on us.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in government regulations
  encouraging the use of biodegradable alternatives to plastic products may have an adverse effect on our business.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We anticipate one of
  the key markets for our products being compostable and biodegradable substitutes for non-biodegradable plastics, which are created
  in part by laws, regulations and policies designed to encourage or mandate the increased use of compostable and biodegradable
  alternatives to plastics. Several countries and other political subdivisions of countries have enacted or are considering enacting
  such laws and regulations. Failure to implement these or similar laws and regulations and changes to existing laws and regulations
  may adversely affect the demand for our product candidates in the future.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to protect adequately
  our patents and other intellectual property assets, which could adversely affect our competitive position and reduce the value
  of our products, and litigation to protect our patents and intellectual property assets may be costly.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our commercial success
  may depend in part on our ability to obtain patent protection for technologies and products we develop, to preserve trade secrets
  and to operate without infringing the proprietary rights of others. There can be no assurance that any patents or patent applications
  that we own, obtain or file or are able to obtain or license from third parties will afford any competitive advantages or will
  not be challenged or circumvented by third parties. Furthermore, there can be no assurance that others will not independently develop
  similar technologies or duplicate any technology developed by us. Because of the extensive time required for development, testing
  and regulatory review of a potential product, it is possible that before any of our potential products can be commercialized, any
  related patents may expire or may have only a brief remaining life span following commercialization, thus reducing any advantage
  of the patents.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If we are not able to
  obtain patent coverage or defend the patent protection for our technologies, then we will not be able to exclude competitors from
  developing or marketing competing technologies, and we may not generate enough revenues from product sales to justify the cost
  of development of our technologies and to achieve or maintain profitability. The patents currently in the portfolio have expiration
  dates ranging from 2022 to 2040 and any patents resulting from pending patent applications are expected to have durations that
  will expire between 2038 and 2041.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 11 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our patent position
  involves complex legal and factual questions. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced
  in our patents or in third-party patents. Patents may not be issued for any pending or future pending patent applications owned
  by or licensed to us, and claims allowed under any issued patent or future issued patent owned or licensed by us may not be valid
  or sufficiently broad to protect our technologies. Moreover, we may be unable to protect certain of our intellectual property in
  the United States or in foreign countries. Foreign jurisdictions may not afford the same protections as U.S. law, and we cannot
  ensure that foreign patent applications will have the same scope as the U.S. patents. There will be many countries in which we
  will choose not to file or maintain patents because of the costs involved. Competitors may also design around our technology or
  develop competing technologies.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Additionally, any issued
  patents owned by or licensed to us now or in the future may be challenged, invalidated or circumvented. To the extent competitors
  or other third parties develop and market products or procedures that we believe infringe our patents and proprietary rights, we
  may be compelled to initiate lawsuits to protect and enforce our intellectual property rights. Such litigation is typically expensive,
  time-consuming and uncertain as to outcome, and may involve opponents who have much more extensive financial resources than we
  do. An unfavorable outcome of any such litigation could have a material adverse effect on our business and results of operations.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may claim that we infringe
  on their proprietary rights and may prevent us from commercializing and selling our products.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">There has been substantial
  litigation in the manufacturing industry with respect to the manufacture, use and sale of new products. These lawsuits often involve
  claims relating to the validity of patents supporting the new products and/or the validity and alleged infringement of patents
  or proprietary rights of third parties. We may be required to defend against challenges to the validity of our patents and against
  claims relating to the alleged infringement of patent or proprietary rights of third parties.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Litigation initiated
  by a third-party claiming patent invalidity or patent infringement could:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">require us to incur substantial litigation expense,
  even if we are successful in the litigation;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">require us to divert significant time and effort of
  our management;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">result in the loss of our rights to develop, manufacture
  or market our products; and</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">require us to pay substantial monetary damages or
  royalties in order to license proprietary rights from third parties or to satisfy judgments or to settle actual or threatened
  litigation.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Although patent and
  intellectual property disputes within the biopolymer industry have often been settled through licensing or similar arrangements,
  costs associated with these arrangements may be substantial and could include the long-term payment of royalties. Furthermore,
  the required licenses may not be made available to us on acceptable terms. Accordingly, an adverse determination in a judicial
  or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing and selling our products
  or increase our costs to market our products.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely in part on trade secrets
  to protect our technology, and our failure to obtain or maintain trade secret protection could limit our ability to compete.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We rely on trade secrets
  to protect some of our technology and proprietary information, especially where we believe patent protection is not appropriate
  or obtainable. However, trade secrets are difficult to protect. Litigating a claim that a third party had illegally obtained and
  was using our trade secrets would be expensive and time consuming, and the outcome would be unpredictable. Moreover, if our competitors
  independently develop similar knowledge, methods and know-how, it will be difficult for us to enforce our rights and our business
  could be harmed.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to generate sufficient
  cash to service all of our debt and operating lease obligations, and may be forced to take other actions to satisfy our obligations
  under our debt and operating lease obligations, which may not be successful.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our ability to make
  scheduled payments on or to refinance our debt service and operating lease obligations and other obligations depends on our ability
  to generate cash in the future and our financial condition and operating performance, which are subject to prevailing economic
  and competitive conditions and to certain financial, business and other factors beyond our control. We cannot assure you that we
  will maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and
  interest on our debt, or to pay our operating lease obligations. As of September 30, 2020, we had principal and interest payments
  on debt due in the next twelve months of $12.3 million and $3.1 million, respectively.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 12 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If our cash flows and
  capital resources are insufficient to fund our debt service, operating lease obligations and other obligations, we may be forced
  to reduce or delay investments and capital expenditures, or to sell assets, seek additional capital or restructure or refinance
  our debt.&nbsp; These alternative measures may not be successful and may not permit us to meet our scheduled debt obligations.&nbsp;
  If our operating results and available cash are insufficient to meet our debt service, operating lease obligations and other obligations,
  we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt
  service and other obligations.&nbsp; We may not be able to consummate those dispositions or to obtain the proceeds sought from
  them, and these proceeds may not be adequate to meet any debt service or other obligations then due.&nbsp; Further, we may need
  to refinance all or a portion of our debt on or before maturity, and we cannot assure you that we will be able to refinance any
  of our debt on commercially reasonable terms or at all. Additionally, if we are unable to service our operating lease payments
  for our facilities in Bainbridge, Georgia and Winchester, Kentucky, which we lease pursuant to a sale-leaseback transaction that
  was entered into in 2018 with a commercial property REIT, we could lose the ability to occupy and operate those facilities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Despite our current significant indebtedness,
  we may be able to incur more debt in the future, which could further exacerbate the risks of leverage, including the ability to
  service our indebtedness.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may need to incur
  additional debt in the future to complete acquisitions of facilities, equipment, machinery and other assets or capital projects
  or for working capital. Although the covenants contained in our current indebtedness instruments may impose some limits on our
  ability to incur new debt, these agreements may permit the incurrence of significant additional debt if we satisfy certain conditions
  or such debt instruments may be amended in the future to do so. If we incur new debt, the risks related to being in a highly leveraged
  company that we now face could intensify, including our ability to service such indebtedness.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to a number of restrictive
  debt covenants under our loan agreements</I></B><I>.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Many of our loan agreements
  contain certain restrictive covenants, which restrict our ability to, among other things, incur additional indebtedness, incur
  certain liens on our assets or sell assets, make investments, make capital expenditures, pay dividends and make other restricted
  payments. Many of our loan agreements also require us to maintain specified financial ratios under certain conditions and satisfy
  financial condition tests, including a consolidated senior leverage ratio and consolidated fixed charge coverage ratio.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our ability to meet
  those financial ratios and tests and otherwise comply with our financial covenants may be affected by the factors described herein
  and other factors outside our control, and we may not be able to meet those ratios, tests and covenants. Our ability to generate
  sufficient cash from operations to meet our debt obligations will depend upon our future operating performance, which will be affected
  by general economic, financial, competitive, business and other factors beyond our control. A breach of any of these covenants,
  ratios, tests or restrictions, as applicable, or any inability to pay interest on, or principal of, our outstanding debt as it
  becomes due could result in an event of default. Upon an event of default, if not waived by our lenders, our lenders may declare
  all amounts outstanding as due and payable. Such an acceleration of the maturity of our indebtedness may, among other things, prevent
  or limit us from engaging in transactions that benefit us, including responding to changing business and economic conditions and
  taking advantage of attractive business opportunities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to satisfy the
  requirements of our participation in a New Markets Tax Credit (&ldquo;NMTC&rdquo;) program for funding our plant expansions.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have entered into
  several arrangements under the NMTC program with various third-party financial institutions (the &ldquo;Investors&rdquo;) to help
  fund various phases of plant expansions at our Bainbridge, Georgia, and Winchester, Kentucky locations. In connection with the
  NMTC transactions we received proceeds which were restricted for use on approved capital expenditures and working capital needs
  at specific subsidiaries. The NMTCs are subject to 100% recapture of the tax credit for a period of seven years as provided in
  the Code. We are required to be in compliance with various regulations and contractual provisions that apply to the NMTC arrangements.
  we have agreed to indemnify the Investors for any loss or recapture of the NMTCs until such time as our obligation to deliver tax
  benefits is relieved. The maximum potential amount of future payments under this indemnification could be up to the face amount
  of the related debt, net of certain leverage loans receivable in connection with the NMTC transactions, which amount totaled $13.2
  million as of September 30, 2020. Our obligation to deliver tax benefits is relieved in various stages from April 2026 through
  November 2026. Non-compliance with applicable requirements could result in projected tax benefits not being realized by an Investor
  and our being required to indemnify such Investor, which could have a material adverse effect on our financial position, results
  of operations or liquidity.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 13 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to obtain forgiveness
  of the PPP Loan, in whole or in part, in accordance with the provisions of the CARES Act, which could adversely affect our financial
  condition.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In April 2020, we entered
  into a promissory note with Truist Bank (&ldquo;Truist&rdquo;), under the Paycheck Protection Program of the CARES Act pursuant
  to which Truist made a loan to us in the amount of approximately $1.8 million (the &ldquo;PPP Loan&rdquo;). The PPP Loan matures
  in April 2022, bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months
  after the date of disbursement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The PPP Loan is unsecured
  and guaranteed by the Small Business Administration (&ldquo;SBA&rdquo;). Under the terms of the PPP Loan, the principal amount
  of the loan may be forgiven to the extent it is used for qualifying expenses as described in the CARES Act and we otherwise request
  forgiveness in accordance with the terms of the PPP Loan and the requirements of the SBA. While we expect to request that all of
  the principal amount of the PPP Loan be forgiven and to comply with all corresponding requirements, we cannot guarantee that we
  will be successful in obtaining forgiveness of all or any part of such principal amount. We will be required to repay any principal
  amount of the PPP Loan that is not forgiven, together with accrued and unpaid interest. In connection with the closing of the Business
  Combination, we deposited funds in an escrow account in an amount to repay the outstanding principal and accrued interest on the
  PPP loan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to use net operating
  losses to offset future taxable income will be subject to certain limitations as a result of the Business Combination, PIPE and
  past transactions.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As of December 31, 2019,
  we had federal net operating loss carryforwards of $48.0 million of which $47 million will begin to expire in 2028 and $1 million
  can be carried forward indefinitely. As of December 31, 2019, we had state net operating loss carryforwards of $45 million which
  begin to expire in various amounts in 2028.&nbsp; We may have generated additional net operating losses since then. A portion of
  these net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition,
  in general, under Section 382 of the Code, a corporation that undergoes an &ldquo;ownership change&rdquo; is subject to limitations
  on its ability to utilize its pre-change net operating losses (&ldquo;NOLs&rdquo;) to offset future taxable income or taxes. For
  these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups
  of stockholders who owns at least 5% of a corporation&rsquo;s stock increases its ownership by more than 50 percentage points over
  its lowest ownership percentage within a specified testing period. A portion of our existing NOLs are subject to limitations arising
  from previous ownership changes in 2014. In addition, the Business Combination and the PIPE is expected to constitute an ownership
  change under Section 382 of the Code. Our NOLs may also be impaired under state law. A portion of our existing NOLs are also subject
  to the so called separate-return-limitation-year (&ldquo;SRLY&rdquo;) rules that may apply to consolidated tax groups. Although
  depending on applicable law and particular computations, it is expected that the amount of our NOLs that we will be able to utilize
  per year could be only up to $3.8 million per year. Accordingly, we may not be able to utilize a material portion of our NOLs.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Company&rsquo;s
  ability to utilize our NOLs is also conditioned upon our attaining profitability and generating U.S. federal and state taxable
  income. We have incurred significant net losses in the past, and it is anticipated that we will continue to incur significant losses
  for the foreseeable future; therefore, we do not know whether or when we will generate the U.S. federal or state taxable income
  necessary to utilize our NOL carryforwards, even to the extent they are not subject to limitation by Section&nbsp;382 of the Code
  or the SRLY rules.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face various risks related to
  the ongoing coronavirus (COVID-19) pandemic and similar public health crises, which may have material adverse effects on our business,
  financial position, results of operations and/or liquidity.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We face various risks
  related to health epidemics, pandemics and similar outbreaks, including the global outbreak of coronavirus disease 2019 (&ldquo;COVID-19&rdquo;).
  Such risks include disruptions or restrictions on our employees&rsquo; ability to work effectively, as well as temporary closures
  of our facilities or the facilities of our customers or suppliers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">It is possible that
  the continued spread of COVID-19 could also further cause disruption in our supply chain; cause delay or limit the ability of other
  customers to perform, including in making timely payments to us; and, cause other unpredictable events. In addition, the continued
  spread of COVID-19 has led to disruption and volatility in the global capital markets, which increases the cost of capital and
  adversely impacts access to capital.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 14 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We continue to work
  with our stakeholders (including customers, employees, suppliers and local communities) to responsibly address this global pandemic.
  Our management is focused on mitigating the impact of the pandemic, which has required and will continue to require a substantial
  investment of time and resources across Danimer and could delay other value-added initiatives. We continue to monitor the situation,
  to assess further possible implications to our business, supply chain and customers, and to take actions in an effort to mitigate
  adverse consequences.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The situation surrounding
  COVID-19 remains fluid and the ongoing impact on our business and results of operations, financial condition, expected cash flows
  and liquidity increases the longer the virus impacts activity levels in the United States and globally, both during the initial
  outbreak, as well as if additional outbreaks occur at a later date. For this reason, we cannot reasonably estimate with any degree
  of certainty the future impact COVID-19 may have on our results of operations, financial position and liquidity. The extent to
  which the COVID-19 pandemic may impact our business, operating results, financial condition or liquidity will depend on future
  developments and numerous and evolving factors that are highly uncertain, vary by market and cannot be accurately predicted or
  quantified at this time, including the duration and spread of the outbreak; new information concerning its transmission and severity;
  government mandated restrictions and regulations; business and workforce disruptions; impact on demand for our products, and the
  effectiveness of actions taken to contain and treat the disease; actions taken or that might be taken by governments, businesses
  or individuals to contain or reduce its repercussions and mitigate its economic implications; evolving macroeconomic factors, including
  general economic uncertainty, unemployment rates and recessionary pressures; decreased consumer spending levels; reduction or changes
  in customer demand for our products and services; our ability to manufacture, sell and provide our products and services, including
  as a result of travel restrictions, closed borders, operating restrictions imposed on our facilities or reduced ability of our
  employees to continue to work efficiently; increased operating costs (whether as a results of changes to our supply chain or increases
  in employee costs or otherwise); collectability of customer accounts; additional and prolonged devaluation of other countries&rsquo;
  currencies relative to the dollar; and the general impact of the pandemic on our customers, employees, suppliers, vendors and other
  stakeholders. Additionally, customers might defer decision making, delay orders or seek to renegotiate or terminate existing agreements.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The continuing global
  pandemic may also result in delays in our ability to apply for and obtain further regulatory approval for our products in various
  jurisdictions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The impact of COVID-19
  may also exacerbate other risks discussed herein, any of which could have a material effect on us. This situation is changing rapidly,
  and additional impacts may arise that we are not aware of currently.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on key personnel</I></B><I>.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We depend greatly on
  our executive officers and other employees. Our success will depend, in part, upon our ability to attract and retain additional
  skilled personnel, which will require substantial additional funds. There can be no assurance that we will be able to find, attract
  and retain additional qualified employees, directors, and advisors having the skills necessary to operate, develop and grow our
  business. Our inability to hire qualified personnel, the loss of services of any of our executive officers, or the loss of services
  of other key employees, or advisors that may be hired in the future, may have a material and adverse effect on our business.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we experience a significant disruption
  in our information technology systems, including security breaches, or if we fail to implement new systems and software successfully,
  our business operations and financial condition could be adversely affected.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We depend on information
  technology systems throughout Danimer to, among other functions, control our manufacturing processes, process orders and bill,
  collect and make payments, interact with customers and suppliers, manage inventory and otherwise conduct business. We also depend
  on these systems to respond to customer inquiries, contribute to our overall internal control processes, maintain records of our
  property, plant and equipment and record and pay amounts due to vendors and other creditors. The failure of our information technology
  systems to perform as we anticipate could disrupt our business and could result in transaction errors, processing inefficiencies
  and the loss of sales and customers. As we upgrade or change systems, we may also experience interruptions in service, loss of
  data or reduced functionality and other unforeseen material issues which could adversely impact our ability to provide quotes,
  take customer orders and otherwise run our business in a timely manner. In addition, if our new systems fail to provide accurate
  and increased visibility into pricing and cost structures, it may be difficult to improve or maximize our profit margins. As a
  result, our results of operations could be adversely affected.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, cyber-attacks
  or security breaches could compromise confidential, business critical information, cause a disruption in our operations or harm
  our reputation. Our information technology systems are subject to potential disruptions, including significant network or power
  outages, cyberattacks, computer viruses, other malicious codes and/or unauthorized access attempts, any of which, if successful,
  could result in data leaks or otherwise compromise our confidential or proprietary information and disrupt our operations. Despite
  our efforts to protect sensitive information and comply with and implement data security measures, there can be no assurance that
  any controls and procedures that we have in place will be sufficient to protect us. Further, as cyber threats are continually evolving,
  our controls and procedures may become inadequate and we may be required to devote additional resources to modify or enhance our
  systems in the future. We may also be required to expend resources to remediate cyber-related incidents or to enhance and strengthen
  our cyber security. Any such disruptions to our information technology systems, breaches or compromises of data, and/or misappropriation
  of information could result in violation of privacy and other laws, litigation, fines, negative publicity, lost sales or business
  delays, any of which could have a material adverse effect on our business, financial condition or results of operations.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <!-- Field: Page; Sequence: 15 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Government regulation of our business
  is extensive and regulatory approvals are uncertain, expensive and time-consuming.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our research, development,
  testing, manufacturing and marketing of most of our intended products are subject to an extensive regulatory approval process by
  the FDA and other regulatory agencies in the U.S. and abroad. The process of obtaining FDA and other required regulatory approvals
  is lengthy, expensive and uncertain. There can be no assurance that, even after such time and expenditures, we will be able to
  obtain necessary regulatory approvals for the manufacturing or marketing of any products. Even if regulatory clearance is obtained,
  a marketed product is subject to continual review, and later discovery of previously unknown safety issues or failure to comply
  with the applicable regulatory requirements may result in restrictions on a product&rsquo;s marketing or withdrawal of the product
  from the market, as well as possible civil or criminal sanctions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in sentiment regarding and
  laws and regulations relating to plastic products could reduce demand for our products and/or increase the cost of producing our
  products and have an adverse effect on our business.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Plastic products have
  recently faced increasingly negative public sentiment and scrutiny. In addition, state and local governments have increasingly
  proposed, or in some cases implemented, restrictions or bans on plastic-based products, including single-use plastics, plastic
  straws and utensils. Notwithstanding the fact that our bio-plastic products are intended to address many of the concerns regarding
  traditional petroleum-based plastics, increased regulation of, or prohibition on, the use of plastics generally, as well as negative
  public sentiment regarding such products, could increase the costs incurred by our customers to use such products or otherwise
  limit the use of these products, and could lead to a decrease in demand for the products we make or an increase in the cost of
  production of such products. Such a decrease in demand could adversely affect our business, operating results and financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Common Stock</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>An active trading market for our
  Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. Our stock price may be
  extremely volatile, and our stockholders could lose a significant part of their investment.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">An active trading market
  for shares of our Common Stock may not be sustained on a consistent basis. The public trading price for our Common Stock will be
  affected by a number of factors, including:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">reported progress of our business and technology development,
  relative to investor expectations;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in earnings estimates, investors&rsquo; perceptions,
  recommendations by securities analysts or our failure to achieve analysts&rsquo; earnings estimates;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">quarterly variations in our or our competitors&rsquo;
  results of operations;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general market conditions and other factors unrelated
  to our operating performance or the operating performance of our competitors;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">future issuance and/or sale of our common stock or
  preferred stock;</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">announcements by us, or our competitors, of acquisitions,
  new products, significant contracts, commercial relationships or capital commitments;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">commencement of, or involvement in, litigation;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any major change in our board of directors or management;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in governmental regulations or in the status
  of our regulatory approvals;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">announcements related to patents issued to us or our
  competitors and to litigation involving our intellectual property;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a lack of, limited, or negative industry or security
  analyst coverage;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">developments in our industry and general economic
  conditions;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">short-selling or similar activities by third parties;
  and</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">other factors described elsewhere in these &ldquo;<I>Risk
  Factors</I>.&rdquo;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As a result of these
  factors, our stockholders may not be able to resell their shares of Common Stock at, or above, their purchase price. In addition,
  the stock prices of many technology companies have experienced wide fluctuations that have often been unrelated to the operating
  performance of those companies. Any negative change in the public&rsquo;s perception of the prospects of industrial biotechnology
  or &ldquo;clean technology&rdquo; companies could depress our stock price regardless of our results of operations. These factors
  may have a material adverse effect on the market price of our Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of ownership among
  our existing executive officers, directors and their affiliates may prevent new investors from influencing significant corporate
  decisions.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our executive officers
  and directors as a group beneficially own approximately 20.3% of our outstanding Common Stock. As a result, these shareholders
  will be able to exercise a significant level of control over all matters requiring stockholder approval, including the election
  of directors, any amendment of the amended and restated certificate of incorporation and approval of significant corporate transactions.
  This control could have the effect of delaying or preventing a change of control or changes in management and will make the approval
  of certain transactions difficult or impossible without the support of these shareholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <!-- Field: Page; Sequence: 16 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not expect to declare any dividends
  in the foreseeable future.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We do not anticipate
  declaring any cash dividends to holders of our common stock in the foreseeable future. Consequently, investors may need to rely
  on sales of their shares after price appreciation, which may never occur, as the only way to realize any future gains on their
  investment.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There can be no assurance that we
  will be able to comply with the continued listing standards of NYSE.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If NYSE delists our
  securities from trading on its exchange for failure to meet the listing standards, we and our securityholders could face significant
  material adverse consequences including:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a limited availability of market quotations for our
  securities;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a determination that our Common Stock is a &ldquo;penny
  stock&rdquo; which will require brokers trading in Common Stock to adhere to more stringent rules, possibly resulting in a reduced
  level of trading activity in the secondary trading market for shares of our Common Stock;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a limited amount of analyst coverage; and</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a decreased ability to issue additional securities
  or obtain additional financing in the future.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be required to take write-downs
  or write-offs, or we may be subject to restructuring, impairment or other charges that could have a significant negative effect
  on our financial condition, results of operations and the price of Common Stock, which could cause you to lose some or all of your
  investment.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Factors outside of our
  control may, at any time, arise. As a result of these factors, we may be forced to later write-down or write-off assets, restructure
  our operations or incur impairment or other charges that could result in us reporting losses.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Even though these charges
  may be non-cash items and therefore not have an immediate impact on our liquidity, the fact that we report charges of this nature
  could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may cause us to
  be unable to obtain future financing on favorable terms or at all.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not meet the expectations
  of investors or securities analysts, the market price of our securities may decline.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Fluctuations in the
  price of our securities could contribute to the loss of all or part of your investment. If an active market for our securities
  develops and continues, the trading price of our securities following could be volatile and subject to wide fluctuations in response
  to various factors, some of which are beyond our control. Any of the factors listed below could have a material adverse effect
  on your investment in our securities and our securities may trade at prices significantly below the price you paid for them. In
  such circumstances, the trading price of our securities may not recover and may experience a further decline.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Factors affecting the
  trading price of our securities may include:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated fluctuations in our quarterly
  financial results or the quarterly financial results of companies perceived to be similar to us;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in the market&rsquo;s expectations about our
  operating results;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">success of competitors;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our operating results failing to meet the expectation
  of securities analysts or investors in a particular period;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in financial estimates and recommendations
  by securities analysts concerning Danimer or the biopolymer industry in general;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">operating and share price performance of other companies
  that investors deem comparable to ours;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to market new and enhanced products and
  technologies on a timely basis;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in laws and regulations affecting our business;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to meet compliance requirements;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">commencement of, or involvement in, litigation involving
  us;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in our capital structure, such as future issuances
  of securities or the incurrence of additional debt;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the volume of our shares of common stock available
  for public sale;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any major change in our board of directors or management;</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">sales of substantial amounts of our shares of common
  stock by our directors, executive officers or significant stockholders or the perception that such sales could occur; and</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general economic and political conditions such as
  recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Broad market and industry
  factors may materially harm the market price of our securities irrespective of our operating performance. The stock market in general,
  and NYSE in particular, have experienced price and volume fluctuations that have often been unrelated or disproportionate to the
  operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities,
  may not be predictable. A loss of investor confidence in the market for stocks or the stocks of other companies which investors
  perceive to be similar to ours could depress our share price regardless of our business, prospects, financial conditions or results
  of operations. A decline in the market price of our securities also could adversely affect our ability to issue additional securities
  and our ability to obtain additional financing in the future.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 17 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur significant increased
  expenses and administrative burdens as a public company, which could have an adverse effect on our business, financial condition
  and results of operations.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We will face increased
  legal, accounting, administrative and other costs and expenses as a public company that we do not incur as a private company. The
  Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;), including the requirements of Section 404, as well as rules
  and regulations subsequently implemented by the SEC, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and
  the rules and regulations promulgated and to be promulgated thereunder, the PCAOB and the securities exchanges, impose additional
  reporting and other obligations on public companies. Compliance with public company requirements will increase costs and make certain
  activities more time-consuming. A number of those requirements will require us to carry out activities we have not done previously.
  For example, we will create new board committees and adopt new internal controls and disclosure controls and procedures. In addition,
  expenses associated with SEC reporting requirements will be incurred. Furthermore, if any issues in complying with those requirements
  are identified (for example, if the auditors identify a material weakness or significant deficiency in the internal control over
  financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely
  affect our reputation or investor perceptions of us. It may also be more expensive to obtain director and officer liability insurance.
  Risks associated with our status as a public company may make it more difficult to attract and retain qualified persons to serve
  on our board of directors or as executive officers. The additional reporting and other obligations imposed by these rules and regulations
  will increase legal and financial compliance costs and the costs of related legal, accounting and administrative activities. These
  increased costs will require us to divert a significant amount of money that could otherwise be used to expand the business and
  achieve strategic objectives. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance
  and reporting requirements, which could further increase costs.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to timely and effectively
  implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act could have a material adverse effect on
  our business.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The standards required
  for a public company under Section 404(a) of the Sarbanes-Oxley Act are significantly more stringent than those required of us
  as a privately-held company. Management may not be able to effectively and timely implement controls and procedures that adequately
  respond to the increased regulatory compliance and reporting requirements. If we are not able to implement the additional requirements
  of Section 404(a) in a timely manner or with adequate compliance, we may not be able to assess whether our internal controls over
  financial reporting are effective, which may subject us to adverse regulatory consequences and could harm investor confidence and
  the market price of our securities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We qualify as an &ldquo;emerging
  growth company&rdquo; within the meaning of the Securities Act, and if we takes advantage of certain exemptions from disclosure
  requirements available to emerging growth companies, it could make our securities less attractive to investors and may make it
  more difficult to compare our performance to the performance of other public companies.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We qualify as an &ldquo;emerging
  growth company&rdquo; as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we are eligible
  for and intend to take advantage of certain exemptions from various reporting requirements applicable to other public companies
  that are not emerging growth companies for as long as we continue to be an emerging growth company, including (a)&nbsp;the exemption
  from the auditor attestation requirements with respect to internal control over financial reporting under Section 404(b) of the
  Sarbanes-Oxley Act, (b) the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements and (c)
  reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We will remain an
  emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of Common Stock that
  are held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii) the last day of the fiscal year in which
  we have total annual gross revenue of $1.07 billion or more during such fiscal year (as indexed for inflation), (iii) the date
  on which we have issued more than $1 billion in non-convertible debt in the prior three-year period or (iv) the last day of the
  fiscal year following the fifth anniversary of the date of the first sale of Common Stock in the initial public offering of units
  of Live Oak Acquisition Corp., our predecessor, consummated on May 5, 2020. In addition, Section 107 of the JOBS Act also provides
  that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided
  in Section 7(a)(2)(B) of the Securities Act as long as we are an emerging growth company. An emerging growth company can therefore
  delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected
  not to opt out of such extended transition period and, therefore, we may not be subject to the same new or revised accounting standards
  as other public companies that are not emerging growth companies. Investors may find our Common Stock less attractive because we
  will rely on these exemptions, which may result in a less active trading market for our Common Stock and its price may be more
  volatile.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management has limited experience
  in operating a public company.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our executive officers
  have limited experience in the management of a publicly traded company. Our management team may not successfully or effectively
  manage our transition to a public company that will be subject to significant regulatory oversight and reporting obligations under
  federal securities laws. Their limited experience in dealing with the increasingly complex laws pertaining to public companies
  could be a significant disadvantage in that it is likely that an increasing amount of their time may be devoted to these activities
  which will result in less time being devoted to our management and growth. We may not have adequate personnel with the appropriate
  level of knowledge, experience and training in the accounting policies, practices or internal controls over financial reporting
  required of public companies in the United States. The development and implementation of the standards and controls necessary for
  us to achieve the level of accounting standards required of a public company in the United States may require costs greater than
  expected. It is possible that we will be required to expand our employee base and hire additional employees to support our operations
  as a public company which will increase our operating costs in future periods.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 18 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The loss of such key personnel could
  negatively impact the operations and financial results of our business.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our ability to successfully
  operate our business is dependent upon the efforts of certain key personnel of ours and there can be no assurance that they will
  be able to do so. It is possible that we will lose some key personnel, the loss of which could negatively impact our operations
  and profitability. Furthermore, certain of our key personnel may be unfamiliar with the requirements of operating a company regulated
  by the SEC, which could cause us to have to expend time and resources helping them become familiar with such requirements.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may issue additional shares of
  common stock or preferred shares under an employee incentive plan which would dilute the interest of our stockholders.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our Fourth Amended and
  Restated Certificate of Incorporation authorizes the issuance of 200,000,000 shares of Common Stock, and 10,000,000 shares of preferred
  stock, in each case, par value $0.0001 per share. We may issue a substantial number of additional shares of common stock or shares
  of preferred stock under an employee incentive plan. The issuance of additional common stock or preferred shares:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">may subordinate the rights of holders of Common Stock
  if one or more classes of preferred stock are created, and such preferred shares are issued, with rights senior to those afforded
  to Common Stock; and</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">could cause a change in control if a substantial number
  of shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards,
  if any, and could result in the resignation or removal of our present officers and directors.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Fourth Amended and Restated Certificate
  of Incorporation will provide, subject to limited exceptions, that the courts of the State of Delaware will be the sole and exclusive
  forum for certain stockholder litigation matters, which could limit our stockholders&rsquo; ability to obtain a favorable judicial
  forum for disputes with us or our directors, officers, employees or stockholders.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our Fourth Amended and
  Restated Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our
  name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions may be brought in
  the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal
  district court for the District of Delaware. Any person or entity purchasing or otherwise acquiring any interest in shares of our
  capital stock shall be deemed to have notice of and consented to the forum provisions in our Fourth Amended and Restated Certificate
  of Incorporation. In addition, our Fourth Amended and Restated Certificate of Incorporation provides that this choice of forum
  does not apply to any complaint asserting a cause of action under the Securities Act and the Exchange Act. Finally, our Fourth
  Amended and Restated Certificate of Incorporation provides that federal district courts of the United States will be the exclusive
  forum for the resolution of any complaint asserting a cause of action under the Securities Act or the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In March 2020, the Delaware
  Supreme Court issued a decision in Salzburg et al. v. Sciabacucchi, which found that an exclusive forum provision providing for
  claims under the Securities Act to be brought in federal court is facially valid under Delaware law. It is unclear whether this
  decision will be appealed, or what the final outcome of this case will be. We intend to enforce this provision, but we do not know
  whether courts in other jurisdictions will agree with this decision or enforce it.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">This choice of forum
  provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with
  us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims.
  Alternatively, if a court were to find the choice of forum provision contained in the Fourth Amended and Restated Certificate of
  Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action
  in other jurisdictions, which could harm our business, operating results and financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we have no current plans
  to pay cash dividends on Common Stock for the foreseeable future, you may not receive any return on investment unless you sell
  Common Stock for a price greater than that which you paid for it.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may retain future
  earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the
  foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion
  of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements,
  contractual restrictions and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends
  may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you
  may not receive any return on an investment in Common Stock unless you sell Common Stock for a price greater than that which you
  paid for it.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities or industry analysts
  do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations
  regarding our securities adversely, the price and trading volume of our securities could decline.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The trading market for
  our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business,
  market or competitors. If no additional securities or industry analysts commence coverage of our share price and trading volume
  may be negatively impacted. If any of the analysts who may cover us change their recommendation regarding our shares of common
  stock adversely, or provide more favorable relative recommendations about our competitors, the price of our shares of common stock
  would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us,
  we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  <!-- Field: Page; Sequence: 19 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_002"></A><B>FORWARD-LOOKING STATEMENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We make forward-looking
  statements in this prospectus and any accompanying prospectus supplement and in documents incorporated herein by reference. All
  statements, other than statements of present or historical fact included in or incorporated by reference in this prospectus and
  any accompanying prospectus supplement, regarding our future financial performance, as well as our strategy, future operations,
  financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management are forward-looking
  statements. When used in this prospectus and any accompanying prospectus supplement, the words &ldquo;believe,&rdquo; &ldquo;may,&rdquo;
  &ldquo;will,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect,&rdquo;
  &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;seem,&rdquo;
  &ldquo;seek,&rdquo; &ldquo;future,&rdquo; &ldquo;outlook&rdquo; the negative of such terms and other similar expressions are intended
  to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking
  statements are based on management&rsquo;s current <FONT STYLE="background-color: white">expectations, assumptions, hopes, beliefs,
  intentions and strategies regarding </FONT>future events and are based on currently available information as to the outcome and
  timing of future events. We caution you that these forward-looking statements are subject to all of the risks and uncertainties,
  most of which are difficult to predict and many of which are beyond our control, incident to our business.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking
  statements are based on information available as of the date of this prospectus and any accompanying prospectus supplement, and
  current expectations, forecasts and assumptions, and involve a number of risks and uncertainties. Accordingly, forward-<FONT STYLE="background-color: white">looking</FONT>
  statements in this prospectus and any accompanying prospectus supplement and in any document incorporated herein by reference should
  not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking
  statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events
  or otherwise, except as may be required under applicable securities laws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of a number
  of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed
  or implied by these forward-looking statements. Some factors that could cause actual results to differ include:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to recognize the anticipated benefits of the business combination between Live Oak and Meredian Holdings Group, Inc. (&ldquo;Legacy Danimer&rdquo;), which was effected through the merger of a wholly-owned subsidiary of Live Oak with and into Legacy Danimer with Legacy Danimer surviving as the surviving company and becoming a wholly-owned subsidiary of Live Oak, which upon the closing of such merger was renamed Danimer Scientific, Inc. (the &ldquo;Business Combination&rdquo;), and manage growth profitably following the Closing;</FONT></TD></TR>
  </TABLE>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">costs related to the Business Combination;</FONT></TD></TR>
  </TABLE>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in applicable laws or regulations;</FONT></TD></TR>
  </TABLE>
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the outcome of any legal proceedings against us;</FONT></TD></TR>
  </TABLE>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the effect of the COVID-19 pandemic on our business;</FONT></TD></TR>
  </TABLE>
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to execute our business model, including, among other things, market acceptance of our planned products and services and construction delays in connection with the expansion of our facilities;</FONT></TD></TR>
  </TABLE>
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to raise capital;</FONT></TD></TR>
  </TABLE>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and</FONT></TD></TR>
  </TABLE>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other risks and uncertainties set forth in the section entitled &ldquo;Risk Factors&rdquo; beginning on page 1 of this prospectus, which is incorporated herein by reference.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More information on
  potential factors that could affect our financial results is included from time to time in our public reports filed with the Securities
  and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
  All forward-looking statements included in this prospectus are based upon information available to us as of the date of this prospectus,
  and speak only as the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances
  after the date of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should also read
  carefully the factors described or referred to in the &ldquo;Risk Factors&rdquo; section of this prospectus, any accompanying prospectus
  supplement and the documents incorporated by reference herein and therein, to better understand the risks and uncertainties inherent
  in our business and underlying any forward-looking statements. Any forward-looking statements that we make in this prospectus,
  any accompanying prospectus supplement and the documents incorporated by reference herein as well as other written or oral statements
  by us or our authorized officers on our behalf, speak only as of the date of such statement, and we undertake no obligation to
  update such statements. Comparisons of results for current and any prior periods are not intended to express any future trends
  or indications of future performance, unless expressed as such, and should only be viewed as historical data.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 20 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>INCORPORATION OF CERTAIN DOCUMENTS BY
  REFERENCE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Commission allows
  us to &ldquo;incorporate by reference&rdquo; the information we file with it, which means that we can disclose important business,
  financial and other information to you in this prospectus by referring you to the publicly filed documents containing this information.
  The information incorporated by reference is deemed to be a part of this prospectus, except for any information superseded by information
  contained in this prospectus or filed later by us with the Commission. This prospectus incorporates by reference the documents
  set forth below that we have previously filed with the Commission, other than any portion of any such filing that is furnished
  under the applicable commission rules, which documents contain important information about us and our Common Stock:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our Quarterly Reports on Form 10-Q for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020019509/f10q0620_liveoakacq.htm">June 30, 2020</A>,
  filed with the Commission on July 31, 2020, and <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020035279/f10q0920_liveoakacqu.htm">September 30, 2020</A>, filed with the Commission on November 5, 2020;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our Current Reports on Form 8-K filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020011598/ea121585-8k_liveoakacqu.htm">May 11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020012269/ea121702-8k_liveoakacquis.htm">May 14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020013337/ea122279-8k_liveoakacqui.htm">May 22, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000101376220000050/ea127764-8k_liveoak.htm">October 5, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020030681/ea128001-8k_liveoak.htm">October 9, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020042335/ea131454-8k_liveoakacq.htm">December 14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020043107/ea131775-8k_liveoakacq.htm">December 17, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020044899/ea132306-8k_liveoak.htm">December 28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020045183/ea132368-8k_danimerscien.htm">December 29, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000468/ea132630-8k_danimerscien.htm">January 5, 2021</A> (as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000733/ea132840-8ka1_danimer.htm">January 6, 2021</A>); </FONT></TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the description of our Common Stock contained in our registration
  statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020010861/ea121327-8a12b_liveoakacq.htm">Form 8-A</A> filed on May 4, 2020, including any amendments or reports filed for the purpose of updating that description;
  and</FONT></TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our definitive Proxy Statement on Schedule&nbsp;14A with respect to
  the Business Combination filed with the Commission on December 16, 2020 (other than those portions of such Proxy Statement not
  deemed to be &ldquo;filed&rdquo; with the Commission).</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of such documents
  are on file with the Commission. In addition, all documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
  Exchange Act, subsequent to the date of this prospectus are incorporated by reference in this prospectus, other than any portion
  of any such filing that is furnished under the applicable commission rules, and are a part hereof from the date of filing of such
  documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed
  to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any subsequently
  filed document that is also incorporated by reference herein modifies or replaces such statement. Any statements so modified or
  superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any information incorporated
  by reference herein is available to you without charge upon written or oral request. If you would like a copy of any of this information,
  please submit your request to us at Danimer Scientific, Inc., 140 Industrial Boulevard, Bainbridge, Georgia, 39817 Attention: Secretary;
  Telephone number (229) 243-7075.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 21 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>THE COMPANY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Danimer is a performance
  polymer company specializing in bioplastic replacements for traditional petrochemical-based plastics. Danimer, through its principal
  operating subsidiaries, Meredian, Inc., Danimer Scientific, L.L.C. and Danimer Scientific Kentucky, Inc., brings together innovative
  technologies to deliver renewable, environmentally friendly bioplastic materials to global consumer product companies. We have
  core competencies in fermentation process engineering, chemical engineering and polymer science. In addition, we have created an
  extensive intellectual property portfolio to protect our innovations which, together with our technology, serves as a valuable
  foundation for our business and future industry collaborations. We primarily market our products to manufacturers in the plastics
  industry seeking to address environmental, public health, renewability, certification, composting and biodegradability concerns
  because of customer perceptions or government regulations.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we
  are the only commercial company in the bioplastics market to combine the production of a base polymer along with the reactive extrusion
  capacity in order to give customers a &ldquo;drop-in&rdquo; replacement for a wide variety of petrochemical-based plastics. Our
  process uses sustainably sourced canola oil. Our proprietary extraction and extrusion processes are cost competitive and leave
  almost no carbon footprint. Our customized formulations enable us to team up with other makers of biobased products to create an
  even wider range of goods. Our scalable production capacity and modular manufacturing model will soon enable us to serve an increasingly
  large customer base. An industry leader as gauged by its over 16-year history, a patent portfolio of over 150 patents and pending
  patent applications worldwide, supply agreements with some of the largest consumer packaged goods (CPG) companies and numerous
  awards, including PLASTICS Industry Association&rsquo;s 2020 Innovation in Bioplastics award, Danimer is one of the few companies
  anywhere in the world to achieve this level of sustainability in biopolymer products and processes.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>USE OF PROCEEDS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not realize
  any proceeds from the sale of the Common Stock which may be sold pursuant to this prospectus for the respective accounts of the
  Selling Stockholders. We, however, will derive proceeds upon the exercise of the options granted to Selling Stockholders other
  than in the case of exercises made on a cashless or net exercise basis with us. All such proceeds will be available to us for working
  capital and general corporate purposes. No assurances can be given however, as to when or if any or all of the options will be
  exercised.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_006"></A>SELLING STOCKHOLDERS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
  to shares of Common Stock that are being registered for reoffers and resales by the Selling Stockholders named below who have acquired
  or may acquire shares of Common Stock pursuant to the Plans (&ldquo;Shares&rdquo;). Selling Stockholders also include certain unnamed
  non-affiliates of the Company, each of whom holds less than the lesser of 1000 shares or one percent (1%) of the shares issuable
  under the Plans, and who may make reoffers and resales of Shares up to such amount under this prospectus. The Selling Stockholders,
  subject to the expiration or waiver of any applicable lock-up agreements, may resell any or all of the Shares at any time they
  choose while this prospectus is effective.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Executive officers
  and directors, their family members, trusts for their benefit, or entities that they own, that acquire Common Stock under the Plans
  may be added to the Selling Stockholder list below by a prospectus supplement filed with the Commission. The number of Shares to
  be sold by any Selling Stockholder under this prospectus also may be increased or decreased by a prospectus supplement. Non-affiliates
  who purchased restricted securities, as these terms are defined in Rule 144(a) under the Securities Act, under any of our employee
  benefit plans and who are not named below may use this prospectus for the offer or sale of their Common Stock if they hold 1,000
  shares or less. Although a person&rsquo;s name is included in the table below, neither that person nor we are making an admission
  that the named person is our &ldquo;affiliate.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the Selling
  Stockholders is an employee or director of Danimer or one of our subsidiaries. The following table sets forth:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the name and principal position(s), office or other material relationship with the Company and
  our predecessors or affiliates, over the last three years of each Selling Stockholder;</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the number of shares of Common Stock each Selling Stockholder beneficially owned as of February
  1, 2021;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the number of shares of Common Stock acquired by each Selling Stockholder in connection with stock
  options and stock grants pursuant to the Plans and underlying stock options previously granted pursuant to the Plans and being
  registered under this Registration Statement, some or all of which Shares may be sold pursuant to this prospectus; and</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the number of shares of Common Stock and the percentage, if 1% or more, of the total class of Common
  Stock outstanding to be beneficially owned by each Selling Stockholder following this offering, assuming the sale pursuant to this
  offering of all shares acquired by such Selling Stockholder in connection with grants pursuant the Plans and registered under this
  Registration Statement.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 22 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The information
  contained in this &ldquo;Selling Stockholders&rdquo; section of this prospectus is included pursuant to the requirements of Form
  S-8 and includes certain persons eligible to resell &ldquo;restricted securities&rdquo; and/or &ldquo;control securities&rdquo;
  (as such terms are defined in Section C of the General Instructions to Form S-8) pursuant to this prospectus whether or not they
  have a present intent to sell any or all such shares hereunder. As of the date hereof, we have not been informed that any of the
  Selling Stockholders named below has a present intent to resell any such securities.&nbsp; &nbsp;Furthermore, there is no assurance
  that any of the Selling Stockholders will sell any or all of the shares offered by them under this Registration Statement. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The address of each
  Selling Stockholder is c/o Danimer Scientific, Inc., 140 Industrial Boulevard, Bainbridge, Georgia, 39817.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: left">Name of Selling <BR> Stockholder</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Relationship to <BR> the Company</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares of Common Stock <BR> Beneficially<BR> Owned Before Offering<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of&nbsp;Shares<BR> Being&nbsp;Offered <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares of Common <BR> Stock Beneficially <BR> Owned <BR> After Offering<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 1.5pt; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>Percent <BR> (%) <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent <BR> (%) <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; width: 20%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Stephen E. Croskrey<SUP>(4)</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 19%; font-size: 10pt; text-align: left">Chairman of the Board and Chief Executive Officer</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">8,825,267</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">9.5</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">8,723,506</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">101,761</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top"><FONT STYLE="font-size: 10pt">Stuart Pratt<SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt">Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,897,283</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,897,283</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Philip Gregory Calhoun<SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt">Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,581,687</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55,952</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,525,735</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top"><FONT STYLE="font-size: 10pt">Isao Noda<SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt">Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">452,867</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">401,941</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,926</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top"><FONT STYLE="font-size: 10pt">Gregory Hunt<SUP>(8)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt">Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">65,531</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">65,531</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">John P. Amboian<SUP>(9)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt">Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Richard J. Hendrix<SUP>(10)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt">Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,050,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">John A. Dowdy, III<SUP>(11)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">Chief Financial Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,332,440</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,979,768</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">352,672</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Phillip Van Trump<SUP>(12)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">Chief Science &amp; Technology Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,002,662</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,979,768</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,894</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top"><FONT STYLE="font-size: 10pt">Michael Smith<SUP>(13)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">Chief Operating Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,017,342</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.3</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,983,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,342</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top"><FONT STYLE="font-size: 10pt">Scott Tuten<SUP>(14)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">Chief Marketing &amp; Sustainability Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,924,484</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,778,292</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">146,192</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">Raymond M. Feldman</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">Former Employee</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,937</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,937</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">*</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Less than 1%. </FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(1)</TD><TD STYLE="text-align: justify">As used in this table, a beneficial owner of a security includes any person
  who, directly or indirectly, through contract, arrangement, understanding, relationship or otherwise has or shares (a) the power
  to vote, or direct the voting of, such security or (b) investment power which includes the power to dispose, or to direct the disposition
  of, such security. In addition, a person is deemed to be the beneficial owner of a security if that person has the right to acquire
  beneficial ownership of such security within 60 days.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(2)</TD><TD STYLE="text-align: justify">The numbers of shares of Common Stock reflect all shares of Common Stock
  acquired or issuable to a person pursuant to applicable grants previously made under the Plans irrespective of whether such grants
  are exercisable, vested or convertible as of March 10, 2021 or will become exercisable, vested or convertible within 60
  days after March 10, 2021.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(3)</TD><TD STYLE="text-align: justify">Applicable percentage of ownership for each selling stockholder is based
  on 88,007,277 shares of Common Stock outstanding (which is the 84,971,601 shares of Common Stock as of March 2, 2021 plus an aggregate
  of 3,035,676 restricted shares of Common Stock which are deemed to be granted to Messrs. Croskrey, Pratt, Dowdy, Van Trump, Smith
  and Tuten on the date of effectiveness of this Registration Statement on Form S-8), plus the number of shares of Common Stock of
  which such person has the right to acquire pursuant to applicable grants previously made under the Plans irrespective of whether
  such grants are exercisable, vested or convertible as of March 10, 2021 or will become exercisable, vested or convertible
  within 60 days after March 10, 2021.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 23 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(4)</TD><TD STYLE="text-align: justify">Includes 3,726,353 shares underlying options granted pursuant to the 2020
  Incentive Plan in connection with the Business Combination that are not presently exercisable and not exercisable within 60 days
  of the date hereof, of which 1,154,616 shares underly an option that is not exercisable until the later to occur of February 1,
  2024 or the approval by our shareholders of an amendment to the 2020 Incentive Plan to increase the number of shares available
  under the 2020 Incentive Plan in an amount sufficient to permit the exercise of such option. Includes 1,509,036 restricted shares
  of Common Stock which are deemed to be granted to Mr. Croskrey on the date of effectiveness of this Registration Statement on Form
  S-8, one half of which are solely time-based restricted stock and one-half of which are time-based and based on target price thresholds
  for the Common Stock, and all of which are deemed to be beneficially owned because Mr. Croskrey has the right to vote such shares.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(5)</TD><TD STYLE="text-align: justify">Includes 50,000 shares underlying options that are or will become exercisable
  within 60 days after the date hereof. Includes 12,363 shares underlying Assumed Legacy Danimer Options (as defined herein) that
  are or will become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying options issued by Legacy
  Danimer and assumed by the Company in connection with the Business Combination (&ldquo;Assumed Legacy Danimer Options&rdquo;) and
  342,258 shares underlying options granted in connection with the Business Combination that are not presently exercisable and not
  exercisable within 60 days of the date hereof, of which 312,258 shares underly an option that is not exercisable until the later
  to occur of February 1, 2024 or the approval by our shareholders of an amendment to the 2020 Incentive Plan to increase the number
  of shares available under the 2020 Incentive Plan in an amount sufficient to permit the exercise of such option. Mr. Pratt disclaims
  any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly
  or indirectly. Includes 17,604 restricted shares of Common Stock which are deemed to be granted to Mr. Pratt on the date of effectiveness
  of this Registration Statement on Form S-8, one half of which are solely time-based restricted stock and one-half of which are
  time-based and based on target price thresholds for the Common Stock, and all of which are deemed to be beneficially owned because
  Mr. Pratt has the right to vote such shares.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(6)</TD><TD STYLE="text-align: justify">Includes 3,226,006 shares held by the Greg Calhoun DGT Family Trusts u/t/a
  dated September 22, 2020 GST Exempt Trust and 62,851 shares held by the Greg Calhoun DGT Family Trusts u/t/a dated September 22,
  2020 GST Non-Exempt Trust, which may be deemed to be owned by Mr. Calhoun, and 50,000 shares underlying options that are or will
  become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying Assumed Legacy Danimer Options that are
  not presently exercisable and not exercisable within 60 days of the date hereof. Mr. Calhoun disclaims any beneficial ownership
  of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(7)</TD><TD STYLE="text-align: justify">Includes 345,989 shares underlying Assumed Legacy Danimer Options and 50,000
  shares underlying options that are or will become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying
  Assumed Legacy Danimer Options that are not presently exercisable and not exercisable within 60 days after the date hereof.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(8)</TD><TD STYLE="text-align: justify">Includes 4,579 shares underlying Assumed Legacy Danimer Options and 55,000
  shares underlying options that are or will become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying
  Assumed Legacy Danimer Options that are not presently exercisable and not exercisable within 60 days after the date hereof.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(9)</TD><TD STYLE="text-align: justify">Includes 50,000 shares underlying options that are or will become exercisable
  within 60 days after the date hereof.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(10)</TD><TD STYLE="text-align: justify">Includes 50,000 shares underlying options that are or will become exercisable
  within 60 days after the date hereof. Includes 5,000,000 shares held by Live Oak Sponsor Partners, LLC, of which Mr. Hendrix is
  a managing member, and as such, has voting and investment discretion with respect to such shares and may be deemed to have shared
  beneficial ownership of such shares. Mr. Hendrix disclaims any beneficial ownership of the reported shares other than to the extent
  of any pecuniary interest he may have therein, directly or indirectly.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  <!-- Field: Page; Sequence: 24 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(11)</TD><TD STYLE="text-align: justify">Includes 303,054 shares held by the John Adams Dowdy, III Living Trust, which
  shares may be deemed to be owned by Mr. Dowdy, and 917,613 shares underlying Assumed Legacy Danimer Options that are or will become
  exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options and 642,934
  shares underlying options granted in connection with the Business Combination that are not presently exercisable and not exercisable
  within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be granted to Mr.
  Dowdy on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely time-based restricted
  stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and all of which are deemed
  to be beneficially owned because Mr. Dowdy has the right to vote such shares. Mr. Dowdy disclaims any beneficial ownership of the
  reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(12)</TD><TD STYLE="text-align: justify">Includes 867,995 shares underlying Assumed Legacy Danimer Options that are
  or will become exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options
  and 642,934 shares underlying options granted in connection with the Business Combination that are not presently exercisable and
  not exercisable within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be
  granted to Mr. Van Trump on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely
  time-based restricted stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and
  all of which are deemed to be beneficially owned because Mr. Van Trump has the right to vote such shares.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(13)</TD><TD STYLE="text-align: justify">Includes 905,569 shares underlying Assumed Legacy Danimer Options that are
  or will become exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options
  and 642,934 shares underlying options granted in connection with the Business Combination that are not presently exercisable and
  not exercisable within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be
  granted to Mr. Smith on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely time-based
  restricted stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and all of which
  are deemed to be beneficially owned because Mr. Smith has the right to vote such shares.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.35in">(14)</TD><TD STYLE="text-align: justify">Includes and 666,519 shares underlying Assumed Legacy Danimer Options that
  are or will become exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options
  and 642,934 shares underlying options granted in connection with the Business Combination that are not presently exercisable and
  not exercisable within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be
  granted to Mr. Tuten on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely time-based
  restricted stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and all of which
  are deemed to be beneficially owned because Mr. Tuten has the right to vote such shares. Mr. Tuten disclaims any beneficial ownership
  of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will supplement
  this prospectus from time to time as required by the rules of the Commission to include certain information concerning the security
  ownership of the Selling Stockholders or any new Selling Stockholders, the number of shares offered for resale and the position,
  office or other material relationship which a Selling Stockholder has had within the past three years with us or any of our predecessors
  or affiliates.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Other Material Relationships with the Selling Stockholders</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Transactions with Certain Directors and
  Executive Officers</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&#9;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stephen E. Croskrey, our
  chief executive officer and chairman, leases a house from Danimer in Brinson, Georgia for a nominal rental fee and has an option
  to purchase such property from Danimer, which option continues co-terminously with Mr. Croskrey&rsquo;s employment as chief executive
  officer of Danimer.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Croskrey had acquired 483,977 shares of Legacy Danimer Common
  Stock upon exercise of options granted by Legacy Danimer and for which the exercise prices were paid in the form of non-recourse
  notes issued by Mr. Croskrey to Legacy Danimer. The aggregate amount of principal and accrued interest payable by Mr. Croskrey
  to Legacy Danimer in the amount of approximately $22,848,285 was paid off prior to the closing of the Business Combination (the
  &ldquo;Croskrey Note Payoff&rdquo;). In connection with the Croskrey Note Payoff, Mr. Croskrey received upon closing of the Business
  Combination a new option grant to purchase 1,154,616 shares of Common Stock under the 2020 Incentive Plan, which option will not
  be exercisable until the later to occur of February 1, 2024 or the approval by our shareholders of an amendment to the 2020 Incentive
  Plan to increase the number of shares available under the 2020 Incentive Plan in an amount sufficient to permit the exercise of
  the option.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stuart Pratt, a director of Danimer and the former chairman
  of the board of directors of Legacy Danimer, had acquired 187,147 shares of Legacy Danimer common stock upon exercise of options
  granted by Legacy Danimer and for which the exercise prices were paid in the form of non-recourse notes issued by Mr. Pratt to
  Legacy Danimer. The aggregate amount of principal and accrued interest payable by Mr. Pratt to Legacy Danimer in the amount of
  approximately $5,923,821 was paid off prior to the closing of the Business Combination (the &ldquo;Pratt Note Payoff&rdquo;). In
  connection with the Pratt Note Payoff, Mr. Pratt received upon closing of the Business Combination a new option grant to purchase
  312,258 shares of Common Stock under the 2020 Incentive Plan, which option will not be exercisable until the later to occur of
  February 1, 2024 or the approval by our shareholders of an amendment to the 2020 Incentive Plan to increase the number of shares
  available under the 2020 Incentive Plan in an amount sufficient to permit the exercise of the option.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0pt"><!-- Field: Sequence; Type: Arabic --><!-- Field: /Sequence --></P>
  
  <!-- Field: Page; Sequence: 25 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Isao Noda, a former
  director of Legacy Danimer, held an aggregate principal amount of $200,000 of Legacy Danimer&rsquo;s 8% convertible notes, which
  converted into shares of Danimer effective as of the closing of the Business Combination.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Employment and Consulting
  Relationships</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Croskrey entered into
  an employment agreement with us in connection with the Business Combination, Mr. Pratt entered into a consulting agreement with
  us in connection with the Business Combination, and each of Messrs. Dowdy, Van Trump, Smith and Tuten entered into an employment
  agreement with Legacy Danimer in connection with their respective appointment. Each of Messrs. Croskrey, Pratt, Dowdy, Van Trump,
  Smith and Tuten have provided and continue to provide, services to Danimer commensurate with his role.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: 26pt; background-color: white"><I>Lock-Up
  Agreement</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In connection with the closing of the Business Combination,
  on December 29, 2020, the Company and Messrs. Croskrey, Pratt, Dowdy, Van Trump, Smith and Tuten entered into a Lock-Up Agreement
  (the &ldquo;Lock-Up Agreement&rdquo;). The terms of the Lock-Up Agreement provide that our securities held by these individuals
  that were acquired pursuant to the Merger Agreement or otherwise issued pursuant to the Merger Agreement will be locked-up until
  the earlier of (i) one year after the closing of the Business Combination or (ii) subsequent to the closing of the Business Combination,
  (x) if the reported closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends,
  reorganizations, recapitalizations and the like) for any twenty (20) trading days within any 30-trading day period commencing at
  least one hundred fifty (150) days after the closing of the Business Combination, or (y) the date on which Danimer completes a
  liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Danimer&rsquo;s
  stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company has agreed that the restrictions in the Lock-Up
  Agreement will not apply to (i) the delivery to the Company by Messrs. Croskrey or Pratt of the amounts of Common Stock needed
  to effect the Croskrey Note Payoff or Pratt Note Payoff, respectively, and (ii) the sale of Common Stock by either of Messrs. Croskrey
  or Pratt to satisfy their respective tax obligations in connection with the foregoing clause (i).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Indemnification Agreements</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We entered into separate
  indemnification agreements with our directors and executive officers, including each of Messrs. Croskrey, Pratt, Calhoun, Noda,
  Hunt, Amboian, Hendrix, Dowdy, Van Trump, Smith and Tuten. These agreements, among other things, require us to indemnify our directors
  and executive officers for certain expenses, including attorneys&rsquo; fees, judgments, fines and settlement amounts incurred
  by a director or executive officer in any action or proceeding arising out of their services as one of Danimer&rsquo;s directors
  or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services
  at our request.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Sponsor Agreements</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Live Oak Sponsor Partners,
  LLC, a Delaware limited liability company (the &ldquo;Sponsor&rdquo;) that is affiliated with a member of our board of directors,
  has entered certain agreements with Live Oak, our predecessor company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Founder Shares</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2019, the Sponsor purchased 5,031,250 shares (the &ldquo;Founder
  Shares&rdquo;) of Live Oak&rsquo;s Class B common stock for an aggregate price of $25,000. On January 14, 2020, the Sponsor contributed
  back to Live Oak, for no consideration, 718,750 Founder Shares. In February 2020, Live Oak effected a stock dividend for 0.333333333
  shares for each Founder Share outstanding, resulting in the Sponsor holding an aggregate of 5,750,000 Founder Shares, 750,000 of
  which were later forfeited, resulting in 5,000,000 Founder Shares outstanding. Upon the closing of the Business Combination, each
  of the Founder Shares converted into a share of Common Stock on a one-for-one basis.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: 26pt; background-color: white"><I>Private
  Warrants</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Simultaneously with the
  closing of Live Oak&rsquo;s initial public offering, the Sponsor purchased an aggregate of 6,000,000 warrants from Live Oak (each,
  a &ldquo;Private Warrant&rdquo;) at a price of $1.00 per Private Warrant, for an aggregate purchase price of $6,000,000. Each Private
  Warrant is exercisable to purchase one share of Common Stock at a price of $11.50 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0pt"></P>
  
  <!-- Field: Page; Sequence: 26 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: 26pt; background-color: white"><I>Registration
  Rights Agreement</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to a registration
  rights agreement entered into on May 5, 2020, the holders of the Private Warrants (and the shares of Class A common stock underlying
  such Private Warrants) and shares of Common Stock issued upon conversion of the Founder Shares have registration rights to require
  us to register a sale of any of such holders&rsquo; securities held by them. As of the date of this Registration Statement, the
  Sponsor holds 3 million Private Warrants and 5 million shares of Common Stock issued upon conversion of the Founder Shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Subscription Agreement</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the execution of the Merger Agreement, Live Oak
  entered into Subscription Agreements with a number of subscribers, pursuant to which the subscribers agreed to purchase, and Live
  Oak agreed to sell to the subscribers, an aggregate of 21,000,000 shares of Live Oak Class&nbsp;A Common Stock, for a purchase
  price of $10.00 per share and an aggregate purchase price of $210,000,000, in a private placement (the &ldquo;PIPE&rdquo;). Live
  Oak ValFund Plastics Fund LLC, which was affiliated with a member of our board of directors, purchased 4,905,000 shares of Live
  Oak Class&nbsp;A Common Stock in the PIPE for a total purchase price of $49,050,000.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 27 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>DESCRIPTION OF COMMON STOCK</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
  of our Common Stock does not purport to be complete and is subject in all respects to applicable Delaware law and qualified by
  reference to the provisions of our Fourth Amended and Restated Certificate of Incorporation, as amended (the &ldquo;Certificate
  of Incorporation&rdquo;) and Amended and Restated Bylaws, as amended (the &ldquo;Bylaws&rdquo;). Copies of our Certificate of Incorporation
  and Bylaws are incorporated by reference and will be sent to stockholders upon request. See &ldquo;Where Can You Find More Information.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Authorized and Outstanding Stock</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have authorized
  200,000,000 shares of our Common Stock. As of March 2, 2021 there were 84,971,601 shares of our Common Stock outstanding and no
  shares of preferred stock outstanding.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Voting Power</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Except as otherwise
  required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of our
  Common Stock possess all voting power for the election of our directors and all other matters requiring stockholder action. Holders
  of common stock are entitled to one vote per share on matters to be voted on by stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dividends</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Holders of Common Stock
  will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors in its discretion
  out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared
  or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have not paid any
  cash dividends on any class of our common stock to date and do not intend to pay cash dividends. The payment of cash dividends
  in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial conditions.
  The payment of any cash dividends will be within the discretion of our board of directors at such time. Further, if we incur any
  indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Liquidation, Dissolution and Winding Up</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In the event of our
  voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the Common Stock will be
  entitled to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders,
  after the rights of the holders of the preferred stock have been satisfied.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Preemptive or Other Rights</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our stockholders have
  no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Election of Directors</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our board of directors
  will be composed of single class of eight directors, each of whom will generally serve for a term of one year. There is no cumulative
  voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the
  election of directors can elect all of the directors.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Anti-Takeover Effects of Certain Provisions of Delaware Law
  and Our Certificate of Incorporation and Bylaws</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are subject to the
  provisions of Section&nbsp;203 of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;) regulating corporate takeovers. This
  statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &ldquo;business combination&rdquo;
  with:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a stockholder who owns 15% or more of our outstanding
  voting stock (otherwise known as an &ldquo;interested stockholder&rdquo;);</TD>
  </TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an affiliate of an interested stockholder; or</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an associate of an interested stockholder, for three
  years following the date that the stockholder became an interested stockholder.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 28 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">A &ldquo;business combination&rdquo;
  includes a merger or sale of more than 10% of our assets. However, the above provisions of Section&nbsp;203 do not apply if:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our board of directors approves the transaction that
  made the stockholder an &ldquo;interested stockholder,&rdquo; prior to the date of the transaction;</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">after the completion of the transaction that resulted
  in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at
  the time the transaction commenced, other than statutorily excluded shares of common stock; or</TD>
  </TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">on or subsequent to the date of the transaction, the
  initial business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by
  written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our authorized but unissued
  Common Stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety
  of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence
  of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt
  to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>PLAN OF DISTRIBUTION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling
  Stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of
  our Common Stock or interests in shares of our Common Stock received after the date of this prospectus from a Selling
  Stockholder as a gift, pledge, partnership distribution or other transfer, may, after the expiration of any applicable
  lock-up agreements and from time to time, sell, transfer or otherwise dispose of any or all of their shares of our Common
  Stock or interests in shares of our Common Stock on any stock exchange, market or trading facility on which the shares are
  traded, in private transactions or through a combination of such methods. These dispositions may be at fixed prices, at
  prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
  at the time of sale, or at negotiated prices.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders
  may use any one or more of the following methods when disposing of shares or interests therein:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">market transactions in accordance with the rules of NYSE or any other available
  markets or exchanges;</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">ordinary brokerage transactions and transactions in which the broker-dealer
  solicits purchasers;</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">block trades in which the broker-dealer will attempt to sell the shares as
  agent, but may position and resell a portion of the block as principal to facilitate the transaction;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">purchases by a broker-dealer as principal and resale by the broker-dealer
  for its account;</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">privately negotiated transactions;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">short sales entered into after the date of this prospectus;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">through the writing or settlement of options or other hedging transactions,
  whether through an options exchange or otherwise;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">distributions to the partners and/or members of the Selling Stockholders;</TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">redemptions or repurchases of interests owned by partners and/or members
  of the Selling Stockholders;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -40pt; margin: 0pt 0.5in; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 29 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-indent: -40pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">broker-dealers may agree with the Selling Stockholders to sell a specified
  number of such shares at a stipulated price per share;</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">a combination of any such methods of sale; and</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in">any other method permitted pursuant to applicable law.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent permitted,
  this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with
  the sale of our Common Stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
  or other financial institutions, which may in turn engage in short sales of our Common Stock in the course of hedging the positions
  they assume with the selling stockholders. The Selling Stockholders may also sell shares of our Common Stock short and deliver
  these securities to close out their short positions, or loan or pledge our Common Stock to broker-dealers that in turn may sell
  these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial
  institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial
  institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant
  to this prospectus (as supplemented or amended to reflect such transaction).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Short selling occurs
  when a person sells shares of stock which the person does not yet own and promises to buy stock in the future to cover the sale.
  The general objective of the person selling the shares short is to make a profit by buying the shares later, at a lower price,
  to cover the sale. Significant amounts of short selling, or the perception that a significant amount of short sales could occur,
  could depress the market price of our Common Stock. In contrast, purchases to cover a short position may have the effect of preventing
  or retarding a decline in the market price of our Common Stock, and together with the imposition of the penalty bid, may stabilize,
  maintain or otherwise affect the market price of our Common Stock. As a result, the price of our Common Stock may be higher than
  the price that otherwise might exist in the open market. If these activities are commenced, they may be discontinued at any time.
  These transactions may be effected on NYSE, in the over-the-counter market or otherwise.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate proceeds
  to the Selling Stockholders from the sale of our Common Stock offered by them will be the purchase price of our Common Stock less
  discounts or commissions, if any. Each of the Selling Stockholders reserves the right to accept and, together with their agents
  from time to time, to reject, in whole or in part, any proposed purchase of our Common Stock to be made directly or through agents.
  We will not receive any of the proceeds from this offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders
  also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act,
  provided that they meet the criteria and conform to the requirements of that rule.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders
  and any underwriters, broker-dealers or agents that participate in the sale of our Common Stock or interests therein may be &ldquo;underwriters&rdquo;
  within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profits they earn on any
  resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling Stockholders who are &ldquo;underwriters&rdquo;
  within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
  Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent required,
  the shares of our Common Stock to be sold, the names of the Selling Stockholders, the respective purchase prices and public offering
  prices, the names of any agents, dealers or underwriters, any applicable commissions or discounts with respect to a particular
  offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration
  statement that includes this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply
  with the securities laws of some states, if applicable, our Common Stock may be sold in these jurisdictions only through registered
  or licensed brokers or dealers. In addition, in some states our Common Stock may not be sold unless it has been registered or qualified
  for sale or an exemption from registration or qualification requirements is available and is complied with.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have advised the
  Selling Stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the
  market and to the activities of the Selling Stockholders and their affiliates. In addition, we will make copies of this prospectus
  (as it may be supplemented or amended from time to time) available to the Selling Stockholders for the purpose of satisfying the
  prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer that participates
  in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities
  Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 30 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the
  informational requirements of the Exchange Act, and in accordance therewith we are required to file periodic reports, proxy statements
  and other information with the Commission. Such reports, proxy statements and other information filed by us can be inspected and
  copied at the Commission&rsquo;s Public Reference Room located at 100 F Street, N.E. Washington, D.C. 20549, at the prescribed
  rates. The Commission also maintains a site on the World Wide Web that contains reports, proxy and information statements and other
  information regarding registrants that file electronically. The address of such site is http://www.sec.gov. Please call 1-800-SEC-0330
  for further information on the operation of the Commission&rsquo;s Public Reference Room.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is
  traded on NYSE under the symbol &ldquo;DNMR.&rdquo; Certain materials filed by us may be inspected at The New York Stock Exchange
  at 11 Wall St, New York, NY 10005.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus omits
  certain information that is contained in the registration statement on file with the Commission, of which this prospectus is a
  part. For further information with respect to us and our Common Stock, reference is made to the registration statement, including
  the exhibits incorporated therein by reference or filed therewith. Statements herein contained concerning the provisions of any
  document are not necessarily complete and, in each instance, reference is made to the copy of such document filed as an exhibit
  or incorporated by reference to the registration statement. The registration statement and the exhibits may be inspected without
  charge at the offices of the Commission or copies thereof obtained at prescribed rates from the public reference section of the
  Commission at the addresses set forth above.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incorporate information
  into this prospectus by reference, which means that we disclose important information to you by referring you to another document
  filed separately with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) by us. The information incorporated
  by reference is deemed to be part of this prospectus, except to the extent superseded by information contained in this prospectus
  or by information contained in documents filed with the SEC after the date of this prospectus. This prospectus incorporates by
  reference the documents set forth below that have been previously filed with the Commission; provided, however, that, except as
  noted below, we are not incorporating any documents or information deemed to have been furnished rather than filed in accordance
  with the rules of the Commission. These documents contain important information about us and our financial condition.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our Quarterly Reports on Form 10-Q for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020019509/f10q0620_liveoakacq.htm">June 30, 2020</A>,
  filed with the Commission on July 31, 2020, and <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020035279/f10q0920_liveoakacqu.htm">September 30, 2020</A>, filed with the Commission on November 5, 2020;</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our Current Reports on Form 8-K filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020011598/ea121585-8k_liveoakacqu.htm">May 11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020012269/ea121702-8k_liveoakacquis.htm">May 14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020013337/ea122279-8k_liveoakacqui.htm">May 22, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000101376220000050/ea127764-8k_liveoak.htm">October 5, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020030681/ea128001-8k_liveoak.htm">October 9, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020042335/ea131454-8k_liveoakacq.htm">December 14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020043107/ea131775-8k_liveoakacq.htm">December 17, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020044899/ea132306-8k_liveoak.htm">December 28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020045183/ea132368-8k_danimerscien.htm">December 29, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000468/ea132630-8k_danimerscien.htm">January 5, 2021</A> (as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000733/ea132840-8ka1_danimer.htm">January 6, 2021</A>) and <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021006827/ea134693-8k_danimer.htm">February 4, 2021</A> (excluding &ldquo;furnished&rdquo; and
  not &ldquo;filed&rdquo; information); and</FONT></TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
  description of our Common Stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020010861/ea121327-8a12b_liveoakacq.htm">Form
  8-A</A> filed on May 4, 2020, including any amendments or reports filed for the purpose of updating that description.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents subsequently
  filed by us with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended,
  prior to the filing of a post-effective amendment to the registration statement of which this prospectus forms a part which indicates
  that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed incorporated
  by reference into this prospectus and to be a part hereof from the date of the filing of such documents, except that information
  furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and any exhibit relating to such information,
  shall not be deemed to be incorporated by reference in this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 31 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this
  prospectus, any statement contained in a document incorporated, or deemed to be incorporated, by reference herein shall be deemed
  to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently
  filed document which also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such
  statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide without
  charge upon written or oral request to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of
  any and all of the documents which are incorporated by reference in this prospectus but not delivered with this prospectus (other
  than exhibits unless such exhibits are specifically incorporated by reference in such documents). You may request a copy of these
  documents by writing or telephoning us at:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Danimer Scientific, Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">140 Industrial Boulevard</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Bainbridge, Georgia 39817</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(229) 243-7075</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_010"></A>EXPERTS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
  statements of Legacy Danimer as of December 31, 2019 and 2018, and for each of the two years in the period ended December 31, 2019,
  incorporated in this prospectus by reference to the Company&rsquo;s Current Report on Form 8-K filed with the&nbsp;Commission on
  January 5, 2021, have been audited by Thomas Howell Ferguson P.A., independent registered public accounting firm, as stated in
  their report which is incorporated herein by reference (which report expresses an unqualified opinion on the financial statements
  and includes an explanatory paragraph referring to the entity&rsquo;s adoption of ASU No. 2014-09, Revenue from Contracts with
  Customers (Topic 606)), and are so included in reliance upon such report given on the authority of such firm as experts in accounting
  and auditing.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial
  statements as of December 31, 2019 and for the period from May 24, 2019 (inception) through December 31, 2019 of Live Oak
  Acquisition Corp. incorporated in this prospectus by reference to the Company&rsquo;s Current Report on Form 8-K filed with
  the&nbsp;Commission on January 5, 2021 have been audited by WithumSmith+Brown, PC, an independent registered public
  accounting firm, as stated in their report thereon dated February 28, 2020 and referred to in this prospectus, in reliance
  upon such report and upon the authority of such firm as experts in accounting and auditing.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>LEGAL MATTERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the
  shares of Common Stock offered hereby will be passed upon for us by Kane Kessler, P.C., New York, New York.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>
  
  <!-- Field: Page; Sequence: 32 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REOFFER PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">DANIMER SCIENTIFIC,
  INC.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18,969,978 Shares of Class A Common Stock,</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>par value $0.0001 per share</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March 10, 2021</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No dealer, salesperson or other person
  is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized
  information or representations. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances
  and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 33 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3. Incorporation of Documents by
  Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents
  filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) by Danimer Scientific, Inc., a Delaware corporation
  (the &ldquo;Registrant&rdquo;), are incorporated by reference into the Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the Registrant&rsquo;s Quarterly Reports on Form 10-Q for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020019509/f10q0620_liveoakacq.htm">June
                                                                                                                                      30, 2020</A>, filed with the Commission on July 31, 2020, and <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020035279/f10q0920_liveoakacqu.htm">September
                                                                                                                                      30, 2020</A>, filed with the Commission on November 5, 2020;</TD></TR></TABLE>
  
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the Registrant&rsquo;s Current
                                                                                                                                      Reports on Form 8-K filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020011598/ea121585-8k_liveoakacqu.htm">May
                                                                                                                                      11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020012269/ea121702-8k_liveoakacquis.htm">May
                                                                                                                                      14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020013337/ea122279-8k_liveoakacqui.htm">May
                                                                                                                                      22, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000101376220000050/ea127764-8k_liveoak.htm">October 5,
                                                                                                                                      2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020030681/ea128001-8k_liveoak.htm">October 9,
                                                                                                                                      2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020042335/ea131454-8k_liveoakacq.htm">December 14,
                                                                                                                                      2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020043107/ea131775-8k_liveoakacq.htm">December 17,
                                                                                                                                      2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020044899/ea132306-8k_liveoak.htm">December 28,
                                                                                                                                      2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020045183/ea132368-8k_danimerscien.htm">December
                                                                                                                                      29, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000468/ea132630-8k_danimerscien.htm">January
                                                                                                                                      5, 2021</A> (as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000733/ea132840-8ka1_danimer.htm">January
                                                                                                                                      6, 2021</A>) and <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021006827/ea134693-8k_danimer.htm">February
                                                                                                                                      4, 2021</A> (excluding &ldquo;furnished&rdquo; and not &ldquo;filed&rdquo; information); and</FONT></TD></TR></TABLE>
  
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
  description of the Registrant&rsquo;s Common Stock contained in the Registrant&rsquo;s registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020010861/ea121327-8a12b_liveoakacq.htm">Form
  8-A</A> filed on May 4, 2020, including any amendments or reports filed for the purpose of updating that description.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of such documents
  are on file with the Commission. In addition, all documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
  Exchange Act, subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment which
  indicates that all the securities offered hereby have been sold or which deregisters all securities then remaining unsold shall
  be deemed to be incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such
  documents, except that information furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and
  any exhibit relating to such information, shall not be deemed to be incorporated by reference in this prospectus. Any statement
  contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this prospectus to the extent that a statement contained herein or in any subsequently filed document that is also
  incorporated by reference herein modifies or replaces such statement. Any statements so modified or superseded shall not be deemed,
  except as so modified or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 4. Description of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5. Interests of Named Experts and Counsel.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. Indemnification of Directors and Officers.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;145(a)
  of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;) provides, in general, that a corporation may indemnify any person
  who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
  whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because
  he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
  expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by
  the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably
  believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding,
  had No&nbsp;reasonable cause to believe his or her conduct was unlawful.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 34; Options: NewSection -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;145(b)
  of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made
  a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its
  favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
  of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
  enterprise, against expenses (including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with
  the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed
  to be in or not opposed to the best interests of the corporation, except that no&nbsp;indemnification shall be made with respect
  to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to
  the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in
  view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the
  Court of Chancery or other adjudicating court shall deem proper.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;145(g)
  of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was
  a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
  officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability
  asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether
  or not the corporation would have the power to indemnify the person against such liability under Section&nbsp;145 of the DGCL.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant has
  entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant
  will indemnify each of its directors and such officers to the fullest extent permitted by law and its charter and its bylaws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant also
  maintains a general liability insurance policy, which will cover certain liabilities of directors and officers of the Registrant
  arising out of claims based on acts or omissions in their capacities as directors or officers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7. Exemption from Registration Claimed.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The shares being reoffered and resold pursuant
  to the Reoffer Prospectus were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of
  the Securities Act and/or Rule 701 promulgated thereunder, as transactions by an issuer not involving a public offering or pursuant
  to a written compensatory benefit plan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 13%; text-align: left"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 85%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000468/ea132630ex3-1_danimerscien.htm"><FONT STYLE="font-size: 10pt">Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021). </FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000468/ea132630ex3-2_danimerscien.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020006032/ea119265ex4-2_liveoak.htm"><FONT STYLE="font-size: 10pt">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-236800) (as amended, the &ldquo;S-1&rdquo;)).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020043065/f424b31220_liveoakacq.htm"><FONT STYLE="font-size: 10pt">Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Annex C to the Proxy Statement/Prospectus on Form 424B3 (File No. 333-249691) filed on December 16, 2020).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390020043065/f424b31220_liveoakacq.htm"><FONT STYLE="font-size: 10pt">Danimer Scientific, Inc. &nbsp;Employee Stock Purchase Plan (incorporated by reference to Annex D to the Proxy Statement/Prospectus on Form 424B3 (File No. 333-249691) filed on December 16, 2020).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000468/ea132630ex10-29_danimerscien.htm"><FONT STYLE="font-size: 10pt">Form of Stock Option Agreement under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.29 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).</FONT></A></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0"></P>
  
  <!-- Field: Page; Sequence: 35 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center; width: 13%"><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="text-align: justify; width: 85%"><A HREF="http://www.sec.gov/Archives/edgar/data/1779020/000121390021000468/ea132630ex10-30_danimerscien.htm"><FONT STYLE="font-size: 10pt">Form of Restricted Stock Agreement under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.30 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea137293ex4-8_danimer.htm"><FONT STYLE="font-size: 10pt">Meredian Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan, assumed by Danimer Scientific, Inc. (1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.9</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea137293ex4-9_danimer.htm"><FONT STYLE="font-size: 10pt">Meredian Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan, assumed by Danimer Scientific, Inc. (1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea137293ex5-1_danimer.htm"><FONT STYLE="font-size: 10pt">Opinion of Kane Kessler, P.C. (1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea137293ex23-1_danimer.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of WithumSmith+Brown, PC. (1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea137293ex23-2_danimer.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of Thomas Howell Ferguson P.A. (1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea137293ex5-1_danimer.htm"><FONT STYLE="font-size: 10pt">Consent of Kane Kessler, P.C. (Included in Exhibit 5.1). (1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#PA"><FONT STYLE="font-size: 10pt">Power of Attorney (included on the signature page of the Registration Statement hereto). (1)</FONT></A></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Filed herewith.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9. Undertakings </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
  undersigned Registrant hereby undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are being made, a post-effective amendment
  to this registration statement:</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">to include any prospectus required by Section 10(a)(3) of the Securities Act;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">to reflect in the prospectus any facts or events arising after the effective date of the registration
  statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
  change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
  of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
  from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
  pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the
  maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration
  statement; and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">to include any material information with respect to the plan of distribution not previously disclosed
  in the registration statement or any material change to such information in the registration statement;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>provided, however</I>, that
  paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section&nbsp;13 or 15(d)
  of the Exchange Act that are incorporated by reference in the registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">that, for the purpose of determining any liability under the Securities Act, each such post-effective
  amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
  securities at that time shall be deemed to be the initial bona&nbsp;fide offering thereof; and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">to remove from registration by means of a post-effective amendment any of the securities being
  registered which remain unsold at the termination of the offering.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The undersigned Registrant hereby undertakes that, for purposes of determining any liability under
  the Securities Act, each filing of the Registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange
  Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Exchange
  Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating
  to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona&nbsp;fide
  offering thereof.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
  directors, officers and controlling persons of the undersigned Registrant pursuant to the provisions described in Item 6 or otherwise,
  the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed
  in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
  (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
  in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
  with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
  controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</TD></TR></TABLE>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: left; text-indent: 0in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 36 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SIGNATURES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, as amended, the undersigned registrant certifies that it has reasonable grounds to believe that
  it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf
  by the undersigned, thereunto duly authorized, in the City of Bainbridge, State of Georgia, on March 10, 2021.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>DANIMER SCIENTIFIC, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 36%; text-align: left">&nbsp;</TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">/s/ &nbsp;Stephen E. Croskrey</FONT></TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Name: &nbsp;Stephen E. Croskrey</FONT></TD>
      </TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Title: &nbsp;Chief Executive Officer</FONT></TD>
      </TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="PA"></A><B>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY
  THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Stephen E. Croskrey and John A.
  Dowdy, III, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and
  resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments,
  including post-effective amendments, to this registration statement on Form S-8, and to file the same, with exhibits thereto and
  other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and
  agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be
  done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that
  each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue
  hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities
  and on the date indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 15%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Stephen E. Croskrey</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Executive Officer, Director and Chairman of the Board</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Stephen E. Croskrey</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ John A. Dowdy, III</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">John A. Dowdy, III</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ John P. Amboian</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">John P. Amboian</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Richard J. Hendrix</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Richard J. Hendrix</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Christy Basco</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Christy Basco</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Philip Gregory Calhoun</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Philip Gregory Calhoun</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Gregory Hunt</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Gregory Hunt</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Dr. Isao Noda</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Dr. Isao Noda</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Stuart Pratt</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Stuart Pratt</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-4</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea137293-s8_danimer.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 360136}]
metadata_filer: {"company-data": {"conformed-name": "Danimer Scientific, Inc.", "cik": "0001779020", "assigned-sic": "2821", "irs-number": "841924518", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-254085", "film-number": "21729844"}, "business-address": {"street1": "140 INDUSTRIAL BOULEVARD", "city": "BAINBRIDGE", "state": "GA", "zip": "39817", "phone": "229-243-7075"}, "mail-address": {"street1": "140 INDUSTRIAL BOULEVARD", "city": "BAINBRIDGE", "state": "GA", "zip": "39817"}, "former-company": [{"former-conformed-name": "Danimer Scientific, Inc", "date-changed": "20201229"}, {"former-conformed-name": "Live Oak Acquisition Corp", "date-changed": "20200106"}, {"former-conformed-name": "Foxhound Merger Partners, Inc.", "date-changed": "20190605"}]}
text: As filed with the Securities and Exchange Commission on March 10, 2021
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933
  Danimer
  Scientific, Inc.
  (Exact name of registrant as specified in
  charter)
  Delaware
  82-1924518
  (State or other jurisdiction
  of incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  140 Industrial Boulevard
  Bainbridge, Georgia
  39817
  (Address of Principal Executive Offices)
  (Zip Code)
  Danimer Scientific, Inc. 2020 Long-Term
  Incentive Plan
  Danimer Scientific, Inc. Employee Stock
  Purchase Plan
  Meredian Holdings Group, Inc. 2016 Director
  and Executive Officer Stock Incentive Plan,
  assumed by Danimer Scientific, Inc.
  Meredian Holdings Group, Inc. 2016 Omnibus
  Stock Incentive Plan,
  assumed by Danimer Scientific, Inc.
  (Full title of the plan)
  Attn.: Stephen E. Croskrey
  Danimer Scientific, Inc.
  140 Industrial Boulevard
  Bainbridge, Georgia
  (Name and address of agent for service)
  Copy to:
  Robert L. Lawrence, Esq.
  Kane Kessler, P.C.
  600 Third Avenue
  New York, NY 10016
  (212) 541-6222
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
  of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2
  of the Exchange Act.
  Large accelerated filer ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company ☒
  Emerging growth company
  ☒
  If an emerging growth company, indicate by check mark if the
  registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  ☒
  CALCULATION OF REGISTRATION FEE
  Title of securities to be registered
  Amount to be
  registered
  (1)
  Proposed maximum
  offering price
  per share
  Proposed maximum
  aggregate
  offering price
  Amount of
  registration fee
  Class A Common Stock, par value $0.0001 per share ("Common Stock")
  8,572,457
  (3)
  $
  32.13
  (2)
  $
  275,433,044
  (2)
  $
  30,049.75
  (2)
  Common Stock
  2,571,737
  (4)
  $
  27.31
  (5)
  $
  70,234,138
  (5)
  $
  7,662.54
  (5)
  Common Stock
  10,487,283
  (6)
  $
  3.96
  (7)
  $
  41,529,640
  (7)
  $
  4,530.88
  (7)
  Total
  21,618,098
  N/A
  $
  387,143,842
  $
  42,243.17
  (1)
  Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"),
  this Registration Statement covers an indeterminable number of additional shares of Common Stock as may hereafter be offered or
  issued pursuant to the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "2020 Incentive Plan"), Danimer
  Scientific, Inc. Employee Stock Purchase Plan (the "ESPP"), and the Meredian Holdings Group, Inc. 2016 Director and
  Executive Officer Stock Incentive Plan and Meredian Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan (collectively, the "Legacy
  Plans") to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without receipt
  of consideration. In addition, this Registration Statement registers the resale of shares of Danimer Scientific, Inc.'s (the
  "Registrant") Common Stock by certain selling stockholders identified in the Reoffer Prospectus included in and filed
  with this Registration Statement, for which no additional registration fee is required pursuant to Rule 457(h)(3) under the Securities
  Act with respect to such of those shares being registered for issuance by the Registrant pursuant to this Registration Statement
  and on which a registration fee is already being paid.
  (2)
  Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(c) and
  457(h), the proposed maximum offering price per share is based upon a price of $32.13 (the average of the high and low prices of
  the Registrant's Common Stock as reported on The New York Stock Exchange on March 5, 2021).
  (3)
  Represents shares of Common Stock of the Registrant authorized for issuance as awards under the
  2020 Incentive Plan.
  (4)
  Represents shares issuable pursuant to the ESPP.
  (5)
  Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose
  of calculating the registration fee on the basis of 85% of the average of the high and low prices of the Registrant's Common
  Stock as reported on The New York Stock Exchange on March 5, 2021. Pursuant to the ESPP, the purchase price of Common Stock will
  be at least 85% of the lower of the fair market value of the Common Stock on the first trading day of the offering period or on
  the purchase date.
  (6)
  Represents shares of Common Stock issued pursuant to or underlying awards previously granted under
  the Legacy Plans, which awards were assumed by the Registrant in connection with the merger consummated on December 29, 2020 (the
  "Business Combination") pursuant to the Agreement and Plan of Merger, dated as of October 3, 2020 (as amended by Amendment
  No.1 thereto, dated as of October 8, 2020, and Amendment No. 2 thereto, dated as of December 11, 2020, the "Merger Agreement"),
  by and among Live Oak Acquisition Corp., our predecessor company ("Live Oak"), Green Merger Corp., Meredian Holdings
  Group, Inc., ("Legacy Danimer"), Live Oak Sponsor Partners, LLC, as representative for Live Oak, for certain purposes
  described in the Merger Agreement and John A. Dowdy, Jr., as representative of the shareholders of Legacy Danimer for certain purposes
  described in the Merger Agreement.
  (7)
  Computed in accordance with Rule 457(h) of the Securities Act solely for purposes of
  calculating the registration fee. The average weighted exercise price at which the options may be exercised for the shares of Common
  Stock described above in Footnote 6 is $3.96 per share.
  The Registration Statement shall become
  effective upon filing
  in accordance with Rule 462 under
  the Securities Act.
  EXPLANATORY NOTE
  Danimer Scientific,
  Inc., a Delaware corporation ("Danimer"), has prepared this Registration Statement in accordance with the requirements
  of Form S-8 under the Securities Act of 1933, as amended (the "Securities Act"), to register 21,631,477 shares of Class
  A Common Stock, $0.0001 par value per share (the "Common Stock") that are reserved for issuance pursuant to Danimer's
  2020 Long-Term Incentive Plan (the "2020 Incentive Plan") and were issued or reserved for issuance pursuant to Danimer's
  Employee Stock Purchase Plan (the "ESPP" and together with the 2020 Incentive Plan, the "New Plans"), and
  the Meredian Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan and Meredian Holdings Group, Inc. 2016
  Omnibus Stock Incentive Plan (collectively, the "Legacy Plans" and together with the New Plans, the "Plans").
  This Registration Statement
  contains two parts. The first part contains a reoffer prospectus pursuant to Form S-3 (in accordance with Section C of the General
  Instructions to the Form S-8 and in accordance with the requirements of Part I of Form S-3) (the "Reoffer Prospectus")
  which covers reoffers and resales of "restricted securities" and/or "control securities" (as such terms
  are defined in Section C of the General Instructions to Form S-8) of Danimer. This Reoffer Prospectus relates to up to 18,969,978
  shares of Common Stock that have been or may be issued to certain officers and directors of Danimer pursuant to the Plans. Accordingly,
  this Reoffer Prospectus is a combined prospectus pursuant to Rule 429(a) of the Securities Act. The second part of this Registration
  Statement contains information required in the Registration Statement pursuant to Part II of Form S-8 and will be used for offers
  of shares of Common Stock of Danimer pursuant to the Plans. The inclusion of such shares herein does not necessarily represent
  a present intention to sell any or all such shares of Common Stock.
  In accordance with
  the requirements of General Instruction C.2.(b) of Form S-8, because we do not satisfy the registrant requirements for use of Form
  S-3 at the time of filing the reoffer prospectus included in this Registration Statement, the amount of shares of Common Stock
  to be offered or resold by means of the reoffer prospectus, by each person, and any other person with whom he or she is acting
  in concert for the purpose of selling our Common Stock, may not exceed, during any three month period, the amount specified in
  Rule 144(e) promulgated under the Securities Act.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS
  Item
  1. Plan Information.
  The document(s) containing
  the information specified in Part I of Form S-8 will be sent or given to participants in the Plans as specified by Rule 428(b)(1)
  under the Securities Act. Such document(s) are not being filed with the Securities and Exchange Commission, but constitute, along
  with the documents incorporated by reference into this Registration Statement, a prospectus that meets the requirements of Section
  10(a) of the Securities Act.
  Item
  2. Company Information and Employee Plan Annual Information.
  Danimer will furnish
  without charge to each person to whom the prospectus is delivered, upon the written or oral request of such person, a copy of any
  and all of the documents incorporated by reference in Item 3 of Part II of this Registration Statement, other than exhibits to
  such documents (unless such exhibits are specifically incorporated by reference to the information that is incorporated). Those
  documents are incorporated by reference in the Section 10(a) prospectus. Requests should be directed to Danimer Scientific, Inc.,
  140 Industrial Boulevard, Bainbridge, Georgia 39817, Attention: Secretary; Telephone number (229) 243-7075.
  Note
  : The reoffer
  prospectus referred to in the Explanatory Note follows this page.
  REOFFER PROSPECTUS
  DANIMER SCIENTIFIC,
  INC.
  18,969,978 Shares of Class A Common Stock,
  par value $0.0001 per share
  This Prospectus
  relates to shares (the "Shares") of Class A Common Stock, par value $0.0001 per share (the "Common
  Stock"), of Danimer Scientific, Inc., a Delaware corporation (which may be referred to as the "Company,"
  "Danimer," "we," "our" or "us"), which may be offered and sold from time to
  time after the expiration of any applicable lock-up agreements by certain stockholders of ours (the "Selling
  Stockholders") who have acquired or will acquire such Shares pursuant to stock options and stock grants issued or
  issuable under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "2020 Incentive Plan"), the
  Danimer Scientific, Inc. Employee Stock Purchase Plan ("ESPP" and together with the 2020 Incentive Plan, the
  "New Plans"), and the Meredian Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan and
  Meredian Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan (collectively, the "Legacy Plans" and together
  with the New Plans, the "Plans"). See "Selling Stockholders."
  We will not
  receive any of the proceeds from sales of the Shares by any of the Selling Stockholders. The Shares may be offered from time
  to time after the expiration of any applicable lock-up agreements by any or all of the Selling Stockholders (and their donees
  and pledgees) through ordinary brokerage transactions, in negotiated transactions or in other transactions, at such prices as
  he or she may determine, which may relate to market prices prevailing at the time of sale or be a negotiated price. See
  "Plan of Distribution." All costs, expenses and fees in connection with the registration of the Shares will be
  borne by us. Brokerage commissions and similar selling expenses, if any, attributable to the offer or sale of the Shares will
  be borne by the Selling Stockholder (or their donees and pledgees).
  Each Selling Stockholder
  and any broker executing selling orders on behalf of a Selling Stockholder may be deemed to be an "underwriter" as
  defined in the Securities Act of 1933, as amended (the "Securities Act"). If any broker-dealers are used to effect
  sales, any commissions paid to broker-dealers and, if broker-dealers purchase any of the Shares as principals, any profits received
  by such broker-dealers on the resale of the Shares, may be deemed to be underwriting discounts or commissions under the Securities
  Act. In addition, any profits realized by the Selling Stockholders may be deemed to be underwriting commissions.
  Our common stock trades
  on The New York Stock Exchange ("NYSE") under the symbol "DNMR." On March 9, 2021, the last reported sale
  price of our shares on the NYSE was $34.58 per share.
  Please refer
  to "Risk Factors" beginning on page 1 for a description of the risks you should consider when evaluating this investment.
  Neither the Securities
  and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
  prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
  The date of this prospectus is March 10,
  2021
  You should rely only on the information
  included in or incorporated by reference into this prospectus or information we have referred to in this prospectus. We have not
  authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell
  these securities. This prospectus is not an offer to sell, or a solicitation of an offer to buy, in any state where the offer or
  sale is prohibited. The information in this prospectus is accurate on the date of this prospectus and may become obsolete later.
  Neither the delivery of this prospectus, nor any sale made under this prospectus will, under any circumstances, imply that the
  information in this prospectus is correct as of any date after the date of this prospectus. References to "the Company,"
  "Danimer," "we" or "us" refer to Danimer Scientific, Inc.
  TABLE OF CONTENTS
  Page
  RISK FACTORS
  1
  FORWARD-LOOKING STATEMENTS
  14
  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
  15
  THE COMPANY
  16
  USE OF PROCEEDS
  16
  SELLING STOCKHOLDERS
  16
  DESCRIPTION OF COMMON STOCK
  22
  PLAN OF DISTRIBUTION
  23
  WHERE YOU CAN FIND MORE INFORMATION
  25
  EXPERTS
  26
  LEGAL MATTERS
  26
  i
  RISK FACTORS
  You should carefully consider the risk
  factors set forth below as well as the other information contained or incorporated by reference in this prospectus before investing
  in our Common Stock. Any of the following risks could materially and adversely affect our business, financial condition or results
  of operations. In such a case, you may lose all or part of your investment. The risks described below are not the only risks facing
  us. Additional risks and uncertainties not currently known to us or those we currently view to be immaterial may also materially
  adversely affect our business, financial condition or results of operations.
  Risks Related to the Company
  We have a history of net losses and
  our future profitability is uncertain.
  We have recorded a loss
  for the fiscal year ended December 31, 2019, and our future profitability is uncertain. At December 31, 2019, our accumulated deficit
  was approximately $49.1 million. Since our inception, we have been engaged primarily in research and development and early-stage
  commercial activities. Because we have a limited history of commercial operations and we operate in a rapidly evolving industry,
  we cannot be certain that we will generate sufficient revenue to operate our business and become profitable.
  Our ability to generate
  revenues in the near-term is highly dependent on the successful commercialization of our biopolymer products, which is subject
  to many risks and uncertainties as described below. We expect that it will take time for our PHA production to ramp up to an economical
  scale while the market for our products expands. As a result, we expect to have significant losses and negative cash flow for at
  least the next several years, as we incur additional costs and expenses for the continued development and expansion of our business,
  including the costs of establishing manufacturing capacity and ongoing expenses of research and product development. The amount
  we spend will impact our ability to become profitable and this will depend, in part, on the number of new products that we attempt
  to develop. We may not achieve any or all of these goals and, thus, we cannot provide assurances that we will ever be profitable
  or achieve significant revenues.
  Even if we can successfully
  manufacture and sell our products, whether we will be able to generate a profit on any of these products is highly uncertain and
  depends on a number of factors including the cost of production, the price we are able to charge for these products, and the emergence
  of competing products.
  Our operating results may fluctuate
  significantly as a result of a variety of factors, many of which are outside of our control.
  We are subject to, among
  other things, the following factors that may negatively affect our operating results:
  ●
  the announcement or introduction of new products by
  our competitors;
  ●
  our ability to upgrade and develop our systems and
  infrastructure to accommodate growth;
  ●
  our ability to attract and retain key personnel in
  a timely and cost-effective manner;
  ●
  our ability to attract new customer and retain existing
  customers;
  ●
  technical difficulties;
  ●
  the amount and timing of operating costs and capital
  expenditures relating to the expansion of our business, operations and infrastructure;
  ●
  our ability to identify and enter into relationships
  with appropriate and qualified third-party providers of necessary testing and manufacturing services;
  ●
  regulation by federal, state or local governments;
  and
  ●
  general economic conditions, as well as economic conditions
  specific to the plastics industry, and other industries related to compostable or biodegradable substitutes for non-biodegradable
  plastics.
  As a result of our limited
  operating history and the nature of the markets in which we compete, it is difficult for us to forecast our revenues or earnings
  accurately. We have based our anticipated future expense levels largely on our investment plans and estimates of future events,
  although certain of our expense levels will, to a large extent, become fixed. As a strategic response to changes in the competitive
  environment, we may from time to time make certain decisions concerning expenditures, pricing, service or marketing that could
  have a material and adverse effect on our business, results of operations and financial condition. Due to the foregoing factors,
  our revenues and operating results are difficult to forecast.
  1
  We will need to secure additional
  funding and may be unable to raise additional capital on favorable terms, if at all.
  We expect that we will
  have sufficient capital to fund our planned operations through the completion of Phase II of the production capacity buildout at
  the Kentucky Facility and anticipated Greenfield plant. Thereafter, we will need to raise additional capital to continue to scale
  and expand our manufacturing capability. If we issue equity or debt securities to raise additional funds, (i) we may incur
  fees associated with such issuance, (ii) our existing stockholders will experience dilution from the issuance of new equity securities,
  (iii) we may incur ongoing interest expense and be required to grant a security interest in our assets in connection with any debt
  issuance and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of our existing
  stockholders. In addition, utilization of our net operating loss and research and development credit carryforwards may be subject
  to significant annual limitations under Section 382 of the Code due to ownership changes resulting from future equity financing
  transactions. If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary
  to relinquish valuable rights to our potential products or proprietary technologies, or grant licenses on terms that are not favorable
  to us. In the event we are unable to obtain additional financing, we may be unable to successfully implement our business plan,
  which could have a material and adverse impact on our business, including you losing your entire investment.
  Our biopolymer products may not achieve
  market success.
  We currently have limited
  customer commitments for commercial quantities of our biopolymer products. Some prospective customers are currently evaluating
  and testing our products prior to making large-scale purchase decisions. The successful commercialization of our biopolymers is
  also dependent on our customers' ability to commercialize the end-products that they make from our biopolymers, which may
  never gain market acceptance.
  Market acceptance of
  our products will depend on numerous factors, many of which are outside of our control, including among others:
  ●
  public acceptance of such products;
  ●
  our ability to produce products of consistent quality
  that offer functionality comparable or superior to existing or new polymer products;
  ●
  our ability to produce products fit for their intended
  purpose;
  ●
  our ability to obtain necessary regulatory approvals
  for our products;
  ●
  the speed at which potential customers qualify our
  biopolymers for use in their products;
  ●
  the pricing of our products compared to competitive
  products, including petroleum-based plastics;
  ●
  the strategic reaction of companies that market competitive
  products;
  ●
  our reliance on third parties who support or control
  distribution channels; and
  ●
  general market conditions.
  We produce bio-based products from
  renewable resources, whose pricing and availability may be impacted by factors out of our control.
  Pricing and availability
  of raw materials, including renewable resources, for use in our businesses can be volatile due to numerous factors beyond our control,
  including general, domestic and international economic conditions, labor costs, production levels, competition, consumer demand.
  Drought, pestilence, severe weather or other "acts of God" may limit our ability to procure raw materials if crops
  are lost. This volatility can significantly affect the availability and cost of raw materials for us, and may therefore have a
  material adverse effect on our business, results of operations and financial condition.
  We sell formulated resins
  which include raw materials purchased from third parties, including PLA. We currently source all of our PLA from two suppliers,
  NatureWorks LLC and Total Corbion PLA. Due to the high rate of growth in the biopolymer market, the demand for PLA and other raw
  materials used in our products may outpace supply, which could result in price increases and deficits in the supply necessary to
  meet customer demand. If we are unable to secure the required quantities of PLA and other third-party raw materials, we may not
  be able to achieve our financial forecasts and fulfill customer demand.
  If our products and product candidates
  do not gain market acceptance among key market participants, we may be unable to generate significant revenues, if any.
  Even if we obtain regulatory
  approval for our product candidates, they may not gain market acceptance among plastics manufacturers or other plastic users. Market
  acceptance will depend on our ability to demonstrate the benefits of our approved products in terms of safety, efficacy, convenience,
  biodegradability and environmental friendliness, ease of administration and cost effectiveness. In addition, we believe market
  acceptance depends on the effectiveness of our marketing strategy and the pricing of our approved products.
  2
  We have limited experience producing
  PHA in large commercial quantities.
  We have limited experience
  in producing large quantities of PHA. While we have succeeded in producing smaller amounts of PHA in our pilot plant for customer
  trials and testing purposes, we only recently commenced the production of PHA in a large commercial plant with a capacity sufficient
  to meet the anticipated needs of prospective customers. We may not be able to cost effectively produce PHA at a scale consistent
  with customer demand in a timely or economical manner, or that the quality of the commercial product will be acceptable on a consistent
  basis. Further, if the Kentucky Facility is not able to meet customer demands, we will have to expand our facility, which will
  disrupt production and deplete our resources.
  Some of our PHA products may never
  become commercially marketable.
  Although we do currently
  sell commercial quantities of compostable PLA-based resins, we only recently commenced producing commercially viable quantities
  of PHA. Limited research and testing have been completed on some of the products that we may produce using PHA. For some applications,
  we will have to go through extensive research and testing to develop specific products and to determine or demonstrate the safety
  and effectiveness of their proposed use. Although we have already received food contact approval for some grades of PHA, some of
  our product candidates and our proposed testing of those products will require additional regulatory approvals and clearances.
  Accordingly, not all of the products we intend to pursue are presently marketable in the fields of use for which we hope to develop
  them, and it is possible (or even probable) that some or all of them may never become legally and commercially marketable. The
  development and testing of our proposed products is difficult, time-consuming and expensive, and the successful development of
  any products based on innovative technologies is subject to inherent uncertainties and risks of failure. These risks include the
  possibilities that any or all of the proposed products or procedures may be found to be ineffective, or may otherwise fail to receive
  necessary regulatory clearances; that the proposed products or procedures may be uneconomical to produce and market or may never
  achieve broad market acceptance; that third parties may hold proprietary rights that preclude us from marketing our intended products
  or procedures; or that third parties may develop and market superior or equivalent products and procedures.
  We may be unable to obtain certifications
  required by certain customers.
  Many of our customers
  require biopolymer formulations to undergo biodegradability testing to address physical property deterioration in specific environmental
  conditions. Biodegradation certification is important for our customers to ensure those products can be effectively marketed and
  sold and meet customer demands on environmental protection. If our new PHA based resins to be sold out of the Kentucky Facility
  don't achieve the required certifications in a timely manner, we may experience a delay in going to market. Such a delay
  could result in us not achieving our financial forecasts and not fulfilling customer demand.
  We may be unable to manage rapid
  growth effectively.
  Our failure to manage
  growth effectively could have a material and adverse effect on our business, results of operations and financial condition. We
  anticipate that a period of significant expansion will be required to address potential growth and to handle licensing and research
  activities. This expansion will place a significant strain on our management, operational and financial resources. To manage the
  expected growth of our operations and personnel, we must establish appropriate and scalable operational and financial systems,
  procedures and controls and must establish a qualified finance, administrative and operations staff. Our management may be unable
  to hire, train, retain and manage the necessary personnel or to identify, manage and exploit potential strategic relationships
  and market opportunities.
  We may be delayed in or unable to
  procure necessary capital equipment.
  While the equipment
  we use to produce PHA and our other products is currently widely available, we must rely on outside companies to continue to manufacture
  the equipment necessary to produce our products. If our suppliers of capital equipment are unable or unwilling to provide us with
  necessary capital equipment to manufacture our products or if we experience significant delays in obtaining the necessary manufacturing
  equipment, our business, results of operations and financial condition could be adversely affected.
  Our success will be influenced by
  the price of petroleum relative to the price of bio-based feedstocks.
  Our success may be influenced
  by the cost of our products relative to petroleum-based polymers. The cost of petroleum-based polymers is in part based on the
  price of petroleum. To date, our PHA biopolymers have been primarily manufactured using canola oil, an agricultural feedstock.
  As the price of biobased feedstocks increases and/or the price of petroleum decreases, our biobased products may be less competitive
  relative to petroleum-based polymers. A material decrease in the cost of conventional petroleum-based polymers may require a reduction
  in the prices of our products for them to remain attractive in the marketplace and/or reduce the size of our addressable market.
  3
  Certain contracts granting exclusivity
  rights to customers may limit our ability to sell products in certain markets.
  We have entered into
  certain agreements with customers, which, subject to the terms therein, grant these customers the exclusive right to purchase certain
  products and, in some cases, in certain fields and/or territories from us. For example, certain clam-shell food cases we produce
  can only be sold to a single customer; certain stirrers and straw products can only be sold to several end-users, subject to the
  purchaser maintaining minimum purchase requirements; one customer has an exclusive on water bottles, while another customer has
  an exclusive on bottles containing certain alcohol products. These exclusivity arrangements will expire between 2021 and 2026.
  These agreements could prevent us from selling products to certain prospective customers or entering certain markets, which could
  have a material and adverse impact on our potential revenues and our ability more generally to expand our customer base and product
  lines.
  The loss of one or more of our significant
  customers, a significant reduction in their orders, their inability to perform under their contracts, or a significant deterioration
  in their financial condition could have a material adverse effect on our business, results of operations, and financial condition.
  A few significant customers
  have in the past, and may in the future, account for a significant portion of our revenues in any one year or over a period of
  several consecutive years. For example, for the nine months ended September 30, 2020, we had two customers that individually accounted
  for more than 10% of our revenue each and collectively accounted for approximately 53% of our revenue, and for the year ended December
  31, 2019, we had four customers that individually accounted for more than 10% of our revenue each and collectively accounted for
  approximately 65% of our total revenue. The loss of one or more of our significant customers, a substantial reduction in their
  orders, their inability to perform under their contracts, or a significant deterioration in their financial condition could have
  a material adverse effect on our business, results of operations, and financial condition.
  We may rely heavily on future collaborative
  partners.
  We may enter into strategic
  partnerships to develop and commercialize our current and future research and development programs with other companies to accomplish
  one or more of the following:
  ●
  obtain capital, equipment and facilities,
  ●
  obtain funding for research and development programs,
  product development programs and commercialization activities,
  ●
  obtain expertise in relevant markets,
  ●
  obtain access to raw materials and/or
  ●
  obtain sales and marketing services or support.
  We may not be successful
  in establishing or maintaining suitable partnerships, and we may not be able to negotiate collaboration agreements having terms
  satisfactory to us or at all. Failure to make or maintain these arrangements or a delay or failure in a collaborative partner's
  performance under any such arrangements could have a material adverse effect on our business and financial condition.
  We face and will face substantial
  competition.
  We face and will face
  substantial competition from a variety of companies in the biodegradable, renewable resource-based plastic segment, as well as
  from companies in the conventional, non-biodegradable petroleum-based industry segment. Some of their products are suitable for
  use in a range of products at a price which may be lower than our product offerings. Many of these companies have longer operating
  histories, greater name recognition, larger customer bases and significantly greater financial, sales and marketing, manufacturing,
  distribution, technical and other resources than us. Our competitors may be able to adapt more quickly to new or emerging technologies,
  changes in customer requirements and changes in laws and regulations. In addition, current and potential competitors have established
  or may establish financial or strategic relationships among themselves or with existing or potential customers or other third parties.
  Accordingly, new competitors or alliances among competitors could emerge and rapidly acquire significant market share. There can
  be no assurance that we can develop products that are more effective or achieve greater market acceptance than competitive products,
  or that our competitors will not succeed in developing products and technologies that are more effective than those being developed
  by us and that would therefore render our products and technologies less competitive or even obsolete. We cannot assure you that
  we will be able to compete successfully against current or new competitors.
  We may not be able to complete either
  or both phases of the proposed production capacity buildout at our Kentucky Facility.
  In December 2018, we
  consummated the acquisition of the Kentucky Facility, including the equipment, machinery and other personal property located at
  such facility for a purchase price of $23 million, and simultaneously entered into a sale and leaseback transaction with a large,
  diversified commercial property REIT (the "REIT") pursuant to which we sold the Kentucky Facility and certain of our
  facilities located in Bainbridge, Georgia to the REIT and leased-back the same properties from the REIT under a net-lease for an
  initial term of 20 years with renewal terms up to an additional 20 years at our option. The assets available at the Kentucky Facility
  permitted us to embark on a two-phase commissioning strategy, and we commenced production of commercial volumes of PHA in December
  2019. Several components of the first phase of the production capacity buildout were completed at the end of the third quarter
  of 2020 after investing approximately $54 million since the acquisition of the Kentucky Facility, excluding capitalized interest.
  Of this total, $7 million in real-estate improvements for the Kentucky Facility were financed by the REIT and leased back to us
  in May 2020. Once Phase I of the Kentucky Facility production capacity is operating at scale, we expect to produce approximately
  20 million pounds of finished product per year. We believe that the capacity of the plant can be expanded by another 45 million
  additional pounds of finished product, bringing total plant capacity up to approximately 65 million pounds per year, by investing
  another $100 million in the future for the Phase II production capacity buildout at such facility. There can be no assurances,
  though, that we will be able to achieve such production capacity or raise the additional financing required to complete Phase II
  of the production capacity buildout.
  4
  We may not be able to identify additional
  facilities and assets or secure the funding necessary to acquire them.
  Aside from the Kentucky
  Facility, we may need to identify other facilities and assets that would be beneficial to our production of PHA at the commercial
  scale or our growth in general. We cannot provide assurances that we will be successful in identifying such facilities and assets
  or, if we do, securing the funding necessary to acquire them.
  Climate Change may impact the availability
  of our facilities and, in addition, we may incur substantial costs to comply with climate change legislation and related regulatory
  initiatives.
  Changing weather patterns
  and the increase in frequency of severe storms such as hurricanes and tornadoes could cause disruptions or the complete loss of
  our facilities. In addition, climate change concerns, and changes in the regulation of such concerns, including greenhouse gas
  emissions, could also subject us to additional costs and restrictions, including increased energy and raw materials costs which
  could negatively impact our financial condition and results of operations. The effects of climate change can have an adverse effect
  not only to our operations, but also that of our suppliers and customers, and can lead to increased regulations and changes in
  consumer preferences, which could adversely affect our business, results of operations and financial condition.
  We may be subject to product liability
  claims that may not be covered by insurance and could require us to pay substantial sums.
  If we are successful
  in obtaining regulatory approval for our products and/or otherwise begin marketing them, we will become subject to an inherent
  risk of, and adverse publicity associated with, product liability and other liability claims, whether or not such claims are valid.
  We intend to obtain product liability insurance coverage in amounts and scope that we believe will be adequate once we begin marketing
  any products. However, product liability insurance may not be available on commercially acceptable terms, or at all. Even if such
  insurance is available, product liability or other claims may exceed our insurance coverage limits. A successful product liability
  claim that exceeds our insurance coverage limits could require us to pay substantial sums and could have a material adverse effect
  on us.
  Changes in government regulations
  encouraging the use of biodegradable alternatives to plastic products may have an adverse effect on our business.
  We anticipate one of
  the key markets for our products being compostable and biodegradable substitutes for non-biodegradable plastics, which are created
  in part by laws, regulations and policies designed to encourage or mandate the increased use of compostable and biodegradable
  alternatives to plastics. Several countries and other political subdivisions of countries have enacted or are considering enacting
  such laws and regulations. Failure to implement these or similar laws and regulations and changes to existing laws and regulations
  may adversely affect the demand for our product candidates in the future.
  We may not be able to protect adequately
  our patents and other intellectual property assets, which could adversely affect our competitive position and reduce the value
  of our products, and litigation to protect our patents and intellectual property assets may be costly.
  Our commercial success
  may depend in part on our ability to obtain patent protection for technologies and products we develop, to preserve trade secrets
  and to operate without infringing the proprietary rights of others. There can be no assurance that any patents or patent applications
  that we own, obtain or file or are able to obtain or license from third parties will afford any competitive advantages or will
  not be challenged or circumvented by third parties. Furthermore, there can be no assurance that others will not independently develop
  similar technologies or duplicate any technology developed by us. Because of the extensive time required for development, testing
  and regulatory review of a potential product, it is possible that before any of our potential products can be commercialized, any
  related patents may expire or may have only a brief remaining life span following commercialization, thus reducing any advantage
  of the patents.
  If we are not able to
  obtain patent coverage or defend the patent protection for our technologies, then we will not be able to exclude competitors from
  developing or marketing competing technologies, and we may not generate enough revenues from product sales to justify the cost
  of development of our technologies and to achieve or maintain profitability. The patents currently in the portfolio have expiration
  dates ranging from 2022 to 2040 and any patents resulting from pending patent applications are expected to have durations that
  will expire between 2038 and 2041.
  5
  Our patent position
  involves complex legal and factual questions. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced
  in our patents or in third-party patents. Patents may not be issued for any pending or future pending patent applications owned
  by or licensed to us, and claims allowed under any issued patent or future issued patent owned or licensed by us may not be valid
  or sufficiently broad to protect our technologies. Moreover, we may be unable to protect certain of our intellectual property in
  the United States or in foreign countries. Foreign jurisdictions may not afford the same protections as U.S. law, and we cannot
  ensure that foreign patent applications will have the same scope as the U.S. patents. There will be many countries in which we
  will choose not to file or maintain patents because of the costs involved. Competitors may also design around our technology or
  develop competing technologies.
  Additionally, any issued
  patents owned by or licensed to us now or in the future may be challenged, invalidated or circumvented. To the extent competitors
  or other third parties develop and market products or procedures that we believe infringe our patents and proprietary rights, we
  may be compelled to initiate lawsuits to protect and enforce our intellectual property rights. Such litigation is typically expensive,
  time-consuming and uncertain as to outcome, and may involve opponents who have much more extensive financial resources than we
  do. An unfavorable outcome of any such litigation could have a material adverse effect on our business and results of operations.
  Third parties may claim that we infringe
  on their proprietary rights and may prevent us from commercializing and selling our products.
  There has been substantial
  litigation in the manufacturing industry with respect to the manufacture, use and sale of new products. These lawsuits often involve
  claims relating to the validity of patents supporting the new products and/or the validity and alleged infringement of patents
  or proprietary rights of third parties. We may be required to defend against challenges to the validity of our patents and against
  claims relating to the alleged infringement of patent or proprietary rights of third parties.
  Litigation initiated
  by a third-party claiming patent invalidity or patent infringement could:
  ●
  require us to incur substantial litigation expense,
  even if we are successful in the litigation;
  ●
  require us to divert significant time and effort of
  our management;
  ●
  result in the loss of our rights to develop, manufacture
  or market our products; and
  ●
  require us to pay substantial monetary damages or
  royalties in order to license proprietary rights from third parties or to satisfy judgments or to settle actual or threatened
  litigation.
  Although patent and
  intellectual property disputes within the biopolymer industry have often been settled through licensing or similar arrangements,
  costs associated with these arrangements may be substantial and could include the long-term payment of royalties. Furthermore,
  the required licenses may not be made available to us on acceptable terms. Accordingly, an adverse determination in a judicial
  or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing and selling our products
  or increase our costs to market our products.
  We rely in part on trade secrets
  to protect our technology, and our failure to obtain or maintain trade secret protection could limit our ability to compete.
  We rely on trade secrets
  to protect some of our technology and proprietary information, especially where we believe patent protection is not appropriate
  or obtainable. However, trade secrets are difficult to protect. Litigating a claim that a third party had illegally obtained and
  was using our trade secrets would be expensive and time consuming, and the outcome would be unpredictable. Moreover, if our competitors
  independently develop similar knowledge, methods and know-how, it will be difficult for us to enforce our rights and our business
  could be harmed.
  We may not be able to generate sufficient
  cash to service all of our debt and operating lease obligations, and may be forced to take other actions to satisfy our obligations
  under our debt and operating lease obligations, which may not be successful.
  Our ability to make
  scheduled payments on or to refinance our debt service and operating lease obligations and other obligations depends on our ability
  to generate cash in the future and our financial condition and operating performance, which are subject to prevailing economic
  and competitive conditions and to certain financial, business and other factors beyond our control. We cannot assure you that we
  will maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and
  interest on our debt, or to pay our operating lease obligations. As of September 30, 2020, we had principal and interest payments
  on debt due in the next twelve months of $12.3 million and $3.1 million, respectively.
  6
  If our cash flows and
  capital resources are insufficient to fund our debt service, operating lease obligations and other obligations, we may be forced
  to reduce or delay investments and capital expenditures, or to sell assets, seek additional capital or restructure or refinance
  our debt.  These alternative measures may not be successful and may not permit us to meet our scheduled debt obligations. 
  If our operating results and available cash are insufficient to meet our debt service, operating lease obligations and other obligations,
  we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt
  service and other obligations.  We may not be able to consummate those dispositions or to obtain the proceeds sought from
  them, and these proceeds may not be adequate to meet any debt service or other obligations then due.  Further, we may need
  to refinance all or a portion of our debt on or before maturity, and we cannot assure you that we will be able to refinance any
  of our debt on commercially reasonable terms or at all. Additionally, if we are unable to service our operating lease payments
  for our facilities in Bainbridge, Georgia and Winchester, Kentucky, which we lease pursuant to a sale-leaseback transaction that
  was entered into in 2018 with a commercial property REIT, we could lose the ability to occupy and operate those facilities.
  Despite our current significant indebtedness,
  we may be able to incur more debt in the future, which could further exacerbate the risks of leverage, including the ability to
  service our indebtedness.
  We may need to incur
  additional debt in the future to complete acquisitions of facilities, equipment, machinery and other assets or capital projects
  or for working capital. Although the covenants contained in our current indebtedness instruments may impose some limits on our
  ability to incur new debt, these agreements may permit the incurrence of significant additional debt if we satisfy certain conditions
  or such debt instruments may be amended in the future to do so. If we incur new debt, the risks related to being in a highly leveraged
  company that we now face could intensify, including our ability to service such indebtedness.
  We are subject to a number of restrictive
  debt covenants under our loan agreements
  .
  Many of our loan agreements
  contain certain restrictive covenants, which restrict our ability to, among other things, incur additional indebtedness, incur
  certain liens on our assets or sell assets, make investments, make capital expenditures, pay dividends and make other restricted
  payments. Many of our loan agreements also require us to maintain specified financial ratios under certain conditions and satisfy
  financial condition tests, including a consolidated senior leverage ratio and consolidated fixed charge coverage ratio.
  Our ability to meet
  those financial ratios and tests and otherwise comply with our financial covenants may be affected by the factors described herein
  and other factors outside our control, and we may not be able to meet those ratios, tests and covenants. Our ability to generate
  sufficient cash from operations to meet our debt obligations will depend upon our future operating performance, which will be affected
  by general economic, financial, competitive, business and other factors beyond our control. A breach of any of these covenants,
  ratios, tests or restrictions, as applicable, or any inability to pay interest on, or principal of, our outstanding debt as it
  becomes due could result in an event of default. Upon an event of default, if not waived by our lenders, our lenders may declare
  all amounts outstanding as due and payable. Such an acceleration of the maturity of our indebtedness may, among other things, prevent
  or limit us from engaging in transactions that benefit us, including responding to changing business and economic conditions and
  taking advantage of attractive business opportunities.
  We may not be able to satisfy the
  requirements of our participation in a New Markets Tax Credit ("NMTC") program for funding our plant expansions.
  We have entered into
  several arrangements under the NMTC program with various third-party financial institutions (the "Investors") to help
  fund various phases of plant expansions at our Bainbridge, Georgia, and Winchester, Kentucky locations. In connection with the
  NMTC transactions we received proceeds which were restricted for use on approved capital expenditures and working capital needs
  at specific subsidiaries. The NMTCs are subject to 100% recapture of the tax credit for a period of seven years as provided in
  the Code. We are required to be in compliance with various regulations and contractual provisions that apply to the NMTC arrangements.
  we have agreed to indemnify the Investors for any loss or recapture of the NMTCs until such time as our obligation to deliver tax
  benefits is relieved. The maximum potential amount of future payments under this indemnification could be up to the face amount
  of the related debt, net of certain leverage loans receivable in connection with the NMTC transactions, which amount totaled $13.2
  million as of September 30, 2020. Our obligation to deliver tax benefits is relieved in various stages from April 2026 through
  November 2026. Non-compliance with applicable requirements could result in projected tax benefits not being realized by an Investor
  and our being required to indemnify such Investor, which could have a material adverse effect on our financial position, results
  of operations or liquidity.
  7
  We may be unable to obtain forgiveness
  of the PPP Loan, in whole or in part, in accordance with the provisions of the CARES Act, which could adversely affect our financial
  condition.
  In April 2020, we entered
  into a promissory note with Truist Bank ("Truist"), under the Paycheck Protection Program of the CARES Act pursuant
  to which Truist made a loan to us in the amount of approximately $1.8 million (the "PPP Loan"). The PPP Loan matures
  in April 2022, bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months
  after the date of disbursement.
  The PPP Loan is unsecured
  and guaranteed by the Small Business Administration ("SBA"). Under the terms of the PPP Loan, the principal amount
  of the loan may be forgiven to the extent it is used for qualifying expenses as described in the CARES Act and we otherwise request
  forgiveness in accordance with the terms of the PPP Loan and the requirements of the SBA. While we expect to request that all of
  the principal amount of the PPP Loan be forgiven and to comply with all corresponding requirements, we cannot guarantee that we
  will be successful in obtaining forgiveness of all or any part of such principal amount. We will be required to repay any principal
  amount of the PPP Loan that is not forgiven, together with accrued and unpaid interest. In connection with the closing of the Business
  Combination, we deposited funds in an escrow account in an amount to repay the outstanding principal and accrued interest on the
  PPP loan.
  Our ability to use net operating
  losses to offset future taxable income will be subject to certain limitations as a result of the Business Combination, PIPE and
  past transactions.
  As of December 31, 2019,
  we had federal net operating loss carryforwards of $48.0 million of which $47 million will begin to expire in 2028 and $1 million
  can be carried forward indefinitely. As of December 31, 2019, we had state net operating loss carryforwards of $45 million which
  begin to expire in various amounts in 2028.  We may have generated additional net operating losses since then. A portion of
  these net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition,
  in general, under Section 382 of the Code, a corporation that undergoes an "ownership change" is subject to limitations
  on its ability to utilize its pre-change net operating losses ("NOLs") to offset future taxable income or taxes. For
  these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups
  of stockholders who owns at least 5% of a corporation's stock increases its ownership by more than 50 percentage points over
  its lowest ownership percentage within a specified testing period. A portion of our existing NOLs are subject to limitations arising
  from previous ownership changes in 2014. In addition, the Business Combination and the PIPE is expected to constitute an ownership
  change under Section 382 of the Code. Our NOLs may also be impaired under state law. A portion of our existing NOLs are also subject
  to the so called separate-return-limitation-year ("SRLY") rules that may apply to consolidated tax groups. Although
  depending on applicable law and particular computations, it is expected that the amount of our NOLs that we will be able to utilize
  per year could be only up to $3.8 million per year. Accordingly, we may not be able to utilize a material portion of our NOLs.
  The Company's
  ability to utilize our NOLs is also conditioned upon our attaining profitability and generating U.S. federal and state taxable
  income. We have incurred significant net losses in the past, and it is anticipated that we will continue to incur significant losses
  for the foreseeable future; therefore, we do not know whether or when we will generate the U.S. federal or state taxable income
  necessary to utilize our NOL carryforwards, even to the extent they are not subject to limitation by Section 382 of the Code
  or the SRLY rules.
  We face various risks related to
  the ongoing coronavirus (COVID-19) pandemic and similar public health crises, which may have material adverse effects on our business,
  financial position, results of operations and/or liquidity.
  We face various risks
  related to health epidemics, pandemics and similar outbreaks, including the global outbreak of coronavirus disease 2019 ("COVID-19").
  Such risks include disruptions or restrictions on our employees' ability to work effectively, as well as temporary closures
  of our facilities or the facilities of our customers or suppliers.
  It is possible that
  the continued spread of COVID-19 could also further cause disruption in our supply chain; cause delay or limit the ability of other
  customers to perform, including in making timely payments to us; and, cause other unpredictable events. In addition, the continued
  spread of COVID-19 has led to disruption and volatility in the global capital markets, which increases the cost of capital and
  adversely impacts access to capital.
  8
  We continue to work
  with our stakeholders (including customers, employees, suppliers and local communities) to responsibly address this global pandemic.
  Our management is focused on mitigating the impact of the pandemic, which has required and will continue to require a substantial
  investment of time and resources across Danimer and could delay other value-added initiatives. We continue to monitor the situation,
  to assess further possible implications to our business, supply chain and customers, and to take actions in an effort to mitigate
  adverse consequences.
  The situation surrounding
  COVID-19 remains fluid and the ongoing impact on our business and results of operations, financial condition, expected cash flows
  and liquidity increases the longer the virus impacts activity levels in the United States and globally, both during the initial
  outbreak, as well as if additional outbreaks occur at a later date. For this reason, we cannot reasonably estimate with any degree
  of certainty the future impact COVID-19 may have on our results of operations, financial position and liquidity. The extent to
  which the COVID-19 pandemic may impact our business, operating results, financial condition or liquidity will depend on future
  developments and numerous and evolving factors that are highly uncertain, vary by market and cannot be accurately predicted or
  quantified at this time, including the duration and spread of the outbreak; new information concerning its transmission and severity;
  government mandated restrictions and regulations; business and workforce disruptions; impact on demand for our products, and the
  effectiveness of actions taken to contain and treat the disease; actions taken or that might be taken by governments, businesses
  or individuals to contain or reduce its repercussions and mitigate its economic implications; evolving macroeconomic factors, including
  general economic uncertainty, unemployment rates and recessionary pressures; decreased consumer spending levels; reduction or changes
  in customer demand for our products and services; our ability to manufacture, sell and provide our products and services, including
  as a result of travel restrictions, closed borders, operating restrictions imposed on our facilities or reduced ability of our
  employees to continue to work efficiently; increased operating costs (whether as a results of changes to our supply chain or increases
  in employee costs or otherwise); collectability of customer accounts; additional and prolonged devaluation of other countries'
  currencies relative to the dollar; and the general impact of the pandemic on our customers, employees, suppliers, vendors and other
  stakeholders. Additionally, customers might defer decision making, delay orders or seek to renegotiate or terminate existing agreements.
  The continuing global
  pandemic may also result in delays in our ability to apply for and obtain further regulatory approval for our products in various
  jurisdictions.
  The impact of COVID-19
  may also exacerbate other risks discussed herein, any of which could have a material effect on us. This situation is changing rapidly,
  and additional impacts may arise that we are not aware of currently.
  We depend on key personnel
  .
  We depend greatly on
  our executive officers and other employees. Our success will depend, in part, upon our ability to attract and retain additional
  skilled personnel, which will require substantial additional funds. There can be no assurance that we will be able to find, attract
  and retain additional qualified employees, directors, and advisors having the skills necessary to operate, develop and grow our
  business. Our inability to hire qualified personnel, the loss of services of any of our executive officers, or the loss of services
  of other key employees, or advisors that may be hired in the future, may have a material and adverse effect on our business.
  If we experience a significant disruption
  in our information technology systems, including security breaches, or if we fail to implement new systems and software successfully,
  our business operations and financial condition could be adversely affected.
  We depend on information
  technology systems throughout Danimer to, among other functions, control our manufacturing processes, process orders and bill,
  collect and make payments, interact with customers and suppliers, manage inventory and otherwise conduct business. We also depend
  on these systems to respond to customer inquiries, contribute to our overall internal control processes, maintain records of our
  property, plant and equipment and record and pay amounts due to vendors and other creditors. The failure of our information technology
  systems to perform as we anticipate could disrupt our business and could result in transaction errors, processing inefficiencies
  and the loss of sales and customers. As we upgrade or change systems, we may also experience interruptions in service, loss of
  data or reduced functionality and other unforeseen material issues which could adversely impact our ability to provide quotes,
  take customer orders and otherwise run our business in a timely manner. In addition, if our new systems fail to provide accurate
  and increased visibility into pricing and cost structures, it may be difficult to improve or maximize our profit margins. As a
  result, our results of operations could be adversely affected.
  In addition, cyber-attacks
  or security breaches could compromise confidential, business critical information, cause a disruption in our operations or harm
  our reputation. Our information technology systems are subject to potential disruptions, including significant network or power
  outages, cyberattacks, computer viruses, other malicious codes and/or unauthorized access attempts, any of which, if successful,
  could result in data leaks or otherwise compromise our confidential or proprietary information and disrupt our operations. Despite
  our efforts to protect sensitive information and comply with and implement data security measures, there can be no assurance that
  any controls and procedures that we have in place will be sufficient to protect us. Further, as cyber threats are continually evolving,
  our controls and procedures may become inadequate and we may be required to devote additional resources to modify or enhance our
  systems in the future. We may also be required to expend resources to remediate cyber-related incidents or to enhance and strengthen
  our cyber security. Any such disruptions to our information technology systems, breaches or compromises of data, and/or misappropriation
  of information could result in violation of privacy and other laws, litigation, fines, negative publicity, lost sales or business
  delays, any of which could have a material adverse effect on our business, financial condition or results of operations.
  9
  Government regulation of our business
  is extensive and regulatory approvals are uncertain, expensive and time-consuming.
  Our research, development,
  testing, manufacturing and marketing of most of our intended products are subject to an extensive regulatory approval process by
  the FDA and other regulatory agencies in the U.S. and abroad. The process of obtaining FDA and other required regulatory approvals
  is lengthy, expensive and uncertain. There can be no assurance that, even after such time and expenditures, we will be able to
  obtain necessary regulatory approvals for the manufacturing or marketing of any products. Even if regulatory clearance is obtained,
  a marketed product is subject to continual review, and later discovery of previously unknown safety issues or failure to comply
  with the applicable regulatory requirements may result in restrictions on a product's marketing or withdrawal of the product
  from the market, as well as possible civil or criminal sanctions.
  Changes in sentiment regarding and
  laws and regulations relating to plastic products could reduce demand for our products and/or increase the cost of producing our
  products and have an adverse effect on our business.
  Plastic products have
  recently faced increasingly negative public sentiment and scrutiny. In addition, state and local governments have increasingly
  proposed, or in some cases implemented, restrictions or bans on plastic-based products, including single-use plastics, plastic
  straws and utensils. Notwithstanding the fact that our bio-plastic products are intended to address many of the concerns regarding
  traditional petroleum-based plastics, increased regulation of, or prohibition on, the use of plastics generally, as well as negative
  public sentiment regarding such products, could increase the costs incurred by our customers to use such products or otherwise
  limit the use of these products, and could lead to a decrease in demand for the products we make or an increase in the cost of
  production of such products. Such a decrease in demand could adversely affect our business, operating results and financial condition.
  Risks Related to our Common Stock
  An active trading market for our
  Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. Our stock price may be
  extremely volatile, and our stockholders could lose a significant part of their investment.
  An active trading market
  for shares of our Common Stock may not be sustained on a consistent basis. The public trading price for our Common Stock will be
  affected by a number of factors, including:
  ●
  reported progress of our business and technology development,
  relative to investor expectations;
  ●
  changes in earnings estimates, investors' perceptions,
  recommendations by securities analysts or our failure to achieve analysts' earnings estimates;
  ●
  quarterly variations in our or our competitors'
  results of operations;
  ●
  general market conditions and other factors unrelated
  to our operating performance or the operating performance of our competitors;
  ●
  future issuance and/or sale of our common stock or
  preferred stock;
  ●
  announcements by us, or our competitors, of acquisitions,
  new products, significant contracts, commercial relationships or capital commitments;
  ●
  commencement of, or involvement in, litigation;
  ●
  any major change in our board of directors or management;
  ●
  changes in governmental regulations or in the status
  of our regulatory approvals;
  ●
  announcements related to patents issued to us or our
  competitors and to litigation involving our intellectual property;
  ●
  a lack of, limited, or negative industry or security
  analyst coverage;
  ●
  developments in our industry and general economic
  conditions;
  ●
  short-selling or similar activities by third parties;
  and
  ●
  other factors described elsewhere in these "
  Risk
  Factors
  ."
  As a result of these
  factors, our stockholders may not be able to resell their shares of Common Stock at, or above, their purchase price. In addition,
  the stock prices of many technology companies have experienced wide fluctuations that have often been unrelated to the operating
  performance of those companies. Any negative change in the public's perception of the prospects of industrial biotechnology
  or "clean technology" companies could depress our stock price regardless of our results of operations. These factors
  may have a material adverse effect on the market price of our Common Stock.
  Concentration of ownership among
  our existing executive officers, directors and their affiliates may prevent new investors from influencing significant corporate
  decisions.
  Our executive officers
  and directors as a group beneficially own approximately 20.3% of our outstanding Common Stock. As a result, these shareholders
  will be able to exercise a significant level of control over all matters requiring stockholder approval, including the election
  of directors, any amendment of the amended and restated certificate of incorporation and approval of significant corporate transactions.
  This control could have the effect of delaying or preventing a change of control or changes in management and will make the approval
  of certain transactions difficult or impossible without the support of these shareholders.
  10
  We do not expect to declare any dividends
  in the foreseeable future.
  We do not anticipate
  declaring any cash dividends to holders of our common stock in the foreseeable future. Consequently, investors may need to rely
  on sales of their shares after price appreciation, which may never occur, as the only way to realize any future gains on their
  investment.
  There can be no assurance that we
  will be able to comply with the continued listing standards of NYSE.
  If NYSE delists our
  securities from trading on its exchange for failure to meet the listing standards, we and our securityholders could face significant
  material adverse consequences including:
  ●
  a limited availability of market quotations for our
  securities;
  ●
  a determination that our Common Stock is a "penny
  stock" which will require brokers trading in Common Stock to adhere to more stringent rules, possibly resulting in a reduced
  level of trading activity in the secondary trading market for shares of our Common Stock;
  ●
  a limited amount of analyst coverage; and
  ●
  a decreased ability to issue additional securities
  or obtain additional financing in the future.
  We may be required to take write-downs
  or write-offs, or we may be subject to restructuring, impairment or other charges that could have a significant negative effect
  on our financial condition, results of operations and the price of Common Stock, which could cause you to lose some or all of your
  investment.
  Factors outside of our
  control may, at any time, arise. As a result of these factors, we may be forced to later write-down or write-off assets, restructure
  our operations or incur impairment or other charges that could result in us reporting losses.
  Even though these charges
  may be non-cash items and therefore not have an immediate impact on our liquidity, the fact that we report charges of this nature
  could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may cause us to
  be unable to obtain future financing on favorable terms or at all.
  If we do not meet the expectations
  of investors or securities analysts, the market price of our securities may decline.
  Fluctuations in the
  price of our securities could contribute to the loss of all or part of your investment. If an active market for our securities
  develops and continues, the trading price of our securities following could be volatile and subject to wide fluctuations in response
  to various factors, some of which are beyond our control. Any of the factors listed below could have a material adverse effect
  on your investment in our securities and our securities may trade at prices significantly below the price you paid for them. In
  such circumstances, the trading price of our securities may not recover and may experience a further decline.
  Factors affecting the
  trading price of our securities may include:
  ●
  actual or anticipated fluctuations in our quarterly
  financial results or the quarterly financial results of companies perceived to be similar to us;
  ●
  changes in the market's expectations about our
  operating results;
  ●
  success of competitors;
  ●
  our operating results failing to meet the expectation
  of securities analysts or investors in a particular period;
  ●
  changes in financial estimates and recommendations
  by securities analysts concerning Danimer or the biopolymer industry in general;
  ●
  operating and share price performance of other companies
  that investors deem comparable to ours;
  ●
  our ability to market new and enhanced products and
  technologies on a timely basis;
  ●
  changes in laws and regulations affecting our business;
  ●
  our ability to meet compliance requirements;
  ●
  commencement of, or involvement in, litigation involving
  us;
  ●
  changes in our capital structure, such as future issuances
  of securities or the incurrence of additional debt;
  ●
  the volume of our shares of common stock available
  for public sale;
  ●
  any major change in our board of directors or management;
  ●
  sales of substantial amounts of our shares of common
  stock by our directors, executive officers or significant stockholders or the perception that such sales could occur; and
  ●
  general economic and political conditions such as
  recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism.
  Broad market and industry
  factors may materially harm the market price of our securities irrespective of our operating performance. The stock market in general,
  and NYSE in particular, have experienced price and volume fluctuations that have often been unrelated or disproportionate to the
  operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities,
  may not be predictable. A loss of investor confidence in the market for stocks or the stocks of other companies which investors
  perceive to be similar to ours could depress our share price regardless of our business, prospects, financial conditions or results
  of operations. A decline in the market price of our securities also could adversely affect our ability to issue additional securities
  and our ability to obtain additional financing in the future.
  11
  We will incur significant increased
  expenses and administrative burdens as a public company, which could have an adverse effect on our business, financial condition
  and results of operations.
  We will face increased
  legal, accounting, administrative and other costs and expenses as a public company that we do not incur as a private company. The
  Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), including the requirements of Section 404, as well as rules
  and regulations subsequently implemented by the SEC, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and
  the rules and regulations promulgated and to be promulgated thereunder, the PCAOB and the securities exchanges, impose additional
  reporting and other obligations on public companies. Compliance with public company requirements will increase costs and make certain
  activities more time-consuming. A number of those requirements will require us to carry out activities we have not done previously.
  For example, we will create new board committees and adopt new internal controls and disclosure controls and procedures. In addition,
  expenses associated with SEC reporting requirements will be incurred. Furthermore, if any issues in complying with those requirements
  are identified (for example, if the auditors identify a material weakness or significant deficiency in the internal control over
  financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely
  affect our reputation or investor perceptions of us. It may also be more expensive to obtain director and officer liability insurance.
  Risks associated with our status as a public company may make it more difficult to attract and retain qualified persons to serve
  on our board of directors or as executive officers. The additional reporting and other obligations imposed by these rules and regulations
  will increase legal and financial compliance costs and the costs of related legal, accounting and administrative activities. These
  increased costs will require us to divert a significant amount of money that could otherwise be used to expand the business and
  achieve strategic objectives. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance
  and reporting requirements, which could further increase costs.
  Our failure to timely and effectively
  implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act could have a material adverse effect on
  our business.
  The standards required
  for a public company under Section 404(a) of the Sarbanes-Oxley Act are significantly more stringent than those required of us
  as a privately-held company. Management may not be able to effectively and timely implement controls and procedures that adequately
  respond to the increased regulatory compliance and reporting requirements. If we are not able to implement the additional requirements
  of Section 404(a) in a timely manner or with adequate compliance, we may not be able to assess whether our internal controls over
  financial reporting are effective, which may subject us to adverse regulatory consequences and could harm investor confidence and
  the market price of our securities.
  We qualify as an "emerging
  growth company" within the meaning of the Securities Act, and if we takes advantage of certain exemptions from disclosure
  requirements available to emerging growth companies, it could make our securities less attractive to investors and may make it
  more difficult to compare our performance to the performance of other public companies.
  We qualify as an "emerging
  growth company" as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we are eligible
  for and intend to take advantage of certain exemptions from various reporting requirements applicable to other public companies
  that are not emerging growth companies for as long as we continue to be an emerging growth company, including (a) the exemption
  from the auditor attestation requirements with respect to internal control over financial reporting under Section 404(b) of the
  Sarbanes-Oxley Act, (b) the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements and (c)
  reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We will remain an
  emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of Common Stock that
  are held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii) the last day of the fiscal year in which
  we have total annual gross revenue of $1.07 billion or more during such fiscal year (as indexed for inflation), (iii) the date
  on which we have issued more than $1 billion in non-convertible debt in the prior three-year period or (iv) the last day of the
  fiscal year following the fifth anniversary of the date of the first sale of Common Stock in the initial public offering of units
  of Live Oak Acquisition Corp., our predecessor, consummated on May 5, 2020. In addition, Section 107 of the JOBS Act also provides
  that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided
  in Section 7(a)(2)(B) of the Securities Act as long as we are an emerging growth company. An emerging growth company can therefore
  delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected
  not to opt out of such extended transition period and, therefore, we may not be subject to the same new or revised accounting standards
  as other public companies that are not emerging growth companies. Investors may find our Common Stock less attractive because we
  will rely on these exemptions, which may result in a less active trading market for our Common Stock and its price may be more
  volatile.
  Our management has limited experience
  in operating a public company.
  Our executive officers
  have limited experience in the management of a publicly traded company. Our management team may not successfully or effectively
  manage our transition to a public company that will be subject to significant regulatory oversight and reporting obligations under
  federal securities laws. Their limited experience in dealing with the increasingly complex laws pertaining to public companies
  could be a significant disadvantage in that it is likely that an increasing amount of their time may be devoted to these activities
  which will result in less time being devoted to our management and growth. We may not have adequate personnel with the appropriate
  level of knowledge, experience and training in the accounting policies, practices or internal controls over financial reporting
  required of public companies in the United States. The development and implementation of the standards and controls necessary for
  us to achieve the level of accounting standards required of a public company in the United States may require costs greater than
  expected. It is possible that we will be required to expand our employee base and hire additional employees to support our operations
  as a public company which will increase our operating costs in future periods.
  12
  The loss of such key personnel could
  negatively impact the operations and financial results of our business.
  Our ability to successfully
  operate our business is dependent upon the efforts of certain key personnel of ours and there can be no assurance that they will
  be able to do so. It is possible that we will lose some key personnel, the loss of which could negatively impact our operations
  and profitability. Furthermore, certain of our key personnel may be unfamiliar with the requirements of operating a company regulated
  by the SEC, which could cause us to have to expend time and resources helping them become familiar with such requirements.
  We may issue additional shares of
  common stock or preferred shares under an employee incentive plan which would dilute the interest of our stockholders.
  Our Fourth Amended and
  Restated Certificate of Incorporation authorizes the issuance of 200,000,000 shares of Common Stock, and 10,000,000 shares of preferred
  stock, in each case, par value $0.0001 per share. We may issue a substantial number of additional shares of common stock or shares
  of preferred stock under an employee incentive plan. The issuance of additional common stock or preferred shares:
  ●
  may subordinate the rights of holders of Common Stock
  if one or more classes of preferred stock are created, and such preferred shares are issued, with rights senior to those afforded
  to Common Stock; and
  ●
  could cause a change in control if a substantial number
  of shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards,
  if any, and could result in the resignation or removal of our present officers and directors.
  Our Fourth Amended and Restated Certificate
  of Incorporation will provide, subject to limited exceptions, that the courts of the State of Delaware will be the sole and exclusive
  forum for certain stockholder litigation matters, which could limit our stockholders' ability to obtain a favorable judicial
  forum for disputes with us or our directors, officers, employees or stockholders.
  Our Fourth Amended and
  Restated Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our
  name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions may be brought in
  the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal
  district court for the District of Delaware. Any person or entity purchasing or otherwise acquiring any interest in shares of our
  capital stock shall be deemed to have notice of and consented to the forum provisions in our Fourth Amended and Restated Certificate
  of Incorporation. In addition, our Fourth Amended and Restated Certificate of Incorporation provides that this choice of forum
  does not apply to any complaint asserting a cause of action under the Securities Act and the Exchange Act. Finally, our Fourth
  Amended and Restated Certificate of Incorporation provides that federal district courts of the United States will be the exclusive
  forum for the resolution of any complaint asserting a cause of action under the Securities Act or the Exchange Act.
  In March 2020, the Delaware
  Supreme Court issued a decision in Salzburg et al. v. Sciabacucchi, which found that an exclusive forum provision providing for
  claims under the Securities Act to be brought in federal court is facially valid under Delaware law. It is unclear whether this
  decision will be appealed, or what the final outcome of this case will be. We intend to enforce this provision, but we do not know
  whether courts in other jurisdictions will agree with this decision or enforce it.
  This choice of forum
  provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with
  us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims.
  Alternatively, if a court were to find the choice of forum provision contained in the Fourth Amended and Restated Certificate of
  Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action
  in other jurisdictions, which could harm our business, operating results and financial condition.
  Because we have no current plans
  to pay cash dividends on Common Stock for the foreseeable future, you may not receive any return on investment unless you sell
  Common Stock for a price greater than that which you paid for it.
  We may retain future
  earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the
  foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion
  of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements,
  contractual restrictions and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends
  may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you
  may not receive any return on an investment in Common Stock unless you sell Common Stock for a price greater than that which you
  paid for it.
  If securities or industry analysts
  do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations
  regarding our securities adversely, the price and trading volume of our securities could decline.
  The trading market for
  our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business,
  market or competitors. If no additional securities or industry analysts commence coverage of our share price and trading volume
  may be negatively impacted. If any of the analysts who may cover us change their recommendation regarding our shares of common
  stock adversely, or provide more favorable relative recommendations about our competitors, the price of our shares of common stock
  would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us,
  we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.
  13
  FORWARD-LOOKING STATEMENTS
  We make forward-looking
  statements in this prospectus and any accompanying prospectus supplement and in documents incorporated herein by reference. All
  statements, other than statements of present or historical fact included in or incorporated by reference in this prospectus and
  any accompanying prospectus supplement, regarding our future financial performance, as well as our strategy, future operations,
  financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management are forward-looking
  statements. When used in this prospectus and any accompanying prospectus supplement, the words "believe," "may,"
  "will," "estimate," "continue," "anticipate," "intend," "expect,"
  "should," "would," "plan," "predict," "potential," "seem,"
  "seek," "future," "outlook" the negative of such terms and other similar expressions are intended
  to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking
  statements are based on management's current
  expectations, assumptions, hopes, beliefs,
  intentions and strategies regarding
  future events and are based on currently available information as to the outcome and
  timing of future events. We caution you that these forward-looking statements are subject to all of the risks and uncertainties,
  most of which are difficult to predict and many of which are beyond our control, incident to our business.
  These forward-looking
  statements are based on information available as of the date of this prospectus and any accompanying prospectus supplement, and
  current expectations, forecasts and assumptions, and involve a number of risks and uncertainties. Accordingly, forward-
  looking
  statements in this prospectus and any accompanying prospectus supplement and in any document incorporated herein by reference should
  not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking
  statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events
  or otherwise, except as may be required under applicable securities laws.
  As a result of a number
  of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed
  or implied by these forward-looking statements. Some factors that could cause actual results to differ include:
  ●
  our ability to recognize the anticipated benefits of the business combination between Live Oak and Meredian Holdings Group, Inc. ("Legacy Danimer"), which was effected through the merger of a wholly-owned subsidiary of Live Oak with and into Legacy Danimer with Legacy Danimer surviving as the surviving company and becoming a wholly-owned subsidiary of Live Oak, which upon the closing of such merger was renamed Danimer Scientific, Inc. (the "Business Combination"), and manage growth profitably following the Closing;
  ●
  costs related to the Business Combination;
  ●
  changes in applicable laws or regulations;
  ●
  the outcome of any legal proceedings against us;
  ●
  the effect of the COVID-19 pandemic on our business;
  ●
  our ability to execute our business model, including, among other things, market acceptance of our planned products and services and construction delays in connection with the expansion of our facilities;
  ●
  our ability to raise capital;
  ●
  the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and
  ●
  other risks and uncertainties set forth in the section entitled "Risk Factors" beginning on page 1 of this prospectus, which is incorporated herein by reference.
  More information on
  potential factors that could affect our financial results is included from time to time in our public reports filed with the Securities
  and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
  All forward-looking statements included in this prospectus are based upon information available to us as of the date of this prospectus,
  and speak only as the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances
  after the date of this prospectus.
  You should also read
  carefully the factors described or referred to in the "Risk Factors" section of this prospectus, any accompanying prospectus
  supplement and the documents incorporated by reference herein and therein, to better understand the risks and uncertainties inherent
  in our business and underlying any forward-looking statements. Any forward-looking statements that we make in this prospectus,
  any accompanying prospectus supplement and the documents incorporated by reference herein as well as other written or oral statements
  by us or our authorized officers on our behalf, speak only as of the date of such statement, and we undertake no obligation to
  update such statements. Comparisons of results for current and any prior periods are not intended to express any future trends
  or indications of future performance, unless expressed as such, and should only be viewed as historical data.
  14
  INCORPORATION OF CERTAIN DOCUMENTS BY
  REFERENCE
  The Commission allows
  us to "incorporate by reference" the information we file with it, which means that we can disclose important business,
  financial and other information to you in this prospectus by referring you to the publicly filed documents containing this information.
  The information incorporated by reference is deemed to be a part of this prospectus, except for any information superseded by information
  contained in this prospectus or filed later by us with the Commission. This prospectus incorporates by reference the documents
  set forth below that we have previously filed with the Commission, other than any portion of any such filing that is furnished
  under the applicable commission rules, which documents contain important information about us and our Common Stock:
  ●
  our Quarterly Reports on Form 10-Q for the quarters ended
  June 30, 2020
  ,
  filed with the Commission on July 31, 2020, and
  September 30, 2020
  , filed with the Commission on November 5, 2020;
  ●
  our Current Reports on Form 8-K filed with the Commission on
  May 11, 2020
  ,
  May 14, 2020
  ,
  May 22, 2020
  ,
  October 5, 2020
  ,
  October 9, 2020
  ,
  December 14, 2020
  ,
  December 17, 2020
  ,
  December 28, 2020
  ,
  December 29, 2020
  ,
  January 5, 2021
  (as amended on
  January 6, 2021
  );
  ●
  the description of our Common Stock contained in our registration
  statement on
  Form 8-A
  filed on May 4, 2020, including any amendments or reports filed for the purpose of updating that description;
  and
  ●
  our definitive Proxy Statement on Schedule 14A with respect to
  the Business Combination filed with the Commission on December 16, 2020 (other than those portions of such Proxy Statement not
  deemed to be "filed" with the Commission).
  All of such documents
  are on file with the Commission. In addition, all documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
  Exchange Act, subsequent to the date of this prospectus are incorporated by reference in this prospectus, other than any portion
  of any such filing that is furnished under the applicable commission rules, and are a part hereof from the date of filing of such
  documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed
  to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any subsequently
  filed document that is also incorporated by reference herein modifies or replaces such statement. Any statements so modified or
  superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
  Any information incorporated
  by reference herein is available to you without charge upon written or oral request. If you would like a copy of any of this information,
  please submit your request to us at Danimer Scientific, Inc., 140 Industrial Boulevard, Bainbridge, Georgia, 39817 Attention: Secretary;
  Telephone number (229) 243-7075.
  15
  THE COMPANY
  Danimer is a performance
  polymer company specializing in bioplastic replacements for traditional petrochemical-based plastics. Danimer, through its principal
  operating subsidiaries, Meredian, Inc., Danimer Scientific, L.L.C. and Danimer Scientific Kentucky, Inc., brings together innovative
  technologies to deliver renewable, environmentally friendly bioplastic materials to global consumer product companies. We have
  core competencies in fermentation process engineering, chemical engineering and polymer science. In addition, we have created an
  extensive intellectual property portfolio to protect our innovations which, together with our technology, serves as a valuable
  foundation for our business and future industry collaborations. We primarily market our products to manufacturers in the plastics
  industry seeking to address environmental, public health, renewability, certification, composting and biodegradability concerns
  because of customer perceptions or government regulations.
  We believe that we
  are the only commercial company in the bioplastics market to combine the production of a base polymer along with the reactive extrusion
  capacity in order to give customers a "drop-in" replacement for a wide variety of petrochemical-based plastics. Our
  process uses sustainably sourced canola oil. Our proprietary extraction and extrusion processes are cost competitive and leave
  almost no carbon footprint. Our customized formulations enable us to team up with other makers of biobased products to create an
  even wider range of goods. Our scalable production capacity and modular manufacturing model will soon enable us to serve an increasingly
  large customer base. An industry leader as gauged by its over 16-year history, a patent portfolio of over 150 patents and pending
  patent applications worldwide, supply agreements with some of the largest consumer packaged goods (CPG) companies and numerous
  awards, including PLASTICS Industry Association's 2020 Innovation in Bioplastics award, Danimer is one of the few companies
  anywhere in the world to achieve this level of sustainability in biopolymer products and processes.
  USE OF PROCEEDS
  We will not realize
  any proceeds from the sale of the Common Stock which may be sold pursuant to this prospectus for the respective accounts of the
  Selling Stockholders. We, however, will derive proceeds upon the exercise of the options granted to Selling Stockholders other
  than in the case of exercises made on a cashless or net exercise basis with us. All such proceeds will be available to us for working
  capital and general corporate purposes. No assurances can be given however, as to when or if any or all of the options will be
  exercised.
  SELLING STOCKHOLDERS
  This prospectus relates
  to shares of Common Stock that are being registered for reoffers and resales by the Selling Stockholders named below who have acquired
  or may acquire shares of Common Stock pursuant to the Plans ("Shares"). Selling Stockholders also include certain unnamed
  non-affiliates of the Company, each of whom holds less than the lesser of 1000 shares or one percent (1%) of the shares issuable
  under the Plans, and who may make reoffers and resales of Shares up to such amount under this prospectus. The Selling Stockholders,
  subject to the expiration or waiver of any applicable lock-up agreements, may resell any or all of the Shares at any time they
  choose while this prospectus is effective.
  Executive officers
  and directors, their family members, trusts for their benefit, or entities that they own, that acquire Common Stock under the Plans
  may be added to the Selling Stockholder list below by a prospectus supplement filed with the Commission. The number of Shares to
  be sold by any Selling Stockholder under this prospectus also may be increased or decreased by a prospectus supplement. Non-affiliates
  who purchased restricted securities, as these terms are defined in Rule 144(a) under the Securities Act, under any of our employee
  benefit plans and who are not named below may use this prospectus for the offer or sale of their Common Stock if they hold 1,000
  shares or less. Although a person's name is included in the table below, neither that person nor we are making an admission
  that the named person is our "affiliate."
  Each of the Selling
  Stockholders is an employee or director of Danimer or one of our subsidiaries. The following table sets forth:
  ●
  the name and principal position(s), office or other material relationship with the Company and
  our predecessors or affiliates, over the last three years of each Selling Stockholder;
  ●
  the number of shares of Common Stock each Selling Stockholder beneficially owned as of February
  1, 2021;
  ●
  the number of shares of Common Stock acquired by each Selling Stockholder in connection with stock
  options and stock grants pursuant to the Plans and underlying stock options previously granted pursuant to the Plans and being
  registered under this Registration Statement, some or all of which Shares may be sold pursuant to this prospectus; and
  ●
  the number of shares of Common Stock and the percentage, if 1% or more, of the total class of Common
  Stock outstanding to be beneficially owned by each Selling Stockholder following this offering, assuming the sale pursuant to this
  offering of all shares acquired by such Selling Stockholder in connection with grants pursuant the Plans and registered under this
  Registration Statement.
  16
  The information
  contained in this "Selling Stockholders" section of this prospectus is included pursuant to the requirements of Form
  S-8 and includes certain persons eligible to resell "restricted securities" and/or "control securities"
  (as such terms are defined in Section C of the General Instructions to Form S-8) pursuant to this prospectus whether or not they
  have a present intent to sell any or all such shares hereunder. As of the date hereof, we have not been informed that any of the
  Selling Stockholders named below has a present intent to resell any such securities.   Furthermore, there is no assurance
  that any of the Selling Stockholders will sell any or all of the shares offered by them under this Registration Statement.
  The address of each
  Selling Stockholder is c/o Danimer Scientific, Inc., 140 Industrial Boulevard, Bainbridge, Georgia, 39817.
  Name of Selling
  Stockholder
  Relationship to
  the Company
  Shares of Common Stock
  Beneficially
  Owned Before Offering
  (1)
  Number of Shares
  Being Offered
  (2)
  Shares of Common
  Stock Beneficially
  Owned
  After Offering
  (1)
  Number
  (2)
  Percent
  (%)
  (3)
  Number
  (2)
  Percent
  (%)
  (3)
  Stephen E. Croskrey
  (4)
  Chairman of the Board and Chief Executive Officer
  8,825,267
  9.5
  8,723,506
  101,761
  *
  Stuart Pratt
  (5)
  Director
  1,897,283
  3.7
  1,897,283
  —
  —
  Philip Gregory Calhoun
  (6)
  Director
  3,581,687
  4.1
  55,952
  3,525,735
  4.0
  Isao Noda
  (7)
  Director
  452,867
  0.5
  401,941
  50,926
  *
  Gregory Hunt
  (8)
  Director
  65,531
  *
  65,531
  —
  —
  John P. Amboian
  (9)
  Director
  50,000
  *
  50,000
  —
  —
  Richard J. Hendrix
  (10)
  Director
  5,050,000
  5.7
  50,000
  5,000,000
  5.7
  John A. Dowdy, III
  (11)
  Chief Financial Officer
  2,332,440
  2.6
  1,979,768
  352,672
  *
  Phillip Van Trump
  (12)
  Chief Science & Technology Officer
  2,002,662
  2.2
  1,979,768
  22,894
  *
  Michael Smith
  (13)
  Chief Operating Officer
  2,017,342
  2.3
  1,983,000
  34,342
  *
  Scott Tuten
  (14)
  Chief Marketing & Sustainability Officer
  1,924,484
  2.2
  1,778,292
  146,192
  *
  Raymond M. Feldman
  Former Employee
  4,937
  *
  4,937
  —
  *
  *
  Less than 1%.
  (1)
  As used in this table, a beneficial owner of a security includes any person
  who, directly or indirectly, through contract, arrangement, understanding, relationship or otherwise has or shares (a) the power
  to vote, or direct the voting of, such security or (b) investment power which includes the power to dispose, or to direct the disposition
  of, such security. In addition, a person is deemed to be the beneficial owner of a security if that person has the right to acquire
  beneficial ownership of such security within 60 days.
  (2)
  The numbers of shares of Common Stock reflect all shares of Common Stock
  acquired or issuable to a person pursuant to applicable grants previously made under the Plans irrespective of whether such grants
  are exercisable, vested or convertible as of March 10, 2021 or will become exercisable, vested or convertible within 60
  days after March 10, 2021.
  (3)
  Applicable percentage of ownership for each selling stockholder is based
  on 88,007,277 shares of Common Stock outstanding (which is the 84,971,601 shares of Common Stock as of March 2, 2021 plus an aggregate
  of 3,035,676 restricted shares of Common Stock which are deemed to be granted to Messrs. Croskrey, Pratt, Dowdy, Van Trump, Smith
  and Tuten on the date of effectiveness of this Registration Statement on Form S-8), plus the number of shares of Common Stock of
  which such person has the right to acquire pursuant to applicable grants previously made under the Plans irrespective of whether
  such grants are exercisable, vested or convertible as of March 10, 2021 or will become exercisable, vested or convertible
  within 60 days after March 10, 2021.
  17
  (4)
  Includes 3,726,353 shares underlying options granted pursuant to the 2020
  Incentive Plan in connection with the Business Combination that are not presently exercisable and not exercisable within 60 days
  of the date hereof, of which 1,154,616 shares underly an option that is not exercisable until the later to occur of February 1,
  2024 or the approval by our shareholders of an amendment to the 2020 Incentive Plan to increase the number of shares available
  under the 2020 Incentive Plan in an amount sufficient to permit the exercise of such option. Includes 1,509,036 restricted shares
  of Common Stock which are deemed to be granted to Mr. Croskrey on the date of effectiveness of this Registration Statement on Form
  S-8, one half of which are solely time-based restricted stock and one-half of which are time-based and based on target price thresholds
  for the Common Stock, and all of which are deemed to be beneficially owned because Mr. Croskrey has the right to vote such shares.
  (5)
  Includes 50,000 shares underlying options that are or will become exercisable
  within 60 days after the date hereof. Includes 12,363 shares underlying Assumed Legacy Danimer Options (as defined herein) that
  are or will become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying options issued by Legacy
  Danimer and assumed by the Company in connection with the Business Combination ("Assumed Legacy Danimer Options") and
  342,258 shares underlying options granted in connection with the Business Combination that are not presently exercisable and not
  exercisable within 60 days of the date hereof, of which 312,258 shares underly an option that is not exercisable until the later
  to occur of February 1, 2024 or the approval by our shareholders of an amendment to the 2020 Incentive Plan to increase the number
  of shares available under the 2020 Incentive Plan in an amount sufficient to permit the exercise of such option. Mr. Pratt disclaims
  any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly
  or indirectly. Includes 17,604 restricted shares of Common Stock which are deemed to be granted to Mr. Pratt on the date of effectiveness
  of this Registration Statement on Form S-8, one half of which are solely time-based restricted stock and one-half of which are
  time-based and based on target price thresholds for the Common Stock, and all of which are deemed to be beneficially owned because
  Mr. Pratt has the right to vote such shares.
  (6)
  Includes 3,226,006 shares held by the Greg Calhoun DGT Family Trusts u/t/a
  dated September 22, 2020 GST Exempt Trust and 62,851 shares held by the Greg Calhoun DGT Family Trusts u/t/a dated September 22,
  2020 GST Non-Exempt Trust, which may be deemed to be owned by Mr. Calhoun, and 50,000 shares underlying options that are or will
  become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying Assumed Legacy Danimer Options that are
  not presently exercisable and not exercisable within 60 days of the date hereof. Mr. Calhoun disclaims any beneficial ownership
  of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
  (7)
  Includes 345,989 shares underlying Assumed Legacy Danimer Options and 50,000
  shares underlying options that are or will become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying
  Assumed Legacy Danimer Options that are not presently exercisable and not exercisable within 60 days after the date hereof.
  (8)
  Includes 4,579 shares underlying Assumed Legacy Danimer Options and 55,000
  shares underlying options that are or will become exercisable within 60 days after the date hereof. Includes 5,952 shares underlying
  Assumed Legacy Danimer Options that are not presently exercisable and not exercisable within 60 days after the date hereof.
  (9)
  Includes 50,000 shares underlying options that are or will become exercisable
  within 60 days after the date hereof.
  (10)
  Includes 50,000 shares underlying options that are or will become exercisable
  within 60 days after the date hereof. Includes 5,000,000 shares held by Live Oak Sponsor Partners, LLC, of which Mr. Hendrix is
  a managing member, and as such, has voting and investment discretion with respect to such shares and may be deemed to have shared
  beneficial ownership of such shares. Mr. Hendrix disclaims any beneficial ownership of the reported shares other than to the extent
  of any pecuniary interest he may have therein, directly or indirectly.
  18
  (11)
  Includes 303,054 shares held by the John Adams Dowdy, III Living Trust, which
  shares may be deemed to be owned by Mr. Dowdy, and 917,613 shares underlying Assumed Legacy Danimer Options that are or will become
  exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options and 642,934
  shares underlying options granted in connection with the Business Combination that are not presently exercisable and not exercisable
  within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be granted to Mr.
  Dowdy on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely time-based restricted
  stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and all of which are deemed
  to be beneficially owned because Mr. Dowdy has the right to vote such shares. Mr. Dowdy disclaims any beneficial ownership of the
  reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
  (12)
  Includes 867,995 shares underlying Assumed Legacy Danimer Options that are
  or will become exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options
  and 642,934 shares underlying options granted in connection with the Business Combination that are not presently exercisable and
  not exercisable within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be
  granted to Mr. Van Trump on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely
  time-based restricted stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and
  all of which are deemed to be beneficially owned because Mr. Van Trump has the right to vote such shares.
  (13)
  Includes 905,569 shares underlying Assumed Legacy Danimer Options that are
  or will become exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options
  and 642,934 shares underlying options granted in connection with the Business Combination that are not presently exercisable and
  not exercisable within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be
  granted to Mr. Smith on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely time-based
  restricted stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and all of which
  are deemed to be beneficially owned because Mr. Smith has the right to vote such shares.
  (14)
  Includes and 666,519 shares underlying Assumed Legacy Danimer Options that
  are or will become exercisable within 60 days after the date hereof. Includes 91,580 shares underlying Assumed Legacy Danimer Options
  and 642,934 shares underlying options granted in connection with the Business Combination that are not presently exercisable and
  not exercisable within 60 days after the date hereof. Includes 377,259 restricted shares of Common Stock which are deemed to be
  granted to Mr. Tuten on the date of effectiveness of this Registration Statement on Form S-8, one half of which are solely time-based
  restricted stock and one-half of which are time-based and based on target price thresholds for the Common Stock, and all of which
  are deemed to be beneficially owned because Mr. Tuten has the right to vote such shares. Mr. Tuten disclaims any beneficial ownership
  of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
  We will supplement
  this prospectus from time to time as required by the rules of the Commission to include certain information concerning the security
  ownership of the Selling Stockholders or any new Selling Stockholders, the number of shares offered for resale and the position,
  office or other material relationship which a Selling Stockholder has had within the past three years with us or any of our predecessors
  or affiliates.
  Other Material Relationships with the Selling Stockholders
  Transactions with Certain Directors and
  Executive Officers
  Stephen E. Croskrey, our
  chief executive officer and chairman, leases a house from Danimer in Brinson, Georgia for a nominal rental fee and has an option
  to purchase such property from Danimer, which option continues co-terminously with Mr. Croskrey's employment as chief executive
  officer of Danimer.
  Mr. Croskrey had acquired 483,977 shares of Legacy Danimer Common
  Stock upon exercise of options granted by Legacy Danimer and for which the exercise prices were paid in the form of non-recourse
  notes issued by Mr. Croskrey to Legacy Danimer. The aggregate amount of principal and accrued interest payable by Mr. Croskrey
  to Legacy Danimer in the amount of approximately $22,848,285 was paid off prior to the closing of the Business Combination (the
  "Croskrey Note Payoff"). In connection with the Croskrey Note Payoff, Mr. Croskrey received upon closing of the Business
  Combination a new option grant to purchase 1,154,616 shares of Common Stock under the 2020 Incentive Plan, which option will not
  be exercisable until the later to occur of February 1, 2024 or the approval by our shareholders of an amendment to the 2020 Incentive
  Plan to increase the number of shares available under the 2020 Incentive Plan in an amount sufficient to permit the exercise of
  the option.
  Stuart Pratt, a director of Danimer and the former chairman
  of the board of directors of Legacy Danimer, had acquired 187,147 shares of Legacy Danimer common stock upon exercise of options
  granted by Legacy Danimer and for which the exercise prices were paid in the form of non-recourse notes issued by Mr. Pratt to
  Legacy Danimer. The aggregate amount of principal and accrued interest payable by Mr. Pratt to Legacy Danimer in the amount of
  approximately $5,923,821 was paid off prior to the closing of the Business Combination (the "Pratt Note Payoff"). In
  connection with the Pratt Note Payoff, Mr. Pratt received upon closing of the Business Combination a new option grant to purchase
  312,258 shares of Common Stock under the 2020 Incentive Plan, which option will not be exercisable until the later to occur of
  February 1, 2024 or the approval by our shareholders of an amendment to the 2020 Incentive Plan to increase the number of shares
  available under the 2020 Incentive Plan in an amount sufficient to permit the exercise of the option.
  19
  Dr. Isao Noda, a former
  director of Legacy Danimer, held an aggregate principal amount of $200,000 of Legacy Danimer's 8% convertible notes, which
  converted into shares of Danimer effective as of the closing of the Business Combination.
  Employment and Consulting
  Relationships
  Mr. Croskrey entered into
  an employment agreement with us in connection with the Business Combination, Mr. Pratt entered into a consulting agreement with
  us in connection with the Business Combination, and each of Messrs. Dowdy, Van Trump, Smith and Tuten entered into an employment
  agreement with Legacy Danimer in connection with their respective appointment. Each of Messrs. Croskrey, Pratt, Dowdy, Van Trump,
  Smith and Tuten have provided and continue to provide, services to Danimer commensurate with his role.
  Lock-Up
  Agreement
  In connection with the closing of the Business Combination,
  on December 29, 2020, the Company and Messrs. Croskrey, Pratt, Dowdy, Van Trump, Smith and Tuten entered into a Lock-Up Agreement
  (the "Lock-Up Agreement"). The terms of the Lock-Up Agreement provide that our securities held by these individuals
  that were acquired pursuant to the Merger Agreement or otherwise issued pursuant to the Merger Agreement will be locked-up until
  the earlier of (i) one year after the closing of the Business Combination or (ii) subsequent to the closing of the Business Combination,
  (x) if the reported closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends,
  reorganizations, recapitalizations and the like) for any twenty (20) trading days within any 30-trading day period commencing at
  least one hundred fifty (150) days after the closing of the Business Combination, or (y) the date on which Danimer completes a
  liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Danimer's
  stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.
  The Company has agreed that the restrictions in the Lock-Up
  Agreement will not apply to (i) the delivery to the Company by Messrs. Croskrey or Pratt of the amounts of Common Stock needed
  to effect the Croskrey Note Payoff or Pratt Note Payoff, respectively, and (ii) the sale of Common Stock by either of Messrs. Croskrey
  or Pratt to satisfy their respective tax obligations in connection with the foregoing clause (i).
  Indemnification Agreements
  We entered into separate
  indemnification agreements with our directors and executive officers, including each of Messrs. Croskrey, Pratt, Calhoun, Noda,
  Hunt, Amboian, Hendrix, Dowdy, Van Trump, Smith and Tuten. These agreements, among other things, require us to indemnify our directors
  and executive officers for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred
  by a director or executive officer in any action or proceeding arising out of their services as one of Danimer's directors
  or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services
  at our request.
  Sponsor Agreements
  Live Oak Sponsor Partners,
  LLC, a Delaware limited liability company (the "Sponsor") that is affiliated with a member of our board of directors,
  has entered certain agreements with Live Oak, our predecessor company.
  Founder Shares
  In June 2019, the Sponsor purchased 5,031,250 shares (the "Founder
  Shares") of Live Oak's Class B common stock for an aggregate price of $25,000. On January 14, 2020, the Sponsor contributed
  back to Live Oak, for no consideration, 718,750 Founder Shares. In February 2020, Live Oak effected a stock dividend for 0.333333333
  shares for each Founder Share outstanding, resulting in the Sponsor holding an aggregate of 5,750,000 Founder Shares, 750,000 of
  which were later forfeited, resulting in 5,000,000 Founder Shares outstanding. Upon the closing of the Business Combination, each
  of the Founder Shares converted into a share of Common Stock on a one-for-one basis.
  Private
  Warrants
  Simultaneously with the
  closing of Live Oak's initial public offering, the Sponsor purchased an aggregate of 6,000,000 warrants from Live Oak (each,
  a "Private Warrant") at a price of $1.00 per Private Warrant, for an aggregate purchase price of $6,000,000. Each Private
  Warrant is exercisable to purchase one share of Common Stock at a price of $11.50 per share.
  20
  Registration
  Rights Agreement
  Pursuant to a registration
  rights agreement entered into on May 5, 2020, the holders of the Private Warrants (and the shares of Class A common stock underlying
  such Private Warrants) and shares of Common Stock issued upon conversion of the Founder Shares have registration rights to require
  us to register a sale of any of such holders' securities held by them. As of the date of this Registration Statement, the
  Sponsor holds 3 million Private Warrants and 5 million shares of Common Stock issued upon conversion of the Founder Shares.
  Subscription Agreement
  In connection with the execution of the Merger Agreement, Live Oak
  entered into Subscription Agreements with a number of subscribers, pursuant to which the subscribers agreed to purchase, and Live
  Oak agreed to sell to the subscribers, an aggregate of 21,000,000 shares of Live Oak Class A Common Stock, for a purchase
  price of $10.00 per share and an aggregate purchase price of $210,000,000, in a private placement (the "PIPE"). Live
  Oak ValFund Plastics Fund LLC, which was affiliated with a member of our board of directors, purchased 4,905,000 shares of Live
  Oak Class A Common Stock in the PIPE for a total purchase price of $49,050,000.
  21
  DESCRIPTION OF COMMON STOCK
  The following description
  of our Common Stock does not purport to be complete and is subject in all respects to applicable Delaware law and qualified by
  reference to the provisions of our Fourth Amended and Restated Certificate of Incorporation, as amended (the "Certificate
  of Incorporation") and Amended and Restated Bylaws, as amended (the "Bylaws"). Copies of our Certificate of Incorporation
  and Bylaws are incorporated by reference and will be sent to stockholders upon request. See "Where Can You Find More Information."
  Authorized and Outstanding Stock
  We have authorized
  200,000,000 shares of our Common Stock. As of March 2, 2021 there were 84,971,601 shares of our Common Stock outstanding and no
  shares of preferred stock outstanding.
  Voting Power
  Except as otherwise
  required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of our
  Common Stock possess all voting power for the election of our directors and all other matters requiring stockholder action. Holders
  of common stock are entitled to one vote per share on matters to be voted on by stockholders.
  Dividends
  Holders of Common Stock
  will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors in its discretion
  out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared
  or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.
  We have not paid any
  cash dividends on any class of our common stock to date and do not intend to pay cash dividends. The payment of cash dividends
  in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial conditions.
  The payment of any cash dividends will be within the discretion of our board of directors at such time. Further, if we incur any
  indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.
  Liquidation, Dissolution and Winding Up
  In the event of our
  voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the Common Stock will be
  entitled to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders,
  after the rights of the holders of the preferred stock have been satisfied.
  Preemptive or Other Rights
  Our stockholders have
  no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the Common Stock.
  Election of Directors
  Our board of directors
  will be composed of single class of eight directors, each of whom will generally serve for a term of one year. There is no cumulative
  voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the
  election of directors can elect all of the directors.
  Anti-Takeover Effects of Certain Provisions of Delaware Law
  and Our Certificate of Incorporation and Bylaws
  We are subject to the
  provisions of Section 203 of the Delaware General Corporation Law ("DGCL") regulating corporate takeovers. This
  statute prevents certain Delaware corporations, under certain circumstances, from engaging in a "business combination"
  with:
  ●
  a stockholder who owns 15% or more of our outstanding
  voting stock (otherwise known as an "interested stockholder");
  ●
  an affiliate of an interested stockholder; or
  ●
  an associate of an interested stockholder, for three
  years following the date that the stockholder became an interested stockholder.
  22
  A "business combination"
  includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:
  ●
  our board of directors approves the transaction that
  made the stockholder an "interested stockholder," prior to the date of the transaction;
  ●
  after the completion of the transaction that resulted
  in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at
  the time the transaction commenced, other than statutorily excluded shares of common stock; or
  ●
  on or subsequent to the date of the transaction, the
  initial business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by
  written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.
  Our authorized but unissued
  Common Stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety
  of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence
  of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt
  to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.
  PLAN OF DISTRIBUTION
  The Selling
  Stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of
  our Common Stock or interests in shares of our Common Stock received after the date of this prospectus from a Selling
  Stockholder as a gift, pledge, partnership distribution or other transfer, may, after the expiration of any applicable
  lock-up agreements and from time to time, sell, transfer or otherwise dispose of any or all of their shares of our Common
  Stock or interests in shares of our Common Stock on any stock exchange, market or trading facility on which the shares are
  traded, in private transactions or through a combination of such methods. These dispositions may be at fixed prices, at
  prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
  at the time of sale, or at negotiated prices.
  The Selling Stockholders
  may use any one or more of the following methods when disposing of shares or interests therein:
  ●
  market transactions in accordance with the rules of NYSE or any other available
  markets or exchanges;
  ●
  ordinary brokerage transactions and transactions in which the broker-dealer
  solicits purchasers;
  ●
  block trades in which the broker-dealer will attempt to sell the shares as
  agent, but may position and resell a portion of the block as principal to facilitate the transaction;
  ●
  purchases by a broker-dealer as principal and resale by the broker-dealer
  for its account;
  ●
  an exchange distribution in accordance with the rules of the applicable exchange;
  ●
  privately negotiated transactions;
  ●
  short sales entered into after the date of this prospectus;
  ●
  through the writing or settlement of options or other hedging transactions,
  whether through an options exchange or otherwise;
  ●
  distributions to the partners and/or members of the Selling Stockholders;
  ●
  redemptions or repurchases of interests owned by partners and/or members
  of the Selling Stockholders;
  23
  ●
  broker-dealers may agree with the Selling Stockholders to sell a specified
  number of such shares at a stipulated price per share;
  ●
  a combination of any such methods of sale; and
  ●
  any other method permitted pursuant to applicable law.
  To the extent permitted,
  this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with
  the sale of our Common Stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
  or other financial institutions, which may in turn engage in short sales of our Common Stock in the course of hedging the positions
  they assume with the selling stockholders. The Selling Stockholders may also sell shares of our Common Stock short and deliver
  these securities to close out their short positions, or loan or pledge our Common Stock to broker-dealers that in turn may sell
  these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial
  institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial
  institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant
  to this prospectus (as supplemented or amended to reflect such transaction).
  Short selling occurs
  when a person sells shares of stock which the person does not yet own and promises to buy stock in the future to cover the sale.
  The general objective of the person selling the shares short is to make a profit by buying the shares later, at a lower price,
  to cover the sale. Significant amounts of short selling, or the perception that a significant amount of short sales could occur,
  could depress the market price of our Common Stock. In contrast, purchases to cover a short position may have the effect of preventing
  or retarding a decline in the market price of our Common Stock, and together with the imposition of the penalty bid, may stabilize,
  maintain or otherwise affect the market price of our Common Stock. As a result, the price of our Common Stock may be higher than
  the price that otherwise might exist in the open market. If these activities are commenced, they may be discontinued at any time.
  These transactions may be effected on NYSE, in the over-the-counter market or otherwise.
  The aggregate proceeds
  to the Selling Stockholders from the sale of our Common Stock offered by them will be the purchase price of our Common Stock less
  discounts or commissions, if any. Each of the Selling Stockholders reserves the right to accept and, together with their agents
  from time to time, to reject, in whole or in part, any proposed purchase of our Common Stock to be made directly or through agents.
  We will not receive any of the proceeds from this offering.
  The Selling Stockholders
  also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act,
  provided that they meet the criteria and conform to the requirements of that rule.
  The Selling Stockholders
  and any underwriters, broker-dealers or agents that participate in the sale of our Common Stock or interests therein may be "underwriters"
  within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profits they earn on any
  resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling Stockholders who are "underwriters"
  within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
  Act.
  To the extent required,
  the shares of our Common Stock to be sold, the names of the Selling Stockholders, the respective purchase prices and public offering
  prices, the names of any agents, dealers or underwriters, any applicable commissions or discounts with respect to a particular
  offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration
  statement that includes this prospectus.
  In order to comply
  with the securities laws of some states, if applicable, our Common Stock may be sold in these jurisdictions only through registered
  or licensed brokers or dealers. In addition, in some states our Common Stock may not be sold unless it has been registered or qualified
  for sale or an exemption from registration or qualification requirements is available and is complied with.
  We have advised the
  Selling Stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the
  market and to the activities of the Selling Stockholders and their affiliates. In addition, we will make copies of this prospectus
  (as it may be supplemented or amended from time to time) available to the Selling Stockholders for the purpose of satisfying the
  prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer that participates
  in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities
  Act.
  24
  WHERE YOU CAN FIND MORE INFORMATION
  We are subject to the
  informational requirements of the Exchange Act, and in accordance therewith we are required to file periodic reports, proxy statements
  and other information with the Commission. Such reports, proxy statements and other information filed by us can be inspected and
  copied at the Commission's Public Reference Room located at 100 F Street, N.E. Washington, D.C. 20549, at the prescribed
  rates. The Commission also maintains a site on the World Wide Web that contains reports, proxy and information statements and other
  information regarding registrants that file electronically. The address of such site is http://www.sec.gov. Please call 1-800-SEC-0330
  for further information on the operation of the Commission's Public Reference Room.
  Our Common Stock is
  traded on NYSE under the symbol "DNMR." Certain materials filed by us may be inspected at The New York Stock Exchange
  at 11 Wall St, New York, NY 10005.
  This prospectus omits
  certain information that is contained in the registration statement on file with the Commission, of which this prospectus is a
  part. For further information with respect to us and our Common Stock, reference is made to the registration statement, including
  the exhibits incorporated therein by reference or filed therewith. Statements herein contained concerning the provisions of any
  document are not necessarily complete and, in each instance, reference is made to the copy of such document filed as an exhibit
  or incorporated by reference to the registration statement. The registration statement and the exhibits may be inspected without
  charge at the offices of the Commission or copies thereof obtained at prescribed rates from the public reference section of the
  Commission at the addresses set forth above.
  We incorporate information
  into this prospectus by reference, which means that we disclose important information to you by referring you to another document
  filed separately with the Securities and Exchange Commission (the "Commission") by us. The information incorporated
  by reference is deemed to be part of this prospectus, except to the extent superseded by information contained in this prospectus
  or by information contained in documents filed with the SEC after the date of this prospectus. This prospectus incorporates by
  reference the documents set forth below that have been previously filed with the Commission; provided, however, that, except as
  noted below, we are not incorporating any documents or information deemed to have been furnished rather than filed in accordance
  with the rules of the Commission. These documents contain important information about us and our financial condition.
  ●
  our Quarterly Reports on Form 10-Q for the quarters ended
  June 30, 2020
  ,
  filed with the Commission on July 31, 2020, and
  September 30, 2020
  , filed with the Commission on November 5, 2020;
  ●
  our Current Reports on Form 8-K filed with the Commission on
  May 11, 2020
  ,
  May 14, 2020
  ,
  May 22, 2020
  ,
  October 5, 2020
  ,
  October 9, 2020
  ,
  December 14, 2020
  ,
  December 17, 2020
  ,
  December 28, 2020
  ,
  December 29, 2020
  ,
  January 5, 2021
  (as amended on
  January 6, 2021
  ) and
  February 4, 2021
  (excluding "furnished" and
  not "filed" information); and
  ●
  the
  description of our Common Stock contained in our registration statement on
  Form
  8-A
  filed on May 4, 2020, including any amendments or reports filed for the purpose of updating that description.
  All documents subsequently
  filed by us with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended,
  prior to the filing of a post-effective amendment to the registration statement of which this prospectus forms a part which indicates
  that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed incorporated
  by reference into this prospectus and to be a part hereof from the date of the filing of such documents, except that information
  furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and any exhibit relating to such information,
  shall not be deemed to be incorporated by reference in this prospectus.
  25
  For purposes of this
  prospectus, any statement contained in a document incorporated, or deemed to be incorporated, by reference herein shall be deemed
  to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently
  filed document which also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such
  statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
  We will provide without
  charge upon written or oral request to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of
  any and all of the documents which are incorporated by reference in this prospectus but not delivered with this prospectus (other
  than exhibits unless such exhibits are specifically incorporated by reference in such documents). You may request a copy of these
  documents by writing or telephoning us at:
  Danimer Scientific, Inc.
  140 Industrial Boulevard
  Bainbridge, Georgia 39817
  (229) 243-7075
  EXPERTS
  The consolidated financial
  statements of Legacy Danimer as of December 31, 2019 and 2018, and for each of the two years in the period ended December 31, 2019,
  incorporated in this prospectus by reference to the Company's Current Report on Form 8-K filed with the Commission on
  January 5, 2021, have been audited by Thomas Howell Ferguson P.A., independent registered public accounting firm, as stated in
  their report which is incorporated herein by reference (which report expresses an unqualified opinion on the financial statements
  and includes an explanatory paragraph referring to the entity's adoption of ASU No. 2014-09, Revenue from Contracts with
  Customers (Topic 606)), and are so included in reliance upon such report given on the authority of such firm as experts in accounting
  and auditing.
  The financial
  statements as of December 31, 2019 and for the period from May 24, 2019 (inception) through December 31, 2019 of Live Oak
  Acquisition Corp. incorporated in this prospectus by reference to the Company's Current Report on Form 8-K filed with
  the Commission on January 5, 2021 have been audited by WithumSmith+Brown, PC, an independent registered public
  accounting firm, as stated in their report thereon dated February 28, 2020 and referred to in this prospectus, in reliance
  upon such report and upon the authority of such firm as experts in accounting and auditing.
  LEGAL MATTERS
  The validity of the
  shares of Common Stock offered hereby will be passed upon for us by Kane Kessler, P.C., New York, New York.
  26
  REOFFER PROSPECTUS
  DANIMER SCIENTIFIC,
  INC.
  18,969,978 Shares of Class A Common Stock,
  par value $0.0001 per share
  March 10, 2021
  No dealer, salesperson or other person
  is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized
  information or representations. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances
  and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT
  Item 3. Incorporation of Documents by
  Reference.
  The following documents
  filed with the Securities and Exchange Commission (the "Commission") by Danimer Scientific, Inc., a Delaware corporation
  (the "Registrant"), are incorporated by reference into the Registration Statement:
  ●
  the Registrant's Quarterly Reports on Form 10-Q for the quarters ended
  June
                                                                                                                                      30, 2020
  , filed with the Commission on July 31, 2020, and
  September
                                                                                                                                      30, 2020
  , filed with the Commission on November 5, 2020;
  ●
  the Registrant's Current
                                                                                                                                      Reports on Form 8-K filed with the Commission on
  May
                                                                                                                                      11, 2020
  ,
  May
                                                                                                                                      14, 2020
  ,
  May
                                                                                                                                      22, 2020
  ,
  October 5,
                                                                                                                                      2020
  ,
  October 9,
                                                                                                                                      2020
  ,
  December 14,
                                                                                                                                      2020
  ,
  December 17,
                                                                                                                                      2020
  ,
  December 28,
                                                                                                                                      2020
  ,
  December
                                                                                                                                      29, 2020
  ,
  January
                                                                                                                                      5, 2021
  (as amended on
  January
                                                                                                                                      6, 2021
  ) and
  February
                                                                                                                                      4, 2021
  (excluding "furnished" and not "filed" information); and
  ●
  the
  description of the Registrant's Common Stock contained in the Registrant's registration statement on
  Form
  8-A
  filed on May 4, 2020, including any amendments or reports filed for the purpose of updating that description.
  All of such documents
  are on file with the Commission. In addition, all documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
  Exchange Act, subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment which
  indicates that all the securities offered hereby have been sold or which deregisters all securities then remaining unsold shall
  be deemed to be incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such
  documents, except that information furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and
  any exhibit relating to such information, shall not be deemed to be incorporated by reference in this prospectus. Any statement
  contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this prospectus to the extent that a statement contained herein or in any subsequently filed document that is also
  incorporated by reference herein modifies or replaces such statement. Any statements so modified or superseded shall not be deemed,
  except as so modified or superseded, to constitute a part of this Registration Statement.
  Item 4. Description of Securities.
  Not applicable.
  Item 5. Interests of Named Experts and Counsel.
  Not applicable.
  Item 6. Indemnification of Directors and Officers.
  Section 145(a)
  of the Delaware General Corporation Law ("DGCL") provides, in general, that a corporation may indemnify any person
  who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
  whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because
  he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
  expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by
  the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably
  believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding,
  had No reasonable cause to believe his or her conduct was unlawful.
  II-
  1
  Section 145(b)
  of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made
  a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its
  favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
  of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
  enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with
  the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed
  to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect
  to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to
  the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in
  view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the
  Court of Chancery or other adjudicating court shall deem proper.
  Section 145(g)
  of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was
  a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
  officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability
  asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether
  or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL.
  The Registrant has
  entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant
  will indemnify each of its directors and such officers to the fullest extent permitted by law and its charter and its bylaws.
  The Registrant also
  maintains a general liability insurance policy, which will cover certain liabilities of directors and officers of the Registrant
  arising out of claims based on acts or omissions in their capacities as directors or officers.
  Item 7. Exemption from Registration Claimed.
  The shares being reoffered and resold pursuant
  to the Reoffer Prospectus were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of
  the Securities Act and/or Rule 701 promulgated thereunder, as transactions by an issuer not involving a public offering or pursuant
  to a written compensatory benefit plan.
  Item 8. Exhibits.
  Exhibit No.
  Description
  4.1
  Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).
  4.2
  Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).
  4.3
  Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-236800) (as amended, the "S-1")).
  4.4
  Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Annex C to the Proxy Statement/Prospectus on Form 424B3 (File No. 333-249691) filed on December 16, 2020).
  4.5
  Danimer Scientific, Inc.  Employee Stock Purchase Plan (incorporated by reference to Annex D to the Proxy Statement/Prospectus on Form 424B3 (File No. 333-249691) filed on December 16, 2020).
  4.6
  Form of Stock Option Agreement under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.29 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).
  II-
  2
  4.7
  Form of Restricted Stock Agreement under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.30 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).
  4.8
  Meredian Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan, assumed by Danimer Scientific, Inc. (1)
  4.9
  Meredian Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan, assumed by Danimer Scientific, Inc. (1)
  5.1
  Opinion of Kane Kessler, P.C. (1)
  23.1
  Consent of WithumSmith+Brown, PC. (1)
  23.2
  Consent of Thomas Howell Ferguson P.A. (1)
  23.2
  Consent of Kane Kessler, P.C. (Included in Exhibit 5.1). (1)
  24.1
  Power of Attorney (included on the signature page of the Registration Statement hereto). (1)
  (1)
  Filed herewith.
  Item 9. Undertakings
  1.       The
  undersigned Registrant hereby undertakes:
  (a)
  To file, during any period in which offers or sales are being made, a post-effective amendment
  to this registration statement:
  (i)
  to include any prospectus required by Section 10(a)(3) of the Securities Act;
  (ii)
  to reflect in the prospectus any facts or events arising after the effective date of the registration
  statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
  change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
  of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
  from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
  pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the
  maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration
  statement; and
  (iii)
  to include any material information with respect to the plan of distribution not previously disclosed
  in the registration statement or any material change to such information in the registration statement;
  provided, however
  , that
  paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d)
  of the Exchange Act that are incorporated by reference in the registration statement.
  (b)
  that, for the purpose of determining any liability under the Securities Act, each such post-effective
  amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
  securities at that time shall be deemed to be the initial bona fide offering thereof; and
  (c)
  to remove from registration by means of a post-effective amendment any of the securities being
  registered which remain unsold at the termination of the offering.
  2.
  The undersigned Registrant hereby undertakes that, for purposes of determining any liability under
  the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange
  Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange
  Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating
  to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
  offering thereof.
  3.
  Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
  directors, officers and controlling persons of the undersigned Registrant pursuant to the provisions described in Item 6 or otherwise,
  the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed
  in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
  (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
  in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
  with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
  controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  II-
  3
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, as amended, the undersigned registrant certifies that it has reasonable grounds to believe that
  it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf
  by the undersigned, thereunto duly authorized, in the City of Bainbridge, State of Georgia, on March 10, 2021.
  DANIMER SCIENTIFIC, INC.
  By:
  /s/  Stephen E. Croskrey
  Name:  Stephen E. Croskrey
  Title:  Chief Executive Officer
  POWER OF ATTORNEY
  KNOW ALL PERSONS BY
  THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Stephen E. Croskrey and John A.
  Dowdy, III, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and
  resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments,
  including post-effective amendments, to this registration statement on Form S-8, and to file the same, with exhibits thereto and
  other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and
  agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be
  done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that
  each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue
  hereof.
  Pursuant to the requirements
  of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities
  and on the date indicated.
  Signature
  Title
  Date
  /s/ Stephen E. Croskrey
  Chief Executive Officer, Director and Chairman of the Board
  March 10, 2021
  Stephen E. Croskrey
  (Principal Executive Officer)
  /s/ John A. Dowdy, III
  Chief Financial Officer
  March 10, 2021
  John A. Dowdy, III
  (Principal Financial Officer and Principal Accounting Officer)
  /s/ John P. Amboian
  Director
  March 10, 2021
  John P. Amboian
  /s/ Richard J. Hendrix
  Director
  March 10, 2021
  Richard J. Hendrix
  /s/ Christy Basco
  Director
  March 10, 2021
  Christy Basco
  /s/ Philip Gregory Calhoun
  Director
  March 10, 2021
  Philip Gregory Calhoun
  /s/ Gregory Hunt
  Director
  March 10, 2021
  Gregory Hunt
  /s/ Dr. Isao Noda
  Director
  March 10, 2021
  Dr. Isao Noda
  /s/ Stuart Pratt
  Director
  March 10, 2021
  Stuart Pratt
  II-4